<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2023 | Cochrane Library</title> <meta content="Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013881.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review - Ghosn, L - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013881.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013881.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review" name="citation_title"/> <meta content="Lina Ghosn" name="citation_author"/> <meta content="Rouba Assi" name="citation_author"/> <meta content="Theodoros Evrenoglou" name="citation_author"/> <meta content="Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004" name="citation_author_institution"/> <meta content="Brian S Buckley" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Nicholas Henschke" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Katrin Probyn" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Carolina Riveros" name="citation_author"/> <meta content="Mauricia Davidson" name="citation_author"/> <meta content="Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004" name="citation_author_institution"/> <meta content="Carolina Graña" name="citation_author"/> <meta content="Hillary Bonnet" name="citation_author"/> <meta content="Alexander Jarde" name="citation_author"/> <meta content="Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), F-75004" name="citation_author_institution"/> <meta content="Camila Ávila" name="citation_author"/> <meta content="Epistemonikos Foundation" name="citation_author_institution"/> <meta content="Camilla Hansen Nejstgaard" name="citation_author"/> <meta content="Sonia Menon" name="citation_author"/> <meta content="Cochrane France" name="citation_author_institution"/> <meta content="Gabriel Ferrand" name="citation_author"/> <meta content="Cochrane France" name="citation_author_institution"/> <meta content="Philipp Kapp" name="citation_author"/> <meta content="Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg" name="citation_author_institution"/> <meta content="Claudia Breuer" name="citation_author"/> <meta content="Christine Schmucker" name="citation_author"/> <meta content="Yanina Sguassero" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Thu Van Nguyen" name="citation_author"/> <meta content="Cochrane France" name="citation_author_institution"/> <meta content="Declan Devane" name="citation_author"/> <meta content="Joerg J Meerpohl" name="citation_author"/> <meta content="Gabriel Rada" name="citation_author"/> <meta content="Asbjørn Hróbjartsson" name="citation_author"/> <meta content="Giacomo Grasselli" name="citation_author"/> <meta content="Department of Anesthesia, Intensive Care and Emergency Department of Anesthesia, Intensive Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan" name="citation_author_institution"/> <meta content="David Tovey" name="citation_author"/> <meta content="Cochrane France" name="citation_author_institution"/> <meta content="Philippe Ravaud" name="citation_author"/> <meta content="Anna Chaimani" name="citation_author"/> <meta content="Isabelle Boutron" name="citation_author"/> <meta content="isabelle.boutron@aphp.fr" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD013881.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/06/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013881.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013881.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013881.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bias; *COVID-19; *COVID-19 Drug Treatment; Cytokines; *Interleukin-6 [antagonists &amp; inhibitors]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013881.pub2&amp;doi=10.1002/14651858.CD013881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="cdmLYOAV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013881\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013881\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","th","ms","ja","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013881.pub2",title:"Interleukin\\u20106 blocking agents for treating COVID\\u201019: a living systematic review",firstPublishedDate:"Jun 1, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Emergency and Critical Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013881.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013881.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013881.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013881.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013881.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013881.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013881.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013881.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013881.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013881.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2694 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013881.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-sec-0137"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-sec-0131"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/appendices#CD013881-sec-0142"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/supinfo/CD013881-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/supinfo/CD013881-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0004">Lina Ghosn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0005">Rouba Assi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0006">Theodoros Evrenoglou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0007">Brian S Buckley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0008">Nicholas Henschke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0009">Katrin Probyn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0010">Carolina Riveros</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0011">Mauricia Davidson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0012">Carolina Graña</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0013">Hillary Bonnet</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0014">Alexander Jarde</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0015">Camila Ávila</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0016">Camilla Hansen Nejstgaard</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0017">Sonia Menon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0018">Gabriel Ferrand</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0019">Philipp Kapp</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0020">Claudia Breuer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0021">Christine Schmucker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0022">Yanina Sguassero</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0023">Thu Van Nguyen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0024">Declan Devane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0025">Joerg J Meerpohl</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0026">Gabriel Rada</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0027">Asbjørn Hróbjartsson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0028">Giacomo Grasselli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0029">David Tovey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0030">Philippe Ravaud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0031">Anna Chaimani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information#CD013881-cr-0032"><i class="icon corresponding-author fa fa-envelope"></i>Isabelle Boutron</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information/en#CD013881-sec-0183">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 June 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013881.pub2">https://doi.org/10.1002/14651858.CD013881.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013881-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013881-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013881-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013881-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013881-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD013881-abs-0005">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013881-abs-0001" lang="en"> <section id="CD013881-sec-0001"> <h3 class="title" id="CD013881-sec-0001">Background</h3> <p>It has been reported that people with COVID‐19 and pre‐existing autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm responsible for severe respiratory symptoms. Since interleukin 6 (IL‐6) is one of the cytokines released during this inflammatory process, IL‐6 blocking agents have been used for treating people with severe COVID‐19. </p> </section> <section id="CD013881-sec-0002"> <h3 class="title" id="CD013881-sec-0002">Objectives</h3> <p>To update the evidence on the effectiveness and safety of IL‐6 blocking agents compared to standard care alone or to a placebo for people with COVID‐19. </p> </section> <section id="CD013881-sec-0003"> <h3 class="title" id="CD013881-sec-0003">Search methods</h3> <p>We searched the World Health Organization (WHO) International Clinical Trials Registry Platform, the Living OVerview of Evidence (L·OVE) platform, and the Cochrane COVID‐19 Study Register to identify studies on 7 June 2022. </p> </section> <section id="CD013881-sec-0004"> <h3 class="title" id="CD013881-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) evaluating IL‐6 blocking agents compared to standard care alone or to placebo for people with COVID‐19, regardless of disease severity. </p> </section> <section id="CD013881-sec-0005"> <h3 class="title" id="CD013881-sec-0005">Data collection and analysis</h3> <p>Pairs of researchers independently conducted study selection, extracted data and assessed risk of bias. We assessed the certainty of evidence using the GRADE approach for all critical and important outcomes. In this update we amended our protocol to update the methods used for grading evidence by establishing minimal important differences for the critical outcomes. </p> </section> <section id="CD013881-sec-0006"> <h3 class="title" id="CD013881-sec-0006">Main results</h3> <p>This update includes 22 additional trials, for a total of 32 trials including 12,160 randomized participants all hospitalized for COVID‐19 disease. We identified a further 17 registered RCTs evaluating IL‐6 blocking agents without results available as of 7 June 2022.  </p> <p>The mean age range varied from 56 to 75 years; 66.2% (8051/12,160) of enrolled participants were men. One‐third (11/32) of included trials were placebo‐controlled. Twenty‐two were published in peer‐reviewed journals, three were reported as preprints, two trials had results posted only on registries, and results from five trials were retrieved from another meta‐analysis. Eight were funded by pharmaceutical companies.  </p> <p>Twenty‐six included studies were multicenter trials; four were multinational and 22 took place in single countries. Recruitment of participants occurred between February 2020 and June 2021, with a mean enrollment duration of 21 weeks (range 1 to 54 weeks). Nineteen trials (60%) had a follow‐up of 60 days or more. Disease severity ranged from mild to critical disease. The proportion of participants who were intubated at study inclusion also varied from 5% to 95%. Only six trials reported vaccination status; there were no vaccinated participants included in these trials, and 17 trials were conducted before vaccination was rolled out. </p> <p>We assessed a total of six treatments, each compared to placebo or standard care. Twenty trials assessed tocilizumab, nine assessed sarilumab, and two assessed clazakizumab. Only one trial was included for each of the other IL‐6 blocking agents (siltuximab, olokizumab, and levilimab). Two trials assessed more than one treatment. </p> <p><b>Efficacy and safety of tocilizumab and sarilumab compared to standard care or placebo for treating COVID‐19</b> </p> <p>At day (D) 28, tocilizumab and sarilumab probably result in little or no increase in clinical improvement (tocilizumab: risk ratio (RR) 1.05, 95% confidence interval (CI) 1.00 to 1.11; 15 RCTs, 6116 participants; moderate‐certainty evidence; sarilumab: RR 0.99, 95% CI 0.94 to 1.05; 7 RCTs, 2425 participants; moderate‐certainty evidence). For clinical improvement at ≥ D60, the certainty of evidence is very low for both tocilizumab (RR 1.10, 95% CI 0.81 to 1.48; 1 RCT, 97 participants; very low‐certainty evidence) and sarilumab (RR 1.22, 95% CI 0.91 to 1.63; 2 RCTs, 239 participants; very low‐certainty evidence). </p> <p>The effect of tocilizumab on the proportion of participants with a WHO Clinical Progression Score (WHO‐CPS) of level 7 or above remains uncertain at D28 (RR 0.90, 95% CI 0.72 to 1.12; 13 RCTs, 2117 participants; low‐certainty evidence) and that for sarilumab very uncertain (RR 1.10, 95% CI 0.90 to 1.33; 5 RCTs, 886 participants; very low‐certainty evidence). </p> <p>Tocilizumab reduces all cause‐mortality at D28 compared to standard care/placebo (RR 0.88, 95% CI 0.81 to 0.94; 18 RCTs, 7428 participants; high‐certainty evidence). The evidence about the effect of sarilumab on this outcome is very uncertain (RR 1.06, 95% CI 0.86 to 1.30; 9 RCTs, 3305 participants; very low‐certainty evidence). </p> <p>The evidence is uncertain for all cause‐mortality at ≥ D60 for tocilizumab (RR 0.91, 95% CI 0.80 to 1.04; 9 RCTs, 2775 participants; low‐certainty evidence) and very uncertain for sarilumab (RR 0.95, 95% CI 0.84 to 1.07; 6 RCTs, 3379 participants; very low‐certainty evidence). </p> <p>Tocilizumab probably results in little to no difference in the risk of adverse events (RR 1.03, 95% CI 0.95 to 1.12; 9 RCTs, 1811 participants; moderate‐certainty evidence). The evidence about adverse events for sarilumab is uncertain (RR 1.12, 95% CI 0.97 to 1.28; 4 RCT, 860 participants; low‐certainty evidence).  </p> <p>The evidence about serious adverse events is very uncertain for tocilizumab (RR 0.93, 95% CI 0.81 to 1.07; 16 RCTs; 2974 participants; very low‐certainty evidence) and uncertain for sarilumab (RR 1.09, 95% CI 0.97 to 1.21; 6 RCTs; 2936 participants; low‐certainty evidence). </p> <p><b>Efficacy and safety of clazakizumab, olokizumab, siltuximab and levilimab compared to standard care or placebo for treating COVID‐19</b> </p> <p>The evidence about the effects of clazakizumab, olokizumab, siltuximab, and levilimab comes from only one or two studies for each blocking agent, and is uncertain or very uncertain. </p> </section> <section id="CD013881-sec-0007"> <h3 class="title" id="CD013881-sec-0007">Authors' conclusions</h3> <p>In hospitalized people with COVID‐19, results show a beneficial effect of tocilizumab on all‐cause mortality in the short term and probably little or no difference in the risk of adverse events compared to standard care alone or placebo. Nevertheless, both tocilizumab and sarilumab probably result in little or no increase in clinical improvement at D28. </p> <p>Evidence for an effect of sarilumab and the other IL‐6 blocking agents on critical outcomes is uncertain or very uncertain. Most of the trials included in our review were done before the waves of different variants of concern and before vaccination was rolled out on a large scale. </p> <p>An additional 17 RCTs of IL‐6 blocking agents are currently registered with no results yet reported. The number of pending studies and the number of participants planned is low. Consequently, we will not publish further updates of this review. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013881-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013881-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD013881-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD013881-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013881-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013881-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013881-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013881-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013881-abs-0011">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD013881-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013881-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013881-abs-0002" lang="en"> <h3>Are medicines that block interleukin‐6 (a protein involved when the body’s immune system overreacts) effective treatments for COVID‐19 and do they cause unwanted effects? </h3> <p><b>Key messages</b> </p> <p>We are very confident that tocilizumab (a medicine that blocks interleukin‐6 (IL‐6)) reduces the number of hospitalized people who die from COVID‐19 within 28 days of treatment. However, it probably results in little or no difference in clinical improvement (defined as leaving the hospital or improvement in COVID‐19 symptoms).  </p> <p>Sarilumab probably results in little or no difference in clinical improvement. </p> <p>We found few studies assessing the other IL‐6‐blocking medicines. We are, therefore, uncertain about their effects. </p> <p>A small number of studies have not published any results. These studies treated relatively low numbers of people and their results would not change our current findings. </p> <p><b>What is IL‐6, and what is its role in COVID‐19?</b> </p> <p>IL‐6 is a type of protein called a cytokine, which helps to regulate the body’s immune system. In particular, IL‐6 triggers inflammation to help the body recognize and fight infection to defend itself against harmful substances, such as viruses. </p> <p>When a person has COVID‐19 it can disrupt their immune system response, causing it to overreact. When the body continually makes IL‐6 as part of this response, it can produce high levels of inflammation that damage the body. This can lead to severe breathing difficulties, organ failure and death. </p> <p><b>What are IL‐6 blocking agents?</b> </p> <p>IL‐6 blocking agents are medicines that stop the IL‐6 from working by blocking signals from IL‐6 to other parts of the immune system. This reduces inflammation and may help the immune system to fight COVID‐19. In turn, this may reduce the need for breathing support with a ventilator (a machine that breathes for a patient) and reduce the number of deaths from COVID‐19. These are already known to be safe and effective when they are used to treat conditions that involve an 'overreactive' immune system, such as rheumatoid arthritis. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to know if IL‐6 blocking agents are effective treatments for people with COVID‐19, compared with standard care alone or with placebo (a dummy treatment that appears identical to the medicine being tested but without any active medicine). We were particularly interested in the effects of IL‐6 blocking agents on: </p> <p>‐ whether people’s symptoms got better or worse;</p> <p>‐ how many people died; and</p> <p>‐ any unwanted effects and serious unwanted effects.</p> <p><b>What did we do?</b> </p> <p>We searched for studies that tested if medicines that block interleukin‐6 can treat COVID‐19 effectively. We looked for randomized controlled studies in which the treatments people received are decided by chance. We compared and summarized the results of the studies. We used a standardized method to rate our confidence in the evidence. The confidence is based on study features such as study design and the number of people included. </p> <p><b>What did we find?</b> </p> <p>We found 32 studies in 12,160 people with COVID‐19. The average age of people was 56 to 75 years, and 66% of the participants were men. The studies took place at hospitals in different countries around the world. Eight studies were funded by pharmaceutical companies. </p> <p>The medicines most tested were tocilizumab and sarilumab. </p> <p>We found 17 additional registered studies of IL‐6‐blocking medicines to treat COVID‐19; these studies have no published results. Ten of these studies have either been completed or are still in progress. Seven were terminated.  </p> <p><b>What are the main results of our review?</b> </p> <p>Compared to placebo or standard treatment, treatment with tocilizumab:</p> <p>‐ reduces the number of people with COVID‐19 dying, of any cause, around 28 days;</p> <p>‐ probably makes little or no difference on clinical improvement around 28 days;</p> <p>‐ probably results in little or no difference in unwanted effects.</p> <p>We are uncertain about the effects of tocilizumab treatment on:</p> <p>‐ clinical improvement around 60 days;</p> <p>‐ severity of COVID‐19; that is, how many patients needed a ventilator or additional organ support or died of COVID‐19 around 28 days; </p> <p>‐ how many patients die, of any cause, around 60 days.</p> <p>Compared to placebo or standard treatment, treatment with sarilumab:</p> <p>‐ probably makes little or no difference in clinical improvement (defined as leaving the hospital or improvement in COVID‐19 symptoms) around 28 days. </p> <p>We are uncertain about the treatment effects and unwanted events of sarilumab, clazakizumab, olokizumab, siltuximab, and levilimab, compared to placebo or standard treatment.  </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the results of clazakizumab, olokizumab, siltuximab, and levilimab is limited because of the low number of studies conducted and the small number of people included in these studies. We were unable to assess the variation in effects due to changes in the standard treatment provided, and we were also unable to see if effects were different in people of different ages or genders. </p> <p>Further, most of the studies included in the review were conducted before the waves of different variants of concern and before vaccination was rolled out on a large scale.   </p> <p><b>How up to date is this evidence?</b>  </p> <p>The evidence is up to date to 7 June 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013881-sec-0137" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013881-sec-0137"></div> <h3 class="title" id="CD013881-sec-0138">Implications for practice</h3> <section id="CD013881-sec-0138"> <p>In people hospitalized with COVID‐19, tocilizumab reduces all‐cause mortality at day 28 (D28) and probably results in little or no difference in the risk of adverse events. Nevertheless, evidence suggests that treatment with either tocilizumab or sarilumab probably results in little or no increase in clinical improvement at D28, and the evidence for their efficacy on other outcomes is uncertain.  </p> <p>Evidence for an effect of each of the other interleukin‐6 (IL‐6) blocking agents, namely, clazakizumab, olokizumab, siltuximab, and levilimab, is uncertain or very uncertain, mainly due to the low number of events and participants. Moreover, most evidence comes from the wild‐type form of the SARS‐CoV2 virus in unvaccinated patients. </p> </section> <h3 class="title" id="CD013881-sec-0139">Implications for research</h3> <section id="CD013881-sec-0139"> <p>For this update of a living systematic review investigating the efficacy and safety of Il‐6 blocking agents for people hospitalized with COVID‐19, we have included data from 32 randomized trials involving 12,160 randomized participants. </p> <p>Little evidence is expected from further trials for IL‐6 blocking agents. Tocilizumab has been provided in clinical practice for treating people with COVID‐19; this will allow for additional information that may show up from real‐world data. With the data available, we were not able to explore heterogeneity related to age and gender. Additionally, we could not provide information on immunocompromised people or the most clinically vulnerable people. Individual participant data meta‐analyses are needed to be able to identify the subgroups of people who are more likely to benefit from this treatment.  </p> <p>The findings of this review have been updated on the COVID‐NMA platform (<a href="https://covid-nma.com/" target="_blank">covid-nma.com</a>) up to 27 September 2022. On this date, the COVID‐NMA initiative set the last search date for this review on IL‐6 blocking agents and other treatment interventions for hospitalized patients. We are unlikely to publish a new update of this review unless there are future trials that show major effects that are likely to alter the conclusions of this review and change treatment decisions. It is worth noting that further analysis can be performed through the metaCOVID tool within the COVID‐NMA platform (<a href="https://covid-nma.com/metacovid/" target="_blank">covid-nma.com/metacovid/</a>). This web application allows the end‐users of the COVID‐NMA platform to directly use the latest COVID‐NMA database and perform meta‐analyses tailored to their needs in a user‐friendly environment. The results of all analyses are summarized in the form of downloadable forest plots. A key feature of the application is that the numerical results are presented alongside study characteristics and risk of bias assessments (<a href="./references#CD013881-bbs2-0071" title="EvrenoglouT , BoutronI , ChaimaniA . metaCOVID: An R-Shiny application for living meta-analyses of COVID-19 trials. medRxiv 2021 [Preprint]. [DOI: doi.org/10.1101/2021.09.07.21263207]">Evrenoglou 2021</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013881-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013881-sec-0008"></div> <div class="table" id="CD013881-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Tociliuzumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Tociliuzumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19<sup>a</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild/moderate/severe/critical COVID‐19 </p> <p><b>Setting:</b> hospital inpatients worldwide </p> <p><b>Intervention:</b> tocilizumab </p> <p><b>Comparison:</b> standard care/placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard care/placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with tocilizumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D28<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>545 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>573 per 1000</b><br/>(545 to 605) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/>(1.00 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6116<br/>(15 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D60 or more<sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>609 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>670 per 1000</b><br/>(493 to 901) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b><br/>(0.81 to 1.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>h,i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO progression score (level 7 or above) D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>217 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>196 per 1000</b><br/>(157 to 244) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b><br/>(0.72 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2117<br/>(13 RCTs)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>j,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>284 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b><br/>(230 to 267) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b><br/>(0.81 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7428<br/>(18 RCTs)<sup>m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One additional study (<a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>) also reported on the outcome in 26 participants. There were zero events in both groups and the study not contribute to the pooled effect estimate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D60 or more</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>264 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b><br/>(211 to 274) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b><br/>(0.80 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2775<br/>(9 RCTs)<sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>j,o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One additional study (<a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>) also reported on the outcome in 26 participants. There were zero events in both groups and the study not contribute to the pooled effect estimate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>443 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>456 per 1000</b><br/>(421 to 496) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b><br/>(0.95 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1811<br/>(9 RCTs)<sup>p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>q,r</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>156 per 1000</b><br/>(136 to 180) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b><br/>(0.81 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2974<br/>(16 RCTs)<sup>s</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>j,r,t</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One additional study (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>) also reported on the outcome in 21 participants. There were zero events in both groups and the study not contribute to the pooled effect estimate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; D: day; RCT: randomized controlled trial; RR: risk ratio; WHO: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 22 July 2022<br/><sup>b</sup>Defined as a decrease in score by at least 2 points on the 7‐category ordinal scale (<a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>); an increase of at least 2 points on a 6‐category ordinal scale (compared with the worst status at day of randomization) or discharge from the hospital alive (<a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>); discharged at 28‐days (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>); not admitted to hospital (discharged alive) (<a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>).<br/><sup>c</sup><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a><br/><sup>d</sup>Despite some concerns or high risk regarding adequate randomization, deviations from intended interventions, missing data, outcome measurement and selection of reported results, not downgraded for risk of bias because the studies with these concerns contributed only a small proportion of weight to the effect estimate.<br/><sup>e</sup>Imprecision downgraded by 1 level: wide confidence interval consistent with the possibility for benefit and the possibility for a trivial/no effect<br/><sup>f</sup>Defined as hospital discharge.<br/><sup>g</sup><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a><br/><sup>h</sup>Risk of bias downgraded by 1 level: some concerns regarding missing data and outcome measurement.<br/><sup>i</sup>Indirectness downgraded by 1 level: despite a multicenter design this is a single study from a single country, therefore results in this population might not be generalizable to other settings.<br/><sup>j</sup>Imprecision downgraded by 2 levels: very wide confidence interval consistent with the possibility for benefit and the possibility for harm.<br/><sup>k</sup><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a><br/><sup>l</sup>Despite some concerns or high risk regarding adequate randomization, deviations from intended interventions, and selection of reported results, not downgraded for risk of bias because the studies with these concerns contributed only a small proportion of weight to the effect estimate.<br/><sup>m</sup><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a><br/><sup>n</sup><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a><br/><sup>o</sup>Despite some concerns or high risk regarding adequate randomization, deviations from intended interventions, and missing data, not downgraded for risk of bias because the studies with these concerns contributed only a small proportion of weight to the effect estimate.<br/><sup>p</sup><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a><br/><sup>q</sup>Imprecision downgraded by 1 level: wide confidence interval consistent with the possibility for a trivial/no effect and the possibility for harm.<br/><sup>r</sup>One additional study was identified that assessed this outcome (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>), but no results were reported.<br/><sup>s</sup><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a><br/><sup>t</sup>Risk of bias downgraded by 1 level: some concerns regarding adequate randomization, deviations from intended interventions, missing data, outcome measurement and selection of the reported results. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013881-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sarilumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Sarilumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19<sup>a</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild/moderate/severe/critical COVID‐19 </p> <p><b>Setting:</b> hospital inpatients worldwide </p> <p><b>Intervention:</b> sarilumab </p> <p><b>Comparison:</b> standard care/placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with<br/>standard<br/>care/placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sarilumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D28<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>643 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>637 per 1000</b><br/>(604 to 675) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b><br/>(0.94 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2425<br/>(7 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D60 or more<sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>628 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>766 per 1000</b><br/>(572 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b><br/>(0.91 to 1.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>g,h,i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO progression score (level 7 or above) D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>275 per 1000</b><br/>(225 to 333) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b><br/>(0.90 to 1.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>886<br/>(5 RCTs)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>j,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>224 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>238 per 1000</b><br/>(193 to 292) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b><br/>(0.86 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3305<br/>(9 RCTs)<sup>m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>j,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D60 or more</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>294 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>279 per 1000</b><br/>(247 to 314) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b><br/>(0.84 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3379<br/>(6 RCTs)<sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>j,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>408 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>457 per 1000</b><br/>(396 to 522) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b><br/>(0.97 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>860<br/>(4 RCTs)<sup>o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>p,q,r</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>243 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>265 per 1000</b><br/>(236 to 294) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.09</b><br/>(0.97 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2936<br/>(6 RCTs)<sup>s</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>q,r,t</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; D: day; RCT: randomized controlled trial; RR: risk ratio; WHO: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 6 September 2022<br/><sup>b</sup>Defined as discharge at day 28 (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>); as a 2‐point rise in a 7‐category ordinal scale or hospital discharge, whichever occurred first (<a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>); as proportion with 1‐point improvement in clinical status using a 7‐point ordinal scale on day 22 (<a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>).<br/><sup>c</sup><a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (phase 2 and 3)<br/><sup>d</sup>Risk of bias downgraded by 1 level: some concerns regarding adequate randomization, deviations from intended intervention, missing data, outcome measurement and selection of the reported result.<br/><sup>e</sup>Defined as hospital discharge.<br/><sup>f</sup><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a><br/><sup>g</sup>Risk of bias downgraded by 1 level: some concerns regarding deviation from intended intervention, missing data, outcome measurement and selection of the reported results<br/><sup>h</sup>Inconsistency downgraded by 1 level: I² = 50.1%<br/><sup>i</sup>Indirectness downgraded by 1 level: studies from a single country, therefore results in this population might not be generalizable to other settings.<br/><sup>j</sup>Imprecision downgraded by 2 levels: very wide confidence interval consistent with the possibility for benefit and the possibility for harm<br/><sup>k</sup><a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (phase 2)<br/><sup>l</sup>Risk of bias downgraded by 1 level: some concerns regarding adequate randomization, deviations from intended interventions, and missing data<br/><sup>m</sup><a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (phase 2 and 3)<br/><sup>n</sup><a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (phase 2)<br/><sup>o</sup><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a><br/><sup>p</sup>Risk of bias downgraded by 1 level: some concerns regarding deviations from intended intervention, missing data, outcome measurement and selection of the reported results.<br/><sup>q</sup>Imprecision downgraded by 1 level: wide confidence interval consistent with the possibility for no effect/trivial effect and the possibility for harm.<br/><sup>r</sup>One additional study was identified that assessed this outcome (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>), but no results were reported.<br/><sup>s</sup><a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (phase 2)<br/><sup>t</sup>Risk of bias downgraded by 1 level: some concerns regarding adequate randomization, deviations from intended intervention, missing data, and outcome measurement. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013881-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Clazakizumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Clazakizumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19<sup>a</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild/moderate/severe/critical COVID‐19 </p> <p><b>Setting:</b> hospital inpatients worldwide </p> <p><b>Intervention:</b> clazakizumab </p> <p><b>Comparison:</b> standard care/placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard care/placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with clazakizumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D28<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>640 per 1000</b><br/>(485 to 850) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.28</b><br/>(0.97 to 1.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D60 or more</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>541 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>692 per 1000</b><br/>(535 to 897) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.28</b><br/>(0.99 to 1.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO progression score (level 7 or above) D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>446 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>294 per 1000</b><br/>(192 to 450) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.66</b><br/>(0.43 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>253 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1000</b><br/>(137 to 392) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.91</b><br/>(0.54 to 1.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>g,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D60 or more</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>361 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>278 per 1000</b><br/>(177 to 430) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.77</b><br/>(0.49 to 1.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>g,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>251 per 1000</b><br/>(44 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.12</b><br/>(0.20 to 6.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17<br/>(1 RCT)<sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>h,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>434 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>299 per 1000</b><br/>(200 to 451) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.69</b><br/>(0.46 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>h,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; D: day; RCT: randomized controlled trial; RR: risk ratio; WHO: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 21 July 2022<br/><sup>b</sup>Defined as change in clinical status, defined by an improvement in status by at least 2 score points on WHO 11‐point ordinal scale.<br/><sup>c</sup><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a><br/><sup>d</sup>Indirectness downgraded by 1 level: despite a multicenter design this is a single study from a single country, therefore results in this population might not be generalizable to other settings.<br/><sup>e</sup>Imprecision downgraded by 2 levels: due to wide confidence interval consistent with the possibility for benefit and the possibility of no effect/trivial effect and small sample. <br/><sup>f</sup><a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a><br/><sup>g</sup>Indirectness downgraded by 1 level: studies from a single country, therefore results in this population might not be generalizable to other settings.<br/><sup>h</sup>Imprecision downgraded by 2 levels: very wide confidence interval consistent with the possibility for benefit and the possibility for harm. <br/><sup>i</sup><a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a><br/><sup>j</sup>We presume that the adverse event rates, and the corresponding relative risks, are similar across diverse settings; therefore not downgraded for indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013881-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Olokizumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Olokizumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19<sup>a</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild/moderate/severe/critical COVID‐19 </p> <p><b>Setting:</b> hospital inpatients worldwide </p> <p><b>Intervention:</b> olokizumab </p> <p><b>Comparison:</b> standard care/placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard care/placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with olokizumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D28<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>758 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>834 per 1000</b><br/>(728 to 940) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b><br/>(0.96 to 1.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D60 or more ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO progression score (level 7 or above) D28 ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b><br/>(27 to 198) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.50</b><br/>(0.55 to 4.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D60 or more ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b><br/>(33 to 197) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b><br/>(0.51 to 3.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,g,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; D: day; RCT: randomized controlled trial; RR: risk ratio; WHO: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 29 June 2022<br/><sup>b</sup>Defined as the proportion of patients with an improvement in clinical status by 2 or more points on the 6‐point ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) during the study with no use of tocilizumab or sarilumab. <br/><sup>c</sup><a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a><br/><sup>d</sup>Risk of bias downgraded by 1 level: some concerns regarding adequate randomization and deviations from intended interventions.<br/><sup>e</sup>Indirectness downgraded by 1 level: despite a multicenter design this is a single study from a single country, therefore results in this population might not be generalizable to other settings.<br/><sup>f</sup>Imprecision downgraded by 2 levels: wide confidence interval consistent with the possibility for benefit and the possibility for trivial effect/no effect, and small sample size.<br/><sup>g</sup>Imprecision downgraded by 2 levels: very wide confidence interval consistent with the possibility for benefit and the possibility for harm.<br/><sup>h</sup>We presume that the adverse event rates and the corresponding relative risks are similar across diverse settings; therefore not downgraded for indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013881-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Siltuximab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Siltuximab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19<sup>a</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild/moderate/severe/critical COVID‐19 </p> <p><b>Setting:</b> hospital inpatients worldwide </p> <p><b>Intervention:</b> siltuximab </p> <p><b>Comparison:</b> standard care/placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard care/placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with siltuximab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D28<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>736 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b><br/>(582 to 869) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b><br/>(0.79 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D60 or more ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO progression score (level 7 or above) D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b><br/>(178 to 605) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.97</b><br/>(1.07 to 3.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>131 per 1000</b><br/>(53 to 327) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.35</b><br/>(0.54 to 3.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D60 or more</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>198 per 1000</b><br/>(93 to 423) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.58</b><br/>(0.74 to 3.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>197 per 1000</b><br/>(98 to 400) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b><br/>(0.64 to 2.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>e,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; D: day; RCT: randomized controlled trial; RR: risk ratio; WHO: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 21 July 2022<br/><sup>b</sup>Defined as an increase of at least 2 points on a 6‐category ordinal scale (compared with the worst status at day of randomization) or discharge from the hospital alive.<br/><sup>c</sup><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a><br/><sup>d</sup>Indirectness downgraded by 1 level: despite a multicenter design this is a single study from a single country, therefore results in this population might not be generalizable to other settings.<br/><sup>e</sup>Imprecision downgraded by 2 levels: very wide confidence interval consistent with the possibility for benefit and the possibility for harm.<br/><sup>f</sup>Imprecision downgraded by 1 level: low number of events and/or participants.<br/><sup>g</sup>We presume that the adverse event rates and the corresponding relative risks are similar across diverse settings; therefore not downgraded for indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013881-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Levilimab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Levilimab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19<sup>a</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild/moderate/severe/critical COVID‐19 </p> <p><b>Setting:</b> hospital inpatients worldwide </p> <p><b>Intervention:</b> levilimab </p> <p><b>Comparison:</b> standard care/placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard care/placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with levilimab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D28<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>553 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>847 per</b> 1000<br/>(697 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.53</b><br/>(1.26 to 1.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D60 or more ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO progression score (level 7 or above) D28 ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per</b> 1000<br/>(10 to 151) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/>(0.26 to 3.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D60 or more</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per</b> 1000<br/>(10 to 151) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/>(0.26 to 3.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>233 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273 per</b> 1000<br/>(170 to 436) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.17</b><br/>(0.73 to 1.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per</b> 1000<br/>(1 to 105) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b><br/>(0.05 to 5.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 29 June 2022<br/><sup>b</sup>Defined as an improvement of 2 or more point scales of clinical status from baseline on the 7‐category ordinal scale or reaching the clinical status of categories 1 or 2 on Day 14.<br/><sup>c</sup><a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a><br/><sup>d</sup>Indirectness downgraded by 1 level: despite a multicenter design this is a single study from a single country, therefore results in this population might not be generalizable to other settings.<br/><sup>e</sup>Imprecision downgraded by 1 level: small sample size.<br/><sup>f</sup>Imprecision downgraded by 2 levels: very wide confidence interval consistent with the possibility for benefit and the possibility for harm.<br/><sup>g</sup>We presume that the adverse event rates and the corresponding relative risks are similar across diverse settings; therefore not downgraded for indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013881-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013881-sec-0009"></div> <section id="CD013881-sec-0010"> <h3 class="title" id="CD013881-sec-0010">Description of the condition</h3> <p>Coronavirus disease 2019 (COVID‐19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). SARS‐CoV‐2 was first recognized in China in December 2019 and declared as a pandemic on 11 March 2020 by the World Health Organization (WHO). As of July 2022, over 565 million cases have been confirmed worldwide, including more than 6.3 million deaths (<a href="./references#CD013881-bbs2-0124" title="Coronavirus Symptoms (COVID-19) - Worldometer. Coronavirus Symptoms (COVID-19). www.worldometers.info/coronavirus/coronavirus-symptoms/ (accessed on 19 July 2022).">Worldometers 2022</a>). The clinical spectrum of SARS‐CoV‐2 pneumonia ranges from asymptomatic or mild to severe and critical manifestations. Approximately 15% to 30% of patients infected with the wild‐type variant of SARS‐CoV‐2 suffered from acute respiratory distress syndrome (<a href="./references#CD013881-bbs2-0057" title="AttawayAH , ScheragaRG , BhimrajA , BiehlM , HatipoğluU . Severe covid-19 pneumonia: pathogenesis and clinical management. BMJ2021;372:n436.">Attaway 2021</a>). Persons with underlying conditions and weakened immune systems are at higher risk of severe illness (<a href="./references#CD013881-bbs2-0082" title="JuulS , NielsenEE , FeinbergJ , SiddiquiF , JørgensenCK , BarotE , et al. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS One2021;16(3):e0248132.">Juul 2021</a>).  </p> <p>Enormous efforts have focused on finding treatments to reduce the need for invasive mechanical ventilation and/or the risk of death in these patients. Some treatments have shown to be promising, including interleukin 6 (IL‐6) inhibitors (<a href="./references#CD013881-bbs2-0081" title="HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine2021;384(8):693-704.">Horby 2021a</a>). </p> <p>People with severe COVID‐19 experience a “cytokine storm syndrome”; a complex milieu of immune misfiring characterized by an early interferonopathy followed by hypercytokinemia with high inflammatory markers and low reparative growth factors (<a href="./references#CD013881-bbs2-0059" title="BastardP , RosenLB , ZhangQ , MichailidisE , HoffmannHH , ZhangY , et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science2020;370(6515):eabd4585. [DOI: 10.1126/science.abd4585] [PMID: 32972996]">Bastard 2020</a>; <a href="./references#CD013881-bbs2-0072" title="GalaniIE , RovinaN , LampropoulouV , TriantafylliaV , ManioudakiM , PavlosE , et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nature Immunology2021;22(1):32-40. [DOI: 10.1038/s41590-020-00840-x] [PMID: 33277638]">Galani 2020</a>; <a href="./references#CD013881-bbs2-0091" title="LucasC , WongP , KleinJ , CastroTBR , SilvaJ , SundaramM , et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature2020;584(7821):463-9.">Lucas 2020</a>; <a href="./references#CD013881-bbs2-0095" title="MehtaP , McAuleyDF , BrownM , SanchezE , TattersallRS , MansonJJ , HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet2020;395(10229):1033-4. [DOI: 10.1016/S0140-6736(20)30628-0] [PMID: 32192578]">Mehta 2020</a>; <a href="./references#CD013881-bbs2-0100" title="PedersenSF , HoYC . SARS-CoV-2: a storm is raging. Journal of Clinical Investigation2020;130(5):2202-5. [DOI: 10.1172/JCI137647] [PMID: 32217834]">Pedersen 2020</a>). In this milieu, interleukin 6 (IL‐6) stands out as a particularly important biomarker (<a href="./references#CD013881-bbs2-0068" title="ChenLY , HoilandRL , StukasS , WellingtonCL , SekhonMS . Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome. European Respiratory Journal2020;56(4):2003006. [DOI: 10.1183/13993003.03006-2020] [PMID: 32883678]">Chen 2020</a>; <a href="./references#CD013881-bbs2-0077" title="HeroldT , JurinovicV , ArnreichC , LipworthBJ , HellmuthJC , vonBergwelt-BaildonM , et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. Journal of Allergy and Clinical Immunology2020;146(1):128-36.e4. [DOI: 10.1016/j.jaci.2020.05.008] [PMID: 32425269]">Herold 2020</a>; <a href="./references#CD013881-bbs2-0090" title="Laguna-GoyaR , Utrero-RicoA , TalayeroP , Lasa-LazaroM , Ramirez-FernandezA , NaranjoL , et al. IL-6-based mortality risk model for hospitalized patients with COVID-19. Journal of Allergy and Clinical Immunology2020;146(4):799-807. [DOI: 10.1016/j.jaci.2020.07.009] [PMID: 32710975]">Laguna‐Goya 2020</a>; <a href="./references#CD013881-bbs2-0111" title="StukasS , HoilandRL , CooperJ , ThiaraS , GriesdaleDE , ThomasAD , et al. The association of inflammatory cytokines in the pulmonary pathophysiology of respiratory failure in critically ill patients with Coronavirus Disease 2019. Critical Care Explorations2020;2(9):e0203. [DOI: 10.1097/CCE.0000000000000203] [PMID: 33063041]">Stukas 2020</a>). IL‐6 levels or C‐reactive protein (CRP), a marker of IL‐6‐driven inflammation, are associated with the severity of the disease (<a href="./references#CD013881-bbs2-0066" title="CaricchioR , GallucciM , DassC , ZhangX , GallucciS , FleeceD , et al, Temple University COVID-19 Research Group. Preliminary predictive criteria for COVID-19 cytokine storm. Annals of the Rheumatic Diseases2021;80(1):88-95. [DOI: 10.1136/annrheumdis-2020-218323] [PMID: 32978237]">Caricchio 2020</a>; <a href="./references#CD013881-bbs2-0073" title="Galván-RománJM , Rodríguez-GarcíaSC , Roy-VallejoE , Marcos-JiménezA , Sánchez-AlonsoS , Fernández-DíazC , et al, REINMUN-COVID Group. IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study. Journal of Allergy and Clinical Immunology2021;147(1):72-80. [DOI: 10.1016/j.jaci.2020.09.018] [PMID: 33010257]">Galvan‐Roman 2021</a>; <a href="./references#CD013881-bbs2-0092" title="MansonJJ , CrooksC , NajaM , LedlieA , GouldenB , LiddleT , et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. The Lancet Rheumatology2020;2(10):e594-602. [DOI: 10.1016/S2665-9913(20)30275-7] [PMID: 32864628]">Manson 2020</a>; <a href="./references#CD013881-bbs2-0118" title="WebbBJ , PeltanID , JensenP , HodaD , HunterB , SilverA , et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. The Lancet Rheumatology2020;2(12):e754-63. [DOI: 10.1016/S2665-9913(20)30343-X] [PMID: 33015645]">Webb 2020</a>). </p> </section> <section id="CD013881-sec-0011"> <h3 class="title" id="CD013881-sec-0011">Description of the intervention</h3> <p>IL‐6 blocking agents are a class of therapeutic agents directed against the IL‐6 peptide or receptor that decrease the activity of inflammatory cytokines; thus, they are commonly prescribed in autoimmune diseases and other hyperinflammatory states (<a href="./references#CD013881-bbs2-0078" title="HertantoDM , WiratamaBS , SutantoH , WunguCDK . Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future. Journal of Inflammation Research2021;14:3419-3428.">Hertanto 2021</a>; <a href="./references#CD013881-bbs2-0106" title="ScottLJ . Tocilizumab: a review in rheumatoid arthritis. Drugs2017;77(17):1865-79. [PMID: 29094311]">Scott 2017</a>; <a href="./references#CD013881-bbs2-0110" title="StoneJH , TuckwellK , DimonacoS , KlearmanM , AringerM , BlockmansD , et al. Trial of tocilizumab in giant-cell arteritis. New England Journal of Medicine2017;377(4):317-28. [DOI: 10.1056/NEJMoa1613849] [PMID: 28745999]">Stone 2017</a>). Available IL‐6 blocking agents are classified as anti‐IL‐6 receptor monoclonal antibodies (e.g., sarilumab, tocilizumab, and levilimab) or anti‐IL‐6 monoclonal antibodies (siltuximab, olokizumab, and clazakizumab).  </p> </section> <section id="CD013881-sec-0012"> <h3 class="title" id="CD013881-sec-0012">How the intervention might work</h3> <p>It has been reported that pre‐existing autoantibodies neutralizing type I interferons and subsequent high levels of IL‐6 are positively associated with outcomes such as the need for intensive care and death in COVID‐19 patients (<a href="./references#CD013881-bbs2-0115" title="Utrero-RicoA , Ruiz-HornillosJ , González-CuadradoC , RitaCG , AlmogueraB , MinguezP , et al. IL-6-based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts. Journal of Allergy and Clinical Immunology2021;147(5):1652-61.e1.">Utrero‐Rico 2021</a>; <a href="./references#CD013881-bbs2-0126" title="ZhangQ , BastardP , BolzeA , JouanguyE , ZhangSY , CobatA , et al. Life-threatening COVID-19: Defective interferons unleash excessive inflammation. New York Medical Journal2020;1(1):14-20.">Zhang 2020</a>). The inhibition of IL‐6, or its receptors, could curtail the risk of an escalation of the cytokine storm responsible for acute respiratory distress syndrome (ARD), a severe symptom with high mortality (<a href="./references#CD013881-bbs2-0074" title="GhosnL , ChaimaniA , EvrenoglouT , DavidsonM , GrañaC , SchmuckerC , et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 3. Art. No: CD013881. [DOI: 10.1002/14651858.CD013881]">Ghosn 2021</a>; <a href="./references#CD013881-bbs2-0080" title="HojyoS , UchidaM , TanakaK , HasebeR , TanakaY , MurakamiM , HiranoT . How COVID-19 induces cytokine storm with high mortality. Inflammation and Regeneration2020;40:37.">Hojyo 2020</a>; <a href="./references#CD013881-bbs2-0086" title="KimmigLM , WuD , GoldM , PettitNN , PitrakD , MuellerJ , et al. IL-6 Inhibition in critically ill COVID-19 patients is associated with increased secondary infections. Frontiers in Medicine2020;7:583897.">Kimmig 2020</a>; <a href="./references#CD013881-bbs2-0089" title="KyriazopoulouE , PoulakouG , MilionisH , MetallidisS , AdamisG , TsiakosK , et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature Medicine2021;27(10):1752-60.">Kyriazopoulou 2021</a>; <a href="./references#CD013881-bbs2-0122" title="WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA2021;326(6):499-518.">WHO REACT Working Group 2021</a>). </p> <p>There are two signaling pathways used by IL‐6; one relies on the cell membrane (IL‐6 receptor) and the second is a soluble receptor (IL‐6 signal transducer). Available IL‐6 inhibitors bind specifically to the IL‐6 receptor, blocking the signaling cascade (<a href="./references#CD013881-bbs2-0084" title="KangS , NarazakiM , MetwallyH , KishimotoT . Historical overview of the interleukin-6 family cytokine. Journal of Experimental Medicine2020;217(5):e20190347. Erratum in: Journal of Experimental Medicine 2020 May 4;217(5). [DOI: 10.1084/jem.20190347] [PMID: 32267936]">Kang 2020</a>). This immunosuppressive effect of IL‐6 blockers might valuably control inflammation and promote disease tolerance in people with COVID‐19 characterized by substantial immune system dysfunction (<a href="./references#CD013881-bbs2-0063" title="CampochiaroC , DagnaL . The conundrum of interleukin-6 blockade in COVID-19. The Lancet Rheumatology2020;2(10):e579-e80. [DOI: 10.1016/S2665-9913(20)30287-3] [PMID: 32838322]">Campochiaro 2020</a>). </p> </section> <section id="CD013881-sec-0013"> <h3 class="title" id="CD013881-sec-0013">Why it is important to do this review</h3> <p>Given the need for an effective treatment for COVID‐19 globally, people have been treated with several costly immune‐modulating compounds including JAK (janus kinase) inhibitors (<a href="./references#CD013881-bbs2-0065" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019] [PMID: 32470486]">Cao 2020</a>; <a href="./references#CD013881-bbs2-0083" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al, ACTT-2 Study Group Members. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994] [PMID: 33306283]">Kalil 2021</a>), and specific cytokine blockers (<a href="./references#CD013881-bbs2-0076" title="GuaraldiG , MeschiariM , Cozzi-LepriA , MilicJ , TonelliR , MenozziM , et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatology2020;2(8):e474-84. [DOI: 10.1016/S2665-9913(20)30173-9.] [PMID: 32835257]">Guaraldi 2020</a>). The main immunomodulatory therapies that have been explored are JAK inhibition (broad suppression of inflammatory cytokines) and targeted inhibition of IL‐1 and IL‐6 (<a href="./references#CD013881-bbs2-0069" title="CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respiratory Medicine2021;9(3):295-304. [DOI: 10.1016/S2213-2600(20)30556-7] [PMID: 33493450]">CORIMUNO‐19 Collaborative group 2021</a>). Policymakers, scientific experts and the public need high‐‐quality, up‐to‐date evidence evaluating the effectiveness and safety of IL‐6 blocking agents for treating COVID‐19. This is a high‐priority question, for which the existing evidence is inconclusive (<a href="./references#CD013881-bbs2-0108" title="Solis-García Del PozoJ , GalindoMF , NavaE , JordánJ . A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients. European Review for Medical and Pharmacological Sciences2020;24(13):7475-84. [DOI: 10.26355/eurrev_202007_21916] [PMID: 32706087]">Solis‐García Del Pozo 2020</a>). A living systematic review is an optimal approach to track and assess the effectiveness of IL‐6 blocking agents use in people with COVID‐19. </p> <p>In March 2021, we provided a summary of all the evidence available up to February 2021. It is important to continue to update the results to synthesis the newest evidence about IL‐6 blocking agents. A living systematic review is an optimal approach for tracking and assessing the effectiveness of IL‐6 blocking agents in people with COVID‐19. We provide pairwise analysis of IL‐6 blocking agents compared to standard care or placebo. </p> <p>This is an update of the first publication of this review in March 2021 (<a href="./references#CD013881-bbs2-0074" title="GhosnL , ChaimaniA , EvrenoglouT , DavidsonM , GrañaC , SchmuckerC , et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 3. Art. No: CD013881. [DOI: 10.1002/14651858.CD013881]">Ghosn 2021</a>). This updated review covers the best available evidence up to 7 June 2022; findings have also been updated on the COVID‐NMA platform (<a href="https://covid-nma.com/" target="_blank">covid-nma.com</a>) up to 27 September 2022. On this date, the COVID‐NMA Initiative has set the last search date for its review on IL‐6 blocking agents and other treatment interventions for hospitalized people. We will not publish a new update of this review unless new evidence emerges with the potential to change the certainty of the evidence or our conclusions. The process of the living systematic review is described in <a href="./appendices#CD013881-sec-0143">Appendix 1</a>. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013881-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013881-sec-0014"></div> <p>To update the evidence on the effectiveness and safety of IL‐6 blocking agents compared to standard care alone or to placebo in people with COVID‐19. </p> <p>This review is part of a larger project: the COVID‐NMA project (<a href="./references#CD013881-bbs2-0061" title="BoutronI , ChaimaniA , MeerpohlJJ , HróbjartssonA , DevaneD , RadaG , et al. The COVID-NMA project: building an evidence ecosystem for the COVID-19 pandemic. Annals of Internal Medicine2020;173(12):1015-7. [DOI: 10.7326/M20-5261] [PMID: 32931326]">Boutron 2020a</a>), which provides decision‐makers with a complete, high‐quality, and up‐to‐date mapping and synthesis of evidence on interventions for preventing and treating COVID‐19. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013881-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013881-sec-0015"></div> <section id="CD013881-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013881-sec-0017"> <h4 class="title">Types of studies</h4> <p>The protocol of this review update is available on PROSPERO (<a href="./references#CD013881-bbs2-0128" title="GhosnL , BoutronI . Interleukin (IL)-6 blocking agents for the treatment of COVID-19. A living systematic review. PROSPERO 2020 CRD42020214700. Available from: www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020214700 (first received 29 October 2020).">CRD42020214700</a>). The methods for the living process of the review are available in <a href="./appendices#CD013881-sec-0143">Appendix 1</a>. </p> <p>We included randomized controlled trials (RCTs) of any design (parallel‐group, cluster, cross‐over and factorial) with no language restrictions. We also included peer‐reviewed journal publications, preprints, results posted in trial registries, results provided by contacting authors and conference abstracts. Early‐phase clinical trials, single‐arm trials, non‐randomized studies, and modeling studies of interventions for COVID‐19 were excluded, as were prognostic studies, systematic reviews and meta‐analyses, and studies of diagnostic test accuracy. </p> </section> <section id="CD013881-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included trials evaluating children or adults with suspected, probable or confirmed ambulatory or hospitalized COVID‐19 regardless of severity level (see classification in <a href="./appendices#CD013881-sec-0147">Appendix 2</a>; <a href="./references#CD013881-bbs2-0121" title="World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected. Available from who.int/publications/i/item/10665-332299 (accessed 24 February 2021).">WHO 2020b</a>). </p> </section> <section id="CD013881-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included the following IL‐6 blocking agents with no restriction on dose, frequency, or mode of administration. </p> <p> <ul id="CD013881-list-0001"> <li> <p>Tocilizumab (humanized monoclonal antibody against the IL‐6 receptor)</p> </li> <li> <p>Sarilumab (human monoclonal antibody against the IL‐6 receptor)</p> </li> <li> <p>Clazakizumab (humanized rabbit monoclonal antibody against IL‐6)</p> </li> <li> <p>Olokizumab (humanized monoclonal antibody against IL‐6)</p> </li> <li> <p>Siltuximab (chimeric monoclonal antibody against IL‐6)</p> </li> <li> <p>Levilimab (human monoclonal antibody against the IL‐6 receptor)</p> </li> </ul> </p> <p>We assumed that participants receiving the intervention may have also received standard care. </p> <section id="CD013881-sec-0020"> <h5 class="title">Comparators</h5> <p>We considered the following comparators in this review: standard care alone or placebo; standard care as defined by trialists. </p> </section> </section> <section id="CD013881-sec-0021"> <h4 class="title">Types of outcome measures</h4> <p>Our outcome selection was based on the CORE outcome sets developed by the WHO (<a href="./references#CD013881-bbs2-0123" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7] [PMID: 32539990]">WHO Working Group 2020</a>), and advice from content experts. </p> <p>We predefined the following critical and important outcome measures.</p> <section id="CD013881-sec-0022"> <h5 class="title">Critical outcomes</h5> <p>We considered the following outcomes with related time points reported as days (D) of follow‐up. </p> <p> <ul id="CD013881-list-0002"> <li> <p>Clinical improvement (D28/ ≥ D60), defined as a hospital discharge or improvement on a scale used by trialists to evaluate clinical progression and recovery. We recorded the scale and the threshold used by authors to define improvement. </p> </li> <li> <p>WHO clinical progression score (WHO‐CPS) of level 7 or above, i.e. mechanical ventilation +/‐ additional organ support (extracorporeal membrane oxygenation (ECMO), vasopressors or dialysis) or death (D28/ ≥ D60) </p> </li> <li> <p>All‐cause mortality (D28/ ≥ D60</p> </li> </ul> </p> <p>All assessments performed at D60 and later were reported as under ≥ D60.</p> <section id="CD013881-sec-0023"> <h6 class="title">Safety outcomes</h6> <p> <ul id="CD013881-list-0003"> <li> <p>Any adverse events (AE)</p> </li> <li> <p>Serious adverse events (SAE)</p> </li> </ul> </p> <p>For each time point, we considered the time of randomization as D0, except if otherwise reported by authors; in that case, we followed their dating. </p> <p>When outcomes at study level were assessed at time points other than those selected by the review, we chose the closest time point (e.g. D15 for D28). </p> <p>We presented all critical outcomes in the summary of findings tables.</p> </section> </section> <section id="CD013881-sec-0024"> <h5 class="title">Important outcomes</h5> <p> <ul id="CD013881-list-0004"> <li> <p>Time to clinical improvement</p> </li> <li> <p>Time to WHO clinical progression score of level 7 or above</p> </li> <li> <p>Time to death</p> </li> </ul> </p> </section> </section> </section> <section id="CD013881-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <p>The search relied on the search strategies defined in the protocol of the larger COVID‐NMA initiative (<a href="https://covid-nma.com/" target="_blank">covid-nma.com</a>) (<a href="./references#CD013881-bbs2-0061" title="BoutronI , ChaimaniA , MeerpohlJJ , HróbjartssonA , DevaneD , RadaG , et al. The COVID-NMA project: building an evidence ecosystem for the COVID-19 pandemic. Annals of Internal Medicine2020;173(12):1015-7. [DOI: 10.7326/M20-5261] [PMID: 32931326]">Boutron 2020a</a>; <a href="./references#CD013881-bbs2-0127" title="BoutronI , ChaimaniA , DevaneD , MeerpohlJJ , RadaG , HróbjartssonA , et al. Interventions for the prevention and treatment of COVID‐19: a living mapping of research and living network meta‐analysis. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD013769. [DOI: 10.1002/14651858.CD013769]">Boutron 2020b</a>), and outlined in <a href="./appendices#CD013881-sec-0151">Appendix 3</a>. The search methods and strategies to identify records for this review were revised approximately yearly to ensure that they reflect any terminology changes in topic areas and the databases. </p> <section id="CD013881-sec-0026"> <h4 class="title">Electronic searches</h4> <p> <ul id="CD013881-list-0005"> <li> <p>The COVID‐19 Living OVerview of Evidence (L·OVE) platform (<a href="https://app.iloveevidence.com/covid19" target="_blank">app.iloveevidence.com/covid19</a>) (last search: 7 June 2022). This platform is a digital repository built by systematic searches in multiple databases, trial registries and preprint servers. Complete data sources and search methods are available at: <a href="http://app.iloveevidence.com/covid19/methods" target="_blank">app.iloveevidence.com/covid19/methods</a>. </p> </li> <li> <p>The Cochrane COVID‐19 Study Register (<a href="https://covid-19.cochrane.org/" target="_blank">covid-19.cochrane.org/</a>) (last search: 7 June 2022). This specialized register is built within the Cochrane Register of Studies (CRS) and maintained by Cochrane information specialists. </p> </li> </ul> </p> <p>Complete data sources and search methods for the register are available at: <a href="https://community.cochrane.org/about-covid-19-study-register" target="_blank">community.cochrane.org/about-covid-19-study-register</a>. </p> <p>We also searched the Retraction Watch Database for retracted trials (<a href="https://retractionwatch.com/retracted-coronavirus-covid-19-papers/" target="_blank">retractionwatch.com/retracted-coronavirus-covid-19-papers/</a>) (last search 7 June 2022). </p> <p>If no peer‐reviewed publication was available for a given study, we extracted data from the preprint. We recognize that preprints are not peer‐reviewed and are living documents that can be updated or published. Therefore, we systematically searched for updates or publications of the preprints using a preprint tracker developed in collaboration with a research team from the French National Centre for Scientific Research (CNRS) (<a href="./references#CD013881-bbs2-0062" title="CabanacG , OikonomidiT , BoutronI . Day-to-day discovery of preprint-publication links. Scientometrics2021;126(6):5285-5304.">Cabanac 2021</a>; <a href="./references#CD013881-bbs2-0097" title="OikonomidiT , BoutronI , PierreO , CabanacG , RavaudP , COVID-19 NMA Consortium. Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study. BMC Medicine2020;18(1):402. [DOI: 10.1186/s12916-020-01880-8] [PMID: 33334338]">Oikonomidi 2020</a>). As soon as an update was identified, we checked the data for discrepancies against those already extracted, recorded the data not available in the initial report, and updated the analysis if needed. </p> </section> <section id="CD013881-sec-0027"> <h4 class="title">Searching other resources</h4> <section id="CD013881-sec-0028"> <h5 class="title">Trial registries</h5> <p>We searched the following trial registries for completed trials with posted results, unpublished trials and ongoing trials (last search: 7 June 2022). </p> <p> <ul id="CD013881-list-0006"> <li> <p>The World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP, <a href="https://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>) to identify ongoing and completed clinical trials on COVID‐19. We used the List By Health Topic: 2019‐nCoV / COVID‐19 filter and retrieved all studies identified. </p> </li> <li> <p>We also search the EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu/</a>), ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>), and the Iranian Registry of Clinical Trials (<a href="https://www.irct.ir/" target="_blank">www.irct.ir/</a>). </p> </li> </ul> </p> </section> <section id="CD013881-sec-0029"> <h5 class="title">Unpublished literature</h5> <p>We searched the European Medicines Agency (EMA) clinical data website (<a href="https://clinicaldata.ema.europa.eu/web/cdp/home" target="_blank">clinicaldata.ema.europa.eu/web/cdp/home</a>) to identify trials submitted to the EMA and searched for the Clinical Study Report of eligible trials. </p> <p>We also searched the US Food and Drug Administration website to identify FDA approval trials (<a href="https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19" target="_blank">www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19</a>). </p> </section> </section> </section> <section id="CD013881-sec-0030"> <h3 class="title" id="CD013881-sec-0030">Data collection and analysis</h3> <p>We have provided access to the metaCOVID tool (<a href="https://covid-nma.com/" target="_blank">covid-nma.com</a>), which allows readers to explore the data using the latest iteration of the COVID‐NMA database (<a href="./references#CD013881-bbs2-0071" title="EvrenoglouT , BoutronI , ChaimaniA . metaCOVID: An R-Shiny application for living meta-analyses of COVID-19 trials. medRxiv 2021 [Preprint]. [DOI: doi.org/10.1101/2021.09.07.21263207]">Evrenoglou 2021</a>). </p> <section id="CD013881-sec-0031"> <h4 class="title">Selection of studies</h4> <p>We used an Excel spreadsheet to document search dates and the number of citations identified. We used the Rayyan tool to identify duplicates (<a href="./references#CD013881-bbs2-0098" title="OuzzaniM , HammadyH , FedorowiczZ , ElmagarmidA . Rayyan — a web and mobile app for systematic reviews. Systematic Reviews2016;5(1):210. [DOI: 10.1186/s13643-016-0384-4] [PMID: 27919275]">Ouzzani 2016</a>). Discrepancies on exclusion and screening of full texts were resolved by consensus between each pair of reviewers or by involving a third reviewer. We recorded the reasons for exclusion of all studies after full‐text review. </p> <p>Whenever both preprints and subsequent peer‐reviewed publications were available, we updated the results using the latest documents of the trial findings. </p> </section> <section id="CD013881-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>Pairs of reviewers independently read each preprint, peer‐reviewed publication, protocol, and other study reports, extracted needed information, evaluated the completeness of the available data to request what was missing, and assessed the risk of bias. We used a specific structured online data extraction form that allowed for double extraction. The online tool automatically identified the discrepancies between the reviewers, which they then discussed to reach consensus. </p> <p>The information extracted included study characteristics (such as first author, publication year and journal, funding source, the prevalence of variants of concerns during the study period), the number of participants randomized, participant characteristics (e.g. severity of clinical presentation), comorbidities, co‐interventions, intervention details (e.g. dose, schedule), outcome measures, and risk of bias assessment. </p> <p>Disease severity was classified as described below, according to participants’ clinical status or clinical management of participants. This classification relies on an existing classification and clinical expertise (<a href="./references#CD013881-bbs2-0120" title="World Health Organization. Rolling updates on coronavirus diseases (COVID-19). Available from www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen (accessed 24 February 2021).">WHO 2020a</a>; <a href="./references#CD013881-bbs2-0121" title="World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected. Available from who.int/publications/i/item/10665-332299 (accessed 24 February 2021).">WHO 2020b</a>). After considering the description of eligibility criteria as well as the participants’ baseline characteristics, we classified severity as follows. </p> <p> <ul id="CD013881-list-0007"> <li> <p>Ambulatory mild disease — 'outpatients' whose clinical symptoms are mild with no sign of pneumonia on imaging. </p> </li> <li> <p>Mild disease — clinical symptoms requiring hospitalization but no need for supplemental oxygen. </p> </li> <li> <p>Moderate disease — fever and respiratory symptoms with radiological findings of pneumonia and requiring standard oxygen therapy O<sub>2</sub> (3–5 L/min). </p> </li> <li> <p>Severe disease — cases meeting any of the following criteria:</p> <ul id="CD013881-list-0008"> <li> <p>respiratory distress (≧ 30 breaths/min);</p> </li> <li> <p>oxygen saturation ≤ 93% at rest in ambient air or oxygen saturation ≤ 97% with O<sub>2</sub>&gt; 5 L/min; </p> </li> <li> <p>PaO<sub>2</sub>/FiO<sub>2</sub> ≦ 300 mmHg (l mmHg = 0.133 kPa). PaO<sub>2</sub>/FiO<sub>2</sub> in high‐altitude areas (&gt; 1000 m above sea level) is corrected by the following formula: PaO<sub>2</sub>/FiO<sub>2</sub> x [atmospheric pressure (mmHg)/760]; </p> </li> <li> <p>hospitalized patients receiving non‐invasive ventilation (NIV)/high flow nasal oxygen (HFNO). </p> </li> </ul> </li> <li> <p>Critical disease — cases meeting any of the following criteria:</p> <ul id="CD013881-list-0009"> <li> <p>respiratory failure requiring invasive mechanical ventilation;</p> </li> <li> <p>shock;</p> </li> <li> <p>other organ failure requiring admission to an intensive care unit.</p> </li> </ul> </li> </ul> </p> <p>Since the classification of severity was heterogeneous among the studies, we reclassified participant disease severity according to the severity criteria above. Consequently, the severity reported by investigators might differ from the severity reported in this review. For example, <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a> classified the included participants as critical. Yet, according to our definitions, we classified them as severe or critical (patients who receive non‐invasive ventilation or high‐flow nasal cannula are rated as severely ill in the WHO classification). When no data related to these classifications were available, we requested the information from authors. </p> <p>To collect information on the prevalence of variants of concern during the trial, we extracted the information if reported in the paper; otherwise, the information was extrapolated from data about the variants’ prevalence in the population during the study period. This information was obtained from <a href="http://outbreak.info/" target="_blank">outbreak.info/</a> or other sources. </p> <p>For dichotomous outcomes, we calculated the relative risk (RR) with 95% confidence interval (CI) as a measure of effect. We extracted the number of both events and total participants in each trial arm. For time‐to‐event outcomes, we extracted the hazard ratio (HR) with 95% CI. When these were not provided, we attempted to obtain them with the tools provided in <a href="./references#CD013881-bbs2-0113" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16. [DOI: 10.1186/1745-6215-8-16] [PMID: 17555582]">Tierney 2007</a>. When credible intervals were reported instead of confidence intervals, we extracted the former. In the absence of prior information, these two are not expected to have a substantial numerical difference. For time to improvement, when available, we extracted the data with death treated as a competing risk. When several analyses were reported, we extracted results from the intention‐to‐treat (ITT) analysis whenever these were available. If ITT results were not available, we extracted results from any modified ITT analyses. </p> <p>We systematically contacted the trial authors to ask them for supplementary information unavailable from the trial reports. These data were requested by a personalized email sent by the WHO as a partner in the COVID‐NMA project. </p> </section> <section id="CD013881-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the trials with version 2 of the Cochrane risk of bias tool for randomized trials (RoB 2) (<a href="./references#CD013881-bbs2-0109" title="SterneJA , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898. [DOI: 10.1136/bmj.l4898] [PMID: 31462531]">Sterne 2019</a>). </p> <p>RoB 2 is structured into five domains: 1) risk of bias arising from the randomization process, 2) risk of bias due to deviations from intended interventions, 3) risk of bias due to missing outcome data, 4) risk of bias in the measurement of the outcome, 5) risk of bias in the selection of the reported result. A series of 'signaling questions' elicits information relevant to the risk of bias assessment within each domain. The response options to the signaling questions are: 'yes'; 'probably yes'; 'probably no'; 'no'; and 'no information'. An algorithm generates a judgment of risk of bias for each domain, based on answers to the signaling questions. Judgments can be 'low', 'some concerns' or 'high' risk. Overall risk of bias is considered 'low' if all domains are at 'low risk'; 'some concerns' if at least one domain has 'some concern' and no domain is at 'high' risk of bias; and 'high' if at least one domain is at 'high risk'.  </p> <p>We assessed the risk of bias for all critical and important outcomes as predefined in the protocol of the COVID‐NMA living systematic review (<a href="./references#CD013881-bbs2-0127" title="BoutronI , ChaimaniA , DevaneD , MeerpohlJJ , RadaG , HróbjartssonA , et al. Interventions for the prevention and treatment of COVID‐19: a living mapping of research and living network meta‐analysis. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD013769. [DOI: 10.1002/14651858.CD013769]">Boutron 2020b</a>).  </p> <p>In the context of this review update, we are interested in quantifying the effect of assignment to the interventions at baseline, regardless of whether the interventions were received as intended (i.e. ITT effect). </p> <p>We used an online data extraction tool to record judgments for each domain and time point. All risk of bias assessments were done at the outcome level by two independent review authors. Review authors had epidemiological training or were members of the Cochrane Response team. They were trained using materials developed by the Cochrane Bias Methods Group. These training materials were developed for systematic reviewers participating in data extraction and risk of bias assessment using RoB 2 for the COVID‐NMA platform (<a href="./references#CD013881-bbs2-0096" title="NejstgaardCH , FabbriA , HróbjartssonA . Training manual for RoB 2 risk of bias assessment in COVID-19 trials eligible for the COVID-19 living network meta-analysis. Available from zenodo.org/record/4928079. [DOI: 10.5281/zenodo.4928079]">Nejstgaard 2021</a>). Each review author independently assessed included manuscripts and used signaling questions for each domain of bias, fed into the related algorithm to obtain a judgment. Both review authors recorded their judgment and support for judgment. However, answers to signaling questions were not recorded. To achieve the required consensus, all disagreements in judgment were identified and discussed until consensus was reached. If needed, a third reviewer was involved.  </p> <p>In the context of the COVID‐19 pandemic, we also standardized our assessment of some domains. </p> <section id="CD013881-sec-0034"> <h5 class="title">Domain 2. Bias due to deviations from intended interventions</h5> <p>In trials where participants and carers were not blinded, we specified some deviations that could arise because of the trial context and could affect the trial outcomes: </p> <section id="CD013881-sec-0035"> <h6 class="title">Cross over from the control group to the intervention group</h6> <p>When the number of participants in the control group receiving the intervention was important, we rated this domain as of ‘some concern’.  </p> <p>When the cross‐over was planned in the protocol for participants with clinical worsening, we decided to rate this domain as of ‘some concern’ because the trial context could have influenced the decision to provide the treatment. </p> </section> <section id="CD013881-sec-0036"> <h6 class="title">Co‐interventions</h6> <p>The following co‐interventions could affect the trial outcomes.</p> <p> <ul id="CD013881-list-0010"> <li> <p>Remdesivir and other antivirals</p> </li> <li> <p>Corticosteroids</p> </li> <li> <p>Biologics</p> </li> </ul> </p> <p>When these co‐interventions were reported and balanced, we assessed this domain to be at ‘low’ risk of bias. When these co‐interventions were reported but imbalanced, we rated the domain as of ‘some concern’ and not at ‘high risk’ of bias as it is impossible to distinguish deviation due to the trial context from deviation due to the intervention effect.  </p> </section> </section> <section id="CD013881-sec-0037"> <h5 class="title">Domain 2. Analysis to estimate the effect of assignment</h5> <p>We considered ITT analyses to be appropriate. </p> <p>When the analysis was not done on an ITT basis, we rated this domain on a case‐by‐case basis depending on the following. </p> <p> <ul id="CD013881-list-0011"> <li> <p>The number of participants who crossed over and were not analyzed in the group to which they are allocated. </p> </li> <li> <p>The number of participants excluded from the analysis for a reason other than missing data, and any imbalance between arms in terms of the number of and reasons for exclusion. </p> </li> </ul> </p> <p>For critical outcomes (binary outcomes) the analysis evaluated was not always based on the analysis reported by authors, but rather on our own analysis, which considered all randomized participants as the denominator. </p> </section> <section id="CD013881-sec-0038"> <h5 class="title">Domain 4. Bias in the measurement of the outcome</h5> <p>We prespecified the following rules.</p> <p> <ul id="CD013881-list-0012"> <li> <p>Clinical Improvement (D28/ ≥ D60/time to event): assessment of this outcome requires clinical judgment and can be influenced by knowledge of the intervention assignment, but we judged that this is not likely in the context of the pandemic. </p> </li> <li> <p>WHO‐CPS level 7 or above (D28/ ≥ D60/time to event): assessment of this outcome is probably not influenced by knowledge of the intervention assignment. </p> </li> <li> <p>All‐cause mortality (D28/ ≥ D60/time to event): assessment of this outcome is not influenced by knowledge of the intervention assignment. </p> </li> <li> <p>Adverse events and serious adverse event: </p> <ul id="CD013881-list-0013"> <li> <p>when detection of events relies only on measures that cannot be influenced by judgment (e.g. laboratory detected events): assessment of this outcome is probably not influenced by knowledge of the intervention assignment; </p> </li> <li> <p>when detection events rely only on measures that can be influenced by judgment (e.g. clinically and laboratory detected events): assessment of this outcome can be influenced by knowledge of the intervention assignment, but such influence is unlikely in the pandemic context. </p> </li> </ul> </li> </ul> </p> <p>While we relied on the signaling questions to assess each domain and justify our assessment, we did not record the answers of systematic reviewers or how consensus was obtained for the signaling questions. This was done only at the domain level. The risk of bias assessment was considered part of an evaluation of the certainty of the evidence and as a sensitivity analysis. </p> <p>For cluster‐randomized trials, we planned to rely on the extension of the RoB2 tool for cluster‐randomized trials. Particularly, we planned to add the domain 1b: Risk of bias arising from the timing of identification or recruitment of participants in a cluster‐randomized trial. There were, however, no cluster RCTs reported by the date of the last search. </p> <p>For the unpublished trials included in this review update, we consulted the results and the risk of bias assessment for the outcomes as reported in a meta‐analysis by the WHO Rapid Evidence Appraisal for COVID‐19 Therapies (REACT) Working Group.  </p> <p>For the included studies where results were posted only in trials registers, we used that posted information, as well as its protocol, if available. </p> </section> </section> <section id="CD013881-sec-0039"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we calculated the relative risk (RR) and 95% confidence interval (CI) as the measure of effect, using the number of events and total participants in each arm. For time‐to‐event outcomes, we extracted the hazard ratios (HR) and 95% CI from the trial reports, and subsequently pooled these in the meta‐analysis. </p> </section> <section id="CD013881-sec-0040"> <h4 class="title">Unit of analysis issues</h4> <p>We extracted data by arm and considered multi‐arm studies as independent two‐arm studies in the pairwise meta‐analyses. </p> <p>As recommended in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013881-bbs2-0079" title="Higgins, JPT Thomas, J Chandler, J Cumpston, M Li, T Page, MJ Welch, VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook2021.">Higgins 2021</a>), for studies with different doses, we combined arms that used different doses of the same drug. </p> </section> <section id="CD013881-sec-0041"> <h4 class="title">Dealing with missing data</h4> <p>For missing outcome data, we extracted the number of participants who dropped out before completing the trial and noted how trial authors handled missing outcome data. In our primary analysis of the critical outcomes, we followed a conservative approach assuming that participants with missing outcome data did not experience the event of interest. Hence, we calculated all RRs with the number of participants randomized as each group in the denominator. We also conducted sensitivity analyses to assess the potential impact of missing outcome data on the results by using an available case analysis with the number of participants analyzed (e.g. only participants without missing outcome data or only participants who received treatment) in the denominator (see <a href="#CD013881-sec-0047">Sensitivity analysis</a> section). </p> </section> <section id="CD013881-sec-0042"> <h4 class="title">Assessment of heterogeneity</h4> <p>We generated descriptive statistics for both the trial and population characteristics. We examined the distribution of important clinical and methodological variables (e.g. age, disease severity, pre‐existing conditions and comorbidities, location). We used visual inspection of forest plots, the I<sup>2</sup> statistic and the magnitude of between‐study variance (Tau<sup>2</sup>) to estimate the level of heterogeneity. In instances where the level of heterogeneity was estimated to be negligible or close to zero, we refrained from presenting prediction intervals. This is because such intervals would coincide with the confidence intervals of the effect estimate in these cases. Additionally, we avoided reporting prediction intervals for outcomes where only a limited number of studies reported the outcome (<a href="./references#CD013881-bbs2-0079" title="Higgins, JPT Thomas, J Chandler, J Cumpston, M Li, T Page, MJ Welch, VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook2021.">Higgins 2021</a>; <a href="./references#CD013881-bbs2-0103" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta-analyses. BMJ2011;342:d549. [DOI: 10.1136/bmj.d549] [PMID: 21310794]">Riley 2011</a>). </p> </section> <section id="CD013881-sec-0043"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed the selective non‐reporting or under‐reporting of results in the trials identified according to the framework proposed in Chapter 13 of the <i>Cochrane Handbook</i> (<a href="./references#CD013881-bbs2-0079" title="Higgins, JPT Thomas, J Chandler, J Cumpston, M Li, T Page, MJ Welch, VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook2021.">Higgins 2021</a>). </p> <section id="CD013881-sec-0044"> <h5 class="title">Assessing the risk of bias due to missing results in the synthesis</h5> <p>We checked whether the results of all our critical and important outcomes were reported as prespecified in the trial register. When registration was not prospective, we also checked the protocol or statistical analysis plan if available. We contacted the corresponding authors of included trials to obtain the missing data. </p> <p>When trial outcome results were unavailable, we used a matrix indicating the availability of study results as recommended in the <i>Cochrane Handbook</i> (<a href="./references#CD013881-bbs2-0079" title="Higgins, JPT Thomas, J Chandler, J Cumpston, M Li, T Page, MJ Welch, VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook2021.">Higgins 2021</a>; <a href="./references#CD013881-bbs2-0087" title="KirkhamJJ , AltmanDG , ChanAW , GambleC , DwanKM , WilliamsonPR . Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews. BMJ2018;362:k3802. [DOI: 10.1136/bmj.k3802] [PMID: 30266736]">Kirkham 2018</a>). </p> <p>We checked whether the results were unavailable because of the result’s P value, magnitude, or direction. We considered the risk of bias due to missing results if one specified outcome of the registry was missing in the main report for one of these reasons. </p> <p>In this update, we explored potential publication bias by generating funnel plots for outcomes with more than 10 studies included (<a href="./references#CD013881-bbs2-0109" title="SterneJA , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898. [DOI: 10.1136/bmj.l4898] [PMID: 31462531]">Sterne 2019</a>). We considered P &lt; 0.5 as significant for this test. </p> </section> </section> <section id="CD013881-sec-0045"> <h4 class="title">Data synthesis</h4> <p>We combined trials evaluating the same drug to standard care alone or to placebo comparators together in the same comparison. All eligible RCTs were included in the primary analysis, regardless of the risk of bias assessment. </p> <p>For binary outcomes, we used the number of events and the number of total participants in each arm to calculate the logRRs and their standard error. Then we pooled the trial‐specific effect sizes. For time‐to‐event outcomes, we directly extracted the HRs and their 95% CIs from the trial reports and subsequently pooled them in the meta‐analysis. </p> <p>For each direct comparison with at least two trials providing data, we present effect estimates with 95% CIs. We used a random‐effects model to incorporate the anticipated clinical and methodological heterogeneity across trials. Comparisons from multi‐arm or platform trials were treated as independent two‐arm trials since we did not pool comparisons of different drugs in the same meta‐analysis. </p> <p>All analyses were conducted using metaCOVID (<a href="./references#CD013881-bbs2-0071" title="EvrenoglouT , BoutronI , ChaimaniA . metaCOVID: An R-Shiny application for living meta-analyses of COVID-19 trials. medRxiv 2021 [Preprint]. [DOI: doi.org/10.1101/2021.09.07.21263207]">Evrenoglou 2021</a>), an R‐Shiny application that runs in parallel with the COVID‐NMA initiative. The application's aim is to allow all end‐users of the COVID‐NMA platform to perform their own meta‐analyses in a user‐friendly environment. All data analyses are based on the latest updated COVID‐NMA database regarding treatments and vaccines used against Covid‐19. metaCOVID is based on the R‐packages metafor (<a href="./references#CD013881-bbs2-0117" title="ViechtbauerW . Conducting meta-analyses in R with the metafor package. Journal of Statistical Software2010;36(3):48. [DOI: 10.18637/jss.v036.i03]">Viechtbauer 2010</a>) and meta (<a href="./references#CD013881-bbs2-0058" title="BalduzziS , RückerG , SchwarzerG . How to perform a meta-analysis with R: a practical tutorial. BMJ Mental Health2019;22:153-160.">Balduzzi 2019</a>). It is freely available at: <a href="https://covid-nma.com/metacovid/" target="_blank">covid-nma.com/metacovid/</a>. </p> </section> <section id="CD013881-sec-0046"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted prespecified subgroup analyses to explore the impact of trial location (single countries versus multinational), and performed severity subgroup analysis when possible. We also performed post hoc subgroup analyses including funding sources (private versus public/non‐profit versus mixed) and conflict of interests (conflict of interests declared versus no conflict of interests). </p> </section> <section id="CD013881-sec-0047"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses by excluding trials with high overall risk of bias and RCTs reported only as preprint. We also undertook a sensitivity analysis to assess the potential impact of missing outcome data on the results by using an available case analysis with the number of participants analyzed instead of those randomized (<a href="./references#CD013881-bbs2-0067" title="ChaimaniA , MavridisD , HigginsJP , SalantiG , WhiteIR . Allowing for informative missingness in aggregate data meta-analysis with continuous or binary outcomes: extensions to metamiss. Stata Journal2018;18(3):716-40. [PMID: 30595674]">Chaimani 2018</a>; <a href="./references#CD013881-bbs2-0093" title="MavridisD , WhiteIR , HigginsJP , CiprianiA , SalantiG . Allowing for uncertainty due to missing continuous outcome data in pairwise and network meta-analysis. Statistics in Medicine2015;34(5):721-41. [DOI: 10.1002/sim.6365] [PMID: 25393541]">Mavridis 2015</a>; <a href="./references#CD013881-bbs2-0094" title="MavridisD , ChaimaniA , EfthimiouO , SalantiG . Missing outcome data in meta-analysis. Evidence Based Mental Health2018;21(3):123. [DOI: 10.1136/eb-2014-101899] [PMID: 25009176]">Mavridis 2018</a>; <a href="./references#CD013881-bbs2-0119" title="WhiteIR , HigginsJP , WoodAM . Allowing for uncertainty due to missing data in meta-analysis - part 1: two-stage methods. Statistics in Medicine2008;27(5):711-27. [DOI: 10.1002/sim.3008] [PMID: 17703496]">White 2008</a>). </p> </section> <section id="CD013881-sec-0048"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>To evaluate the confidence to be placed in the results of the pairwise comparisons for critical and important outcomes, we used the GRADE approach (<a href="./references#CD013881-bbs2-0105" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022b</a>). We created summary of findings tables to present the estimated relative and absolute risks for all comparisons and prioritized the presentation of the following seven critical outcomes: clinical improvement (D28 and ≥D60), WHO‐CPS level 7 or above (D28), all‐cause mortality (D28 and ≥D60), adverse events and serious adverse events.<br/>We did not include studies with no events in GRADE since they do not contribute to the pooled effect estimate. Absolute effects were calculated with <a href="./references#CD013881-bbs2-0075" title="GRADEpro GDT. Version accessed 21 February 2021. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a> using the baseline risks in the control groups of the included studies for each outcome. We calculated the baseline risk for time‐to‐event outcomes using the baseline risk in the control groups of the included studies in the corresponding dichotomous outcome. One review author assessed overall certainty of the evidence, and another review author cross‐checked this. </p> <p>We used the five GRADE considerations (limitations in design, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence related to studies that contributed data to pairwise meta‐analyses for prespecified outcomes. We used the new approach proposed by GRADE for assessing imprecision (<a href="./references#CD013881-bbs2-0104" title="SchünemannHJ , NeumannI , HultcrantzM , Brignardello-PetersenR , ZengL , MuradMH , et al. GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions. Journal of Clinical Epidemiology2022;150:225-42.">Schünemann 2022</a>). </p> <p>We considered the size of the absolute risk and its confidence intervals and set minimal important difference thresholds at 5% (50 per 1000) for the outcomes of clinical improvement, time to clinical improvement, and adverse events. For mortality outcomes, time to death, WHO score 7 and above, time to WHO score 7 and above, and serious adverse events, we set the threshold at 1% (10 per 1000). Absolute differences smaller than 5% (or 1% respectively) are considered to indicate trivial/no effect, and differences of more than 5% (or 1% respectively) are considered clinically important benefit/harm. </p> <p>The evidence profiles provide the effect estimate and the associated certainty of evidence for each outcome of interest (<a href="./appendices#CD013881-sec-0156">Appendix 4</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013881-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013881-sec-0049"></div> <section id="CD013881-sec-0050"> <h3 class="title">Description of studies</h3> <p>For a full description of studies, please see <a href="./references#CD013881-sec-0189" title="">Characteristics of included studies</a>, In addition, a summary table of baseline characteristics for all trials is available in <a href="./appendices#CD013881-sec-0157">Appendix 5</a>. Characteristics of excluded studies and unpublished registered studies are summarized in <a href="./references#CD013881-sec-0190" title="">Characteristics of excluded studies</a> and <a href="./appendices#CD013881-sec-0158">Appendix 6</a>. </p> <section id="CD013881-sec-0051"> <h4 class="title">Results of the search</h4> <p>The results of the weekly search updates are detailed in <a href="#CD013881-fig-0001">Figure 1</a>. On 7 June 2022, we retrieved a total of 49,770 published references after excluding duplicates; 35 records were eligible for full‐text screening and 30 reports of 32 RCTs evaluating IL‐6 blocking agents were included. The search of clinical trial registries retrieved additional 17 registered trials that had neither published nor posted results and two canceled registered trials. No reports were identified from the EMA or FDA. We did not identify any retracted articles concerning IL‐6 blocking agents. </p> <div class="figure" id="CD013881-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flowchart of included randomized controlled trials (RCTs) of interleukin 6 (IL‐6) blocking agents (last search date: 7 June 2022)ICTRP: World Health Organization (WHO) International Clinical Trials Registry Platforma Multiple arm RCTs evaluated both tocilizumab and sarilumab (one published and one unpublished result),b One factorial RCT evaluated tocilizumab and siltuximab, and consequently, they appear twice." data-id="CD013881-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flowchart of included randomized controlled trials (RCTs) of interleukin 6 (IL‐6) blocking agents (last search date: 7 June 2022) </p> <p>ICTRP: World Health Organization (WHO) International Clinical Trials Registry Platform</p> <p><sup>a</sup> Multiple arm RCTs evaluated both tocilizumab and sarilumab (one published and one unpublished result), </p> <p><sup>b</sup> One factorial RCT evaluated tocilizumab and siltuximab, and consequently, they appear twice. </p> </div> </div> </div> <p>This review update identified 22 new trials with results that are included in the meta‐analysis. The previous review included 10 RCTs (<a href="./references#CD013881-bbs2-0074" title="GhosnL , ChaimaniA , EvrenoglouT , DavidsonM , GrañaC , SchmuckerC , et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 3. Art. No: CD013881. [DOI: 10.1002/14651858.CD013881]">Ghosn 2021</a>). Of the 32 trials included in this current update version, 20 trials evaluated tocilizumab, nine evaluated sarilumab, two evaluated clazakizumab, and there was one each for olokizumab, siltuximab, and levilimab. Of note, one platform multi‐arm trial, REMAP‐CAP, evaluated two IL‐6 blocking agents (tocilizumab and sarilumab) (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>), and one factorial design trial evaluated two IL‐6 blocking agents (tocilizumab and siltuximab) (<a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>).  </p> </section> <section id="CD013881-sec-0052"> <h4 class="title">Included studies</h4> <section id="CD013881-sec-0053"> <h5 class="title">Source of the data</h5> <p>Reports of 22 RCTs with results were published in peer‐reviewed journals (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> (reporting results of CORIMUNO‐TOCI‐1 of the CORIMUNO‐19 Cohort); <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (reporting results of two trials of the CORIMUNO‐19 cohort: CORIMUNO‐TOCI‐2 and CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (reporting results of phase 2 and 3 analysis populations); <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>). Three trials were available as preprints (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>); for REMAP‐CAP, findings were initially published in a peer‐reviewed journal (<a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>), and updated findings were released in a second report (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>), which at the time of writing remains available only as a preprint. Two trials were not published at the time of writing but posted their results on ClinicalTrials.gov (<a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>). We also included results of five unpublished trials (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>), obtained from a meta‐analysis by the WHO Rapid Evidence Appraisal for COVID‐19 Therapies (REACT) Working Group (<a href="./references#CD013881-bbs2-0122" title="WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA2021;326(6):499-518.">WHO REACT Working Group 2021</a>). We contacted authors of 31 included trials for additional information and received replies from eight authors, three of whom shared additional information. Because of the unavailability of contact information, we could not contact the authors of <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a> (<a href="./appendices#CD013881-sec-0164">Appendix 7</a>). </p> </section> <section id="CD013881-sec-0054"> <h5 class="title">Study design</h5> <p>Twenty‐five trials used a two‐arm parallel‐group randomized design (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2; CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>); five had three arms (<a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>(reporting results of phase 2 and 3)), and one had four (REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>)). Finally, there was one factorial‐design study (<a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>). Six studies were platform trials (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2, CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>) and 11 were placebo‐controlled (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>). </p> <p>The total sample comprised 12,160 randomized participants, and the median sample size was 131 (interquartile range (IQR): 54 to 248; range: 17 to 4116). Eight trials did not reach their target sample size. <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a> included 32% (126/398) of the target population when its Scientific Committee decided to interrupt the trial for futility, and <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a> was terminated for futility with an actual enrollment of 33% (26/78) of the planned sample size. <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a> achieved only 35% of its planned sample size (65 randomized/188 planned) because of the rapid decline in the number of people with COVID‐19 in China. REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>) was stopped at a scheduled interim analysis on the decision of the data safety monitoring board. <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a> was terminated after the first interim analysis on the recommendation of the data monitoring committee due to an excessive number of deaths at 15 days in the tocilizumab group. Recruitment to <a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a> was terminated due to concerns about the high probability that intubation or death rates were higher in the sarilumab arm than the standard‐care arm; it thus did not reach its target sample size. <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a> did not provide any information about why it recruited only 28% of its target sample. <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> amended the trial protocol in June 2020 to reduce the target sample size in the protocol from 278 participants (85% power) to 243 (80% power) as the enrollment rate slowed significantly with the waning of the pandemic in the Boston area.  </p> <p>The last known status of <a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>, <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a> and <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a> is "ongoing". <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>'s recruitment status was “recruiting” and was changed by clinicaltrials.gov to “unknown” as the completion date has passed, and the status has not been updated within the last two years. <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a> reported 30‐day outcomes only; the three‐month endpoints have not yet been reported. </p> </section> <section id="CD013881-sec-0055"> <h5 class="title">Study registration</h5> <p>All trial registration records were available; nine were registered retrospectively (<a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>). The interval between registration and the study start was 54 days in <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>, 43 days in <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>, 27 days in <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>, 21 days in <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>, 16 days in <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>, 14 days in <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>, 13 days in <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>, 8 days in <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>, and 7 days in <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>.  </p> </section> <section id="CD013881-sec-0056"> <h5 class="title">Settings</h5> <p>All participants were hospital inpatients when recruited. </p> <p>Multicenter trials comprised 26 of these studies. Of them, four were multinational (REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>), and 22 were conducted in single countries: Belgium (<a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>), Brazil (<a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>), China (<a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>), France (<a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2, CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>), India (<a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>), Israel (<a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>), Italy (<a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>), Russia (<a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>), Spain (<a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>), Sweden (<a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>), the Netherlands (<a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>), the UK (<a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>), and the USA (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>). </p> <p>Of the six single‐center trials, one took place in Iran (<a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>), one in Finland (<a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>), and two each in the USA (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a> <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>) and in Spain (<a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>).  </p> <p>The trials were performed between February 2020 and June 2021, with a mean duration of study enrollment of 21 weeks (range: 1 to 54). Twenty‐eight trials were conducted during exposure to the wild‐type SARS‐CoV‐2 strains in 2020, and four during exposure to the wild‐type and the alpha variant (<a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>) (<a href="./appendices#CD013881-sec-0165">Appendix 8</a>).  </p> <p>Eleven studies had a follow‐up of 90 days (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2, CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>), eight reported a follow‐up of 60 days (<a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>), 12 reported a follow‐up of one month (28 to 30 days) (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>), and one study had a follow‐up of only 14 days (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>).  </p> </section> <section id="CD013881-sec-0057"> <h5 class="title">Characteristics of participants</h5> <p>A total of 12,160 participants (32 RCTs) were included in the analysis of this review. Overall, 8131 participants (20 RCTs) were included in the analysis comparing tocilizumab to standard care or placebo; 3748 participants (nine RCTs) in the analysis comparing sarilumab to standard care or placebo; 169 participants (two RCTs) in the analysis comparing clazakizumab to placebo; and 248 participants (one RCT) in the analysis comparing olokizumab to placebo. The platform trial comparing siltuximab to standard care included 148 participants, and the RCT analyzing levilimab compared to placebo included 206 participants. The mean age range varied from 56 to 75 years and the percentage of men ranged from 5% to 90%.  </p> <p>All participants were hospitalized for COVID‐19. Participants had mild to critical disease in one RCT (n = 452) (<a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>), mild to severe diseases in five RCTs (n = 737) (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>), moderate to severe disease in 10 RCTs (n = 890) (<a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>), moderate to critical disease in eight (n = 7368) (<a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (reporting results of phase 2 and 3); <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>), moderate disease in one (n = 201) (<a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>), severe disease in one RCT (n = 126) (<a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>), severe to critical disease in five (n = 2365) (REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2, CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>), and critical disease in one trial (n = 21) (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>).  </p> <p>C‐reactive protein level varied but was high in most trials with a median between 40 and 200 mg/L, except for <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>, where it was only slightly elevated at 7.58 mg/L. Similarly, IL‐6 level was high in most of the trials with a median between 24 and 255 pg/mL, except for five trials (<a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>), where it was normal to slightly elevated (median, between 9 and 19.20 pg/ml). </p> <p>Only six trials reported the vaccination status of participants (<a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2, CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>); there were no fully vaccinated participants included in these trials. Seventeen trials were conducted before vaccination was rolled out. </p> <p>The percentage of participants who were on oxygen at baseline but not intubated varied at study inclusion from 5% to 100%, specifically: 5% (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>), 26% (<a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>), 39% (<a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>), 52% (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>), 56% (<a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>), 61% (<a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>), 65% (<a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>), 67% (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>), 74% (<a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>), 84% (<a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>), 86% (<a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>), 87% (<a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>), 88% (<a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>), 89% (<a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>), 90% (<a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>), 96% (<a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>), 97% (<a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>), 99% (<a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>), and 100% (<a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>).  </p> <p><a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a> reported that 41% received noninvasive high‐flow oxygen but provided no data on the number of participants receiving low‐flow oxygen. Three trials did not provide this information (<a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>). </p> <p>The following 12 trials reported the percentage of patients who were intubated at baseline: 5% (<a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>), 6% (<a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>), 12% (<a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>), 14% (<a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>), 16% (<a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>), 22% (<a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>), 24% (<a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>), 31% (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>), 37% (<a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>), 61% (<a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2)), 62% (<a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐SARI‐2)), and 95% (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>). Other trials had no participants intubated at baseline (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>), while two (<a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>) each had a single participant in the control group intubated at baseline. Two trials did not provide this information (<a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>).  </p> </section> <section id="CD013881-sec-0058"> <h5 class="title">Details of the interventions</h5> <p>Fifteen trials evaluated tocilizumab 8 mg/kg by infusion for one day with a maximum of an 800 mg single dose (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2); <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>), while <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a> evaluated tocilizumab at a dose of 6 mg/kg. In <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> and <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>, the dose was adapted to participant's weight according to a prespecified algorithm. One trial evaluated a lower dose of 400 mg by infusion for one day (<a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>), and another trial evaluated a one‐off low dose of 40 mg or 120 mg (<a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>). A second infusion was allowed in 13 trials (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2); <a href="./references#CD013881-bbs2-0081" title="HorbyP , LimWS , EmbersonJR , MafhamM , BellJL , LinsellL , et al. Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine2021;384(8):693-704.">Horby 2021a</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>). </p> <p>In three trials, participants received sarilumab at 400 mg in a single‐dose infusion (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a> <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>). Three trials compared two doses of sarilumab 200 mg and 400 mg; participants received sarilumab at 200 mg or 400 mg either by infusion in <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> and <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>, or subcutaneously in <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>. In <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a> and <a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>, participants received 400 mg per day subcutaneously. <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a> used an algorithm to adapt the dose between 200 mg and 400 mg according to the participant's weight. </p> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐SARI‐2) and <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> provided sarilumab as a 400 mg IV infusion once, with a second infusion at day three in the absence of a clinical response. <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a> allowed the possibility of a second dose within 24 to 48 hours. In <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>, re‐dosing was possible for clinical worsening at 24 hours with up to four doses weekly. </p> <p>Clazakizumab was administered as one dose of 25 mg. A second dose was allowed within three days of the first, depending on the CRP level in <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a> allowed a second dose 24 hours after the first dose up to day 14. </p> <p>Olokizumab was provided as a 64 mg subcutaneous dose once only in <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a> siltuximab as a single dose of 11 mg/kg by IV infusion (<a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>), and levilimab was administered subcutaneously twice on day one at a dose of 162 mg; a 324 mg rescue dose was allowed if clinical status worsened (<a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>). </p> <p>The comparator was standard care with placebo in 11 trials (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>) and standard care in the other 21 trials (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2; CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>). </p> <p>The use of steroids at baseline or during the study was reported in 31 trials (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2; CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>). Six trials reported that more participants received steroids in the control group (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>). In <a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a> and <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>, 100% of controls received steroids. In <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; all participants received steroids. <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a> did not report this information.  </p> <p>The protocol of one trial planned for some cross‐over (<a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>), and 22% of participants in the control arm received the experimental treatment.  </p> </section> <section id="CD013881-sec-0059"> <h5 class="title">Funding and conflict of interest</h5> <p>Fourteen trials were funded by public/non‐profit sources (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2; CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>), nine received mixed funding (REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>), and eight were funded by pharmaceutical companies (<a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>). <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> reported that they received no external funds.  </p> <p>The authors of 12 trials declared potential conflict of interest (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>), and those of 13 did not (<a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2; CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>). We could not retrieve information about conflict of interest for seven trials (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>). </p> </section> </section> <section id="CD013881-sec-0060"> <h4 class="title">Excluded studies</h4> <p>We excluded five reports after full‐text screening; the reasons for exclusion were secondary analysis (three reports), not randomized (one report) and prognosis trial (one report). Details of these reports can be found in <a href="./references#CD013881-sec-0190" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD013881-sec-0061"> <h4 class="title">Registered studies with no published results</h4> <p>From the trial registries, we identified an additional 17 trials for which no results have been published or posted in the registries (as of 7 June 2022); in addition, we identified two canceled registered trials, one assessing tocilizumab (<a href="./references#CD013881-bbs2-0053" title="NCT04361552. Tocilizumab for the treatment of cytokine release syndrome in patients with COVID-19 (SARS-CoV-2 infection). clinicaltrials.gov/ct2/show/NCT04361552 (First received April 22, 2020). ">NCT04361552</a>) and one assessing olokizumab (<a href="./references#CD013881-bbs2-0054" title="NCT04452474. Study of the efficacy and safety of a single administration of Olokizumab vs. placebo in addition to standard treatment in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04452474 (First received June 26, 2020). ">NCT04452474</a>). See <a href="./appendices#CD013881-sec-0158">Appendix 6</a>; <a href="./references#CD013881-bbs1-0003" title="">Studies awaiting classification</a>; <a href="./references#CD013881-bbs1-0004" title="">Ongoing studies</a>. </p> <section id="CD013881-sec-0062"> <h5 class="title">Tocilizumab</h5> <p>Eleven trials assessed tocilizumab versus standard care or placebo with unpublished results (<a href="./references#CD013881-bbs2-0038" title="EUCTR2020-001275-32-DK. Effectiveness of Interleukin-6 receptor inhibitors in the management of patients with severe SARS-CoV-2 pneumonia: An open-Label multicenter sequential randomized controlled trial. clinicaltrialsregister.eu/ctr-search/trial/2020-001275-32/DK (first entered 2020-03-24). ">EUCTR2020‐001275‐32‐DK</a>; <a href="./references#CD013881-bbs2-0040" title="EUCTR2020-001408-41-DE. A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia. clinicaltrialsregister.eu//ctr-search/trial/2020-001408-41/DE (first entered 2020-04-07). ">EUCTR2020‐001408‐41‐DE</a>; <a href="./references#CD013881-bbs2-0041" title="EUCTR2020-001770-30-BE. COVID 19: Experimental use of tocilizumab (Roactemra®) in severe SARS-CoV-2 related pneumonia.. clinicaltrialsregister.eu//ctr-search/trial/2020-001770-30/BE (first entered 2020-04-15). ">EUCTR2020‐001770‐30‐BE</a>; <a href="./references#CD013881-bbs2-0042" title="NCT04335071. Tocilizumab in the treatment of Coronavirus induced disease (COVID-19) (CORON-ACT). clinicaltrials.gov/ct2/show/NCT04335071 (first received April 2, 2020). ">NCT04335071</a>; <a href="./references#CD013881-bbs2-0045" title="NCT04690920. Theranostic implication of complementary medicines against interleukin receptors and Gp-130 proteins. clinicaltrials.gov/ct2/show/NCT04690920 (first received 31 December 2020). ">NCT04690920</a>; <a href="./references#CD013881-bbs2-0046" title="ACTRN12620000580976. Tocilizumab for the treatment of COVID-19 in intensive care patients: effect on days free of ventilatory support. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379640&amp;isReview=true (first received 19 May 2020). ">ACTRN12620000580976</a>; <a href="./references#CD013881-bbs2-0047" title="CTRI/2020/12/029793. Efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia on steroid therapy: A prospective, randomized, double blind placebo-controlled trial. ctri.nic.in/Clinicaltrials/showallp.php?mid1=50303&amp;EncHid=&amp;userName=Tocilizumab (first received 15 December 2020). ">CTRI/2020/12/029793</a>; <a href="./references#CD013881-bbs2-0049" title="EUCTR2020-001767-86-IE. An open-label, multi-centre, randomised trial comparing different doses of single-dose tocilizumab in adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive. clinicaltrialsregister.eu/ctr-search/trial/2020-001767-86/IE (first received 15 April 2020). ">EUCTR2020‐001767‐86‐IE</a>; <a href="./references#CD013881-bbs2-0050" title="IRCT20200510047383N1. Evaluation of the effect of Tocilizumab on outcomes of the severe COVID-19 patients. www.irct.ir/trial/48024 (first received 15 May 2020). ">IRCT20200510047383N1</a>; <a href="./references#CD013881-bbs2-0051" title="IRCT20200525047570N1. A comparative study of the effects of tocilizumab, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm. www.irct.ir/trial/48583 (first received 30 July 2020). ">IRCT20200525047570N1</a>; <a href="./references#CD013881-bbs2-0052" title="IRCT20201024049134N2. Efficacy of Tocilizumab in Hospitalized Patients with COVID-19: An open-label placebo-controlled clinical study. www.irct.ir/trial/56613 (first received 4 June 2021). ">IRCT20201024049134N2</a>). Of these, one trial has been completed but results were unavailable (<a href="./references#CD013881-bbs2-0045" title="NCT04690920. Theranostic implication of complementary medicines against interleukin receptors and Gp-130 proteins. clinicaltrials.gov/ct2/show/NCT04690920 (first received 31 December 2020). ">NCT04690920</a>; 200 participants enrolled), and three other RCTs (220 participants) were marked on the registry as “recruitment completed based on the expected completion date” (<a href="./references#CD013881-bbs2-0050" title="IRCT20200510047383N1. Evaluation of the effect of Tocilizumab on outcomes of the severe COVID-19 patients. www.irct.ir/trial/48024 (first received 15 May 2020). ">IRCT20200510047383N1</a>; <a href="./references#CD013881-bbs2-0051" title="IRCT20200525047570N1. A comparative study of the effects of tocilizumab, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm. www.irct.ir/trial/48583 (first received 30 July 2020). ">IRCT20200525047570N1</a>; <a href="./references#CD013881-bbs2-0052" title="IRCT20201024049134N2. Efficacy of Tocilizumab in Hospitalized Patients with COVID-19: An open-label placebo-controlled clinical study. www.irct.ir/trial/56613 (first received 4 June 2021). ">IRCT20201024049134N2</a>); we cannot be sure that these studies were completed (the registry has never been updated since registration). Three were terminated without results available (<a href="./references#CD013881-bbs2-0038" title="EUCTR2020-001275-32-DK. Effectiveness of Interleukin-6 receptor inhibitors in the management of patients with severe SARS-CoV-2 pneumonia: An open-Label multicenter sequential randomized controlled trial. clinicaltrialsregister.eu/ctr-search/trial/2020-001275-32/DK (first entered 2020-03-24). ">EUCTR2020‐001275‐32‐DK</a>; <a href="./references#CD013881-bbs2-0041" title="EUCTR2020-001770-30-BE. COVID 19: Experimental use of tocilizumab (Roactemra®) in severe SARS-CoV-2 related pneumonia.. clinicaltrialsregister.eu//ctr-search/trial/2020-001770-30/BE (first entered 2020-04-15). ">EUCTR2020‐001770‐30‐BE</a>; <a href="./references#CD013881-bbs2-0042" title="NCT04335071. Tocilizumab in the treatment of Coronavirus induced disease (COVID-19) (CORON-ACT). clinicaltrials.gov/ct2/show/NCT04335071 (first received April 2, 2020). ">NCT04335071</a>), and one terminated with results posted for three participants out of 200 planned (<a href="./references#CD013881-bbs2-0040" title="EUCTR2020-001408-41-DE. A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia. clinicaltrialsregister.eu//ctr-search/trial/2020-001408-41/DE (first entered 2020-04-07). ">EUCTR2020‐001408‐41‐DE</a>). One trial was ongoing (<a href="./references#CD013881-bbs2-0049" title="EUCTR2020-001767-86-IE. An open-label, multi-centre, randomised trial comparing different doses of single-dose tocilizumab in adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive. clinicaltrialsregister.eu/ctr-search/trial/2020-001767-86/IE (first received 15 April 2020). ">EUCTR2020‐001767‐86‐IE</a>; 90 participants) and two are not yet recruiting (<a href="./references#CD013881-bbs2-0046" title="ACTRN12620000580976. Tocilizumab for the treatment of COVID-19 in intensive care patients: effect on days free of ventilatory support. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379640&amp;isReview=true (first received 19 May 2020). ">ACTRN12620000580976</a>; <a href="./references#CD013881-bbs2-0047" title="CTRI/2020/12/029793. Efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia on steroid therapy: A prospective, randomized, double blind placebo-controlled trial. ctri.nic.in/Clinicaltrials/showallp.php?mid1=50303&amp;EncHid=&amp;userName=Tocilizumab (first received 15 December 2020). ">CTRI/2020/12/029793</a>; total 204 participants planned). </p> </section> <section id="CD013881-sec-0063"> <h5 class="title">Sarilumab</h5> <p>We identified three unpublished trials: two terminated without results (<a href="./references#CD013881-bbs2-0038" title="EUCTR2020-001275-32-DK. Effectiveness of Interleukin-6 receptor inhibitors in the management of patients with severe SARS-CoV-2 pneumonia: An open-Label multicenter sequential randomized controlled trial. clinicaltrialsregister.eu/ctr-search/trial/2020-001275-32/DK (first entered 2020-03-24). ">EUCTR2020‐001275‐32‐DK</a>; <a href="./references#CD013881-bbs2-0039" title="EUCTR2020-001290-74-ES [Efficacy and safety of sarilumab in the early treatment of hospitalized patients with mild-moderate pneumonia and COVID19 infection versus standard of care]. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001290-74 (first received 11 April 2020). ">EUCTR2020‐001290‐74‐ES</a>) and one trial is ongoing (171 participants planned) (<a href="./references#CD013881-bbs2-0048" title="EUCTR2020-001390-76-IT. A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients with severe COVID-19 pneumonia. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001390-76 (first received 27 April 2020). ">EUCTR2020‐001390‐76‐IT</a>). One terminated multi‐arm trial evaluated sarilumab compared to tocilizumab and standard care (<a href="./references#CD013881-bbs2-0038" title="EUCTR2020-001275-32-DK. Effectiveness of Interleukin-6 receptor inhibitors in the management of patients with severe SARS-CoV-2 pneumonia: An open-Label multicenter sequential randomized controlled trial. clinicaltrialsregister.eu/ctr-search/trial/2020-001275-32/DK (first entered 2020-03-24). ">EUCTR2020‐001275‐32‐DK</a>). </p> </section> <section id="CD013881-sec-0064"> <h5 class="title">Clazakizumab</h5> <p>We identified two unpublished trials assessing clazakizumab compared to standard care or placebo: one terminated without results available (<a href="./references#CD013881-bbs2-0043" title="NCT04381052. Study for the use of the IL-6 Inhibitor clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04381052 (first received 8 May 2020). ">NCT04381052</a>), and one is ongoing (results posted for one participant out of 60 planned) (<a href="./references#CD013881-bbs2-0055" title="NCT04494724. Clazakizumab vs. placebo - COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04494724 (first received 31 July 2020). ">NCT04494724</a>). </p> </section> <section id="CD013881-sec-0065"> <h5 class="title">Olokizumab</h5> <p>We identified one ongoing trial (204 participants planned) (<a href="./references#CD013881-bbs2-0056" title="NCT05187793. Study of efficacy of different treatment regimens of Olokizumab (RESET). clinicaltrials.gov/ct2/show/NCT05187793 (First received December 24, 2021). ">NCT05187793</a>). </p> </section> <section id="CD013881-sec-0066"> <h5 class="title">Siltuximab</h5> <p>We identified one terminated trial (555 participants planned) (<a href="./references#CD013881-bbs2-0044" title="NCT04616586. Siltuximab in viral ARds. Study (SILVAR). clinicaltrials.gov/ct2/show/NCT04616586 (first received October 29, 2020). ">NCT04616586</a>). </p> </section> <section id="CD013881-sec-0067"> <h5 class="title">Levilimab</h5> <p>No unpublished results have been found for levilimab compared to standard care or placebo. </p> </section> </section> </section> <section id="CD013881-sec-0068"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias assessments summarize the risk of bias assessment by comparison and by outcome. For 'tocilizumab vs standard care/placebo' see <a href="#CD013881-tbl-0007">Table 1</a>, <a href="#CD013881-tbl-0008">Table 2</a>, <a href="#CD013881-tbl-0009">Table 3</a>, <a href="#CD013881-tbl-0010">Table 4</a>, <a href="#CD013881-tbl-0011">Table 5</a>, <a href="#CD013881-tbl-0012">Table 6</a>, <a href="#CD013881-tbl-0013">Table 7</a>, <a href="#CD013881-tbl-0014">Table 8</a>, <a href="#CD013881-tbl-0015">Table 9</a>, and <a href="#CD013881-tbl-0016">Table 10</a>. For 'sarilumab vs standard care/placebo', see <a href="#CD013881-tbl-0017">Table 11</a>, <a href="#CD013881-tbl-0018">Table 12</a>, <a href="#CD013881-tbl-0019">Table 13</a>, <a href="#CD013881-tbl-0020">Table 14</a>, <a href="#CD013881-tbl-0021">Table 15</a>, <a href="#CD013881-tbl-0022">Table 16</a>, <a href="#CD013881-tbl-0023">Table 17</a>, <a href="#CD013881-tbl-0024">Table 18</a>, <a href="#CD013881-tbl-0025">Table 19</a>, and <a href="#CD013881-tbl-0026">Table 20</a>. For 'clazakizumab vs standard care/placebo', see <a href="#CD013881-tbl-0027">Table 21</a>, <a href="#CD013881-tbl-0028">Table 22</a>, <a href="#CD013881-tbl-0029">Table 23</a>, <a href="#CD013881-tbl-0030">Table 24</a>, <a href="#CD013881-tbl-0031">Table 25</a>, <a href="#CD013881-tbl-0032">Table 26</a>, and <a href="#CD013881-tbl-0033">Table 27</a>. For 'olokizumab vs standard care/placebo', see <a href="#CD013881-tbl-0034">Table 28</a>, <a href="#CD013881-tbl-0035">Table 29</a>, and <a href="#CD013881-tbl-0036">Table 30</a>. For 'siltuximab vs standard care/placebo', see <a href="#CD013881-tbl-0037">Table 31</a>, <a href="#CD013881-tbl-0038">Table 32</a>, <a href="#CD013881-tbl-0039">Table 33</a>, <a href="#CD013881-tbl-0040">Table 34</a>, <a href="#CD013881-tbl-0041">Table 35</a>, <a href="#CD013881-tbl-0042">Table 36</a>, <a href="#CD013881-tbl-0043">Table 37</a>, and <a href="#CD013881-tbl-0044">Table 38</a>. For 'levilimab vs standard care/placebo', see <a href="#CD013881-tbl-0045">Table 39</a>, <a href="#CD013881-tbl-0046">Table 40</a>, <a href="#CD013881-tbl-0047">Table 41</a>, <a href="#CD013881-tbl-0048">Table 42</a>, and <a href="#CD013881-tbl-0049">Table 43</a>. </p> <div class="table" id="CD013881-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias table: tocilizumab vs standard care/placebo. Clinical improvement (D28)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>1.Randomization</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>2.Deviations from intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>3.Missing outcome data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>4.Measurement of the outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>5.Selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>. <b>Rob 2. Deviations from intervention</b>:<br/>Quote: “Open‐label study”<br/>Comment: Unblinded study.<br/>Deviations from intended intervention arising because of the study context:<br/>No participant cross over.<br/>Administration of co‐interventions of interest (antivirals, corticosteroids, and biologics) were reported. The proportions of patients receiving antivirals and steroids were imbalanced between two arms (&gt;10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced.<br/>Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect.<br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate.<br/>Measurement or ascertainment of outcome probably does not differ between groups.<br/>Unblinded study (outcome assessor).<br/>Mortality is an observer‐reported outcome not involving judgement. </p> <p><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>. <b>Rob 2. Deviations from intervention</b>:<br/>Quote: "the trial was open label" <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>Cross over: 15 (23%) patients in the standard care arm received the study treatment. For 12 (18%) the studied treatment was administered because of clinical worsening as planned in the protocol. Nevertheless, this decision could have been influenced by the trial context. <br/>Administration of co‐interventions of interest were reported and not balanced: antivirals (35% vs 47%) and corticosteroids (10% vs 10.6%). These deviations could affect the outcome. Nevertheless, this domain was rated as Some Concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of clinical improvement probably does not differ between groups. <br/>Unblinded study. <br/>Assessment of this outcome requires clinical judgement and can be influenced by knowledge of the intervention assignment, but is not likely in the context of the pandemic. <br/><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>. <b>Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol and statistical analysis plan were available. <br/>Clinical improvement (defined as discharge) is not present in the protocol or registry. <br/>No information on whether the results were selected from multiple outcome measurements or analyses of the data. </p> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>. <b>Rob 1. Randomization</b>:<br/>RoB assessment consulted from The WHO Rapid Evidence Appraisal for COVID‐19 Therapies (REACT) Working Group "Association Between Administration of IL‐6 Antagonists and Mortality Among Patients Hospitalized for COVID‐19: A Meta‐analysis." JAMA. 2021;326(6):499–518 due to unavailability of trial details. </p> <p><a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>. <b>Rob 1. Randomization</b>:<br/>Quote: "Eligible patients (one or two days after hospitalization) were randomly distributed to the control and intervention groups by block randomization (1:1 ratio." <br/>Comment: Allocation sequence probably random. Unclear allocation concealment. <br/><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>. <b>Rob 2. Deviations from intervention</b>:<br/>*Quote: "In this study, patients, investigators, and outcome assessors did not inform which group received an intervention. Besides, a placebo was not used in the control group." <br/>Comment: Unclear blinding (unclear if participants and personnel/carers blinded) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Biologics were the intervention. <br/>Corticosteroids reported and balanced between groups. Antivirals reported and not balanced between groups: 35% in the Tocilizumab versus 10% in the standard care arm. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were ana lysed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>. <b>Rob 3. Missing outcome data</b>:<br/>Comment: 40 participants randomized; 36 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>3 participants in the treatment arm and 1 in the standard care arm refused to participate before start of the intervention. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome </p> <p><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a><b>. Rob 5. Selection of the reported results</b>:<br/>Comment: The trial registry was available. <br/>clinical improvement outcome (D28) (defined as discharge) not pre‐specified. <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> <p><a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>. <b>Rob 2. Deviations from intervention</b>:<br/>Quote: “open label” trial. <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>Cross over: 2/64 (3%) of the control arm received tocilizumab. <br/>Co‐interventions of interest, corticosteroids, and antivirals were reported, but no information on another co‐intervention of interest: biologics. Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis for this outcome. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study. <br/>Assessment of this outcome requires clinical judgement and can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>. <b>Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids. Antivirals were not administered. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention </p> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>. <b>Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol and statistical analysis plan were not available, and the registry was retrospective (dated October 8, 2021). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as prespecified. </p> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>. <b>Rob 3. Missing outcome data</b>:<br/>Comment: 97 participants randomized; 92 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>. <b>Rob 5. Selection of the reported results</b>:<br/>Comment: The prospective registry was available (dated March 31st, 2020). <br/>Outcomes not pre‐specified in the registry (time point not reported/different).<br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial not analyzed as pre‐specified. </p> </div> </div> <div class="table" id="CD013881-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias table: tocilizumab vs standard care/placebo. Clinical improvement (D60)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>1.Randomization</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>2.Deviations from intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>3.Missing outcome data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>4.Measurement of the outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>5.Selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>. <b>Rob 3. Missing outcome data</b>:<br/>Comment: 97 participants randomized; 92 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> </div> </div> <div class="table" id="CD013881-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. WHO Clinical Progression Score level 7 or above (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Hermine 2020. Rob 2. Deviation from Intervention</b>:<br/>Quote: “Open‐label study”<br/>Comment: Unblinded study.<br/>Deviations from intended intervention arising because of the study context:<br/>No participant cross over.<br/>Administration of co‐interventions of interest (antivirals, corticosteroids, and biologics) were reported. The proportions of patients receiving antivirals and steroids were imbalanced between two arms (&gt;10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced.<br/>Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect.<br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>HMO‐0224‐20 2021. Rob 1. Randomization</b>:<br/>RoB assessment consulted from The WHO Rapid Evidence Appraisal for COVID‐19 Therapies (REACT) Working Group "Association Between Administration of IL‐6 Antagonists and Mortality Among Patients Hospitalized for COVID‐19: A Meta‐analysis." JAMA. 2021;326(6):499–518 due to unavailability of trial details. </p> <p><b>Rutgers 2021.Rob 1. Randomization</b>:<br/>Quote: “Randomization was stratified according to the use of hydroxychloroquine and to (on admission) agreed restrictions for ICU eligibility (ICU eligible or ICU non‐eligible).” <br/>Comment: Allocation sequence probably random. No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. </p> <p><b>Veiga 2021.Rob 2. Deviation from Intervention</b>:<br/>Quote: “open label” trial. <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>Cross over: 2/64 (3%) of the control arm received tocilizumab. <br/>Co‐interventions of interest, corticosteroids, and antivirals were reported, but no information on another co‐intervention of interest: biologics. Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis for this outcome. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Broman 2022. Rob 2. Deviation from Intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids. Antivirals were not administered. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Broman 2022. Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol and statistical analysis plan were not available, and the registry was retrospective (dated October 8, 2021).<br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data.<br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </div> <div class="table" id="CD013881-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. All‐cause mortality (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rosas 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Hermine 2020.Rob 2. Deviations from intervention</b>:<br/>Quote: “Open‐label study”<br/>Comment: Unblinded study.<br/>Deviations from intended intervention arising because of the study context:<br/>No participant cross over.<br/>Administration of co‐interventions of interest (antivirals, corticosteroids, and biologics) were reported. The proportions of patients receiving antivirals and steroids were imbalanced between two arms (&gt;10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced.<br/>Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect.<br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Salvarani 2020. Rob 2. Deviations from intervention:</b> </p> <p>Quote: "the trial was open label"</p> <p>Comment: Unblinded study.</p> <p>Deviations from intended intervention arising because of the study context:</p> <p>Cross over: 15 (23%) patients in the standard care arm received the study treatment. For 12 (18%) the studied treatment was administered because of clinical </p> <p>worsening as planned in the protocol. Nevertheless, this decision could have been influenced by the trial context. </p> <p>Administration of co‐interventions of interest were reported and not balanced: antivirals (35% vs 47%) and corticosteroids (10% vs 10.6%). These deviations </p> <p>could affect the outcome. Nevertheless, this domain was rated as Some Concern as it is impossible to distinguish deviation because of trial context and </p> <p>deviation because of intervention effect.</p> <p>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to </p> <p>intervention.</p> <p><b>Gordon 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: corticosteroids (252/272 vs 46/48 vs 293/312) were administered and balanced; antivirals (remdesivir: 107/341 vs 21/48 vs 133/389) were reported and imbalanced. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>HMO‐0224‐20 2021.Rob 1. Randomization</b>:<br/>RoB assessment consulted from The WHO Rapid Evidence Appraisal for COVID‐19 Therapies (REACT) Working Group "Association Between Administration of IL‐6 Antagonists and Mortality Among Patients Hospitalized for COVID‐19: A Meta‐analysis." JAMA. 2021;326(6):499–518 due to unavailability of trial details. </p> <p><b>Rutgers 2021.Rob 1. Randomization</b>:<br/>Quote: “Randomization was stratified according to the use of hydroxychloroquine and to (on admission) agreed restrictions for ICU eligibility (ICU eligible or ICU non‐eligible).” <br/>Comment: Allocation sequence probably random. No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. </p> <p><b>Soin 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: "After randomization, none of the study personnel or patients was masked to treatment assignment in this open‐label trial." Comment: Unblinded study (participants and personnel/carers). <br/>Deviations from intended intervention arising because of the study context. <br/>One patient randomly assigned to the standard care group inadvertently received tocilizumab at baseline and was included in the tocilizumab group for all analyses (one cross‐over) <br/>Information on the administration of co‐interventions of interest was provided: antivirals and corticosteroids. Biologics were not reported. <br/>Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Participants were not analyzed according to their randomized groups for the outcome. <br/>Of note, 1 participant randomized to the control group was analyzed in the intervention group. Nevertheless, we considered the analysis to be probably appropriate to estimate the effect of assignment to intervention. </p> <p><b>Talaschian 2021.Rob 1. Randomization</b> :<br/>Quote: "Eligible patients (one or two days after hospitalization) were randomly distributed to the control and intervention groups by block randomization (1:1 ratio." <br/>Comment: Allocation sequence probably random. Unclear allocation concealment. <br/><b>Talaschian 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "In this study, patients, investigators, and outcome assessors did not inform which group received an intervention. Besides, a placebo was not used in the control group." <br/>Comment: Unclear blinding (unclear if participants and personnel/carers blinded) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Biologics were the intervention. <br/>Corticosteroids reported and balanced between groups. Antivirals reported and not balanced between groups: 35% in the Tocilizumab versus 10% in the standard care arm. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Talaschian 2021.Rob 3. Missing outcome data</b> :<br/>Comment: 40 participants randomized; 36 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>3 participants in the treatment arm and 1 in the standard care arm refused to participate before start of the intervention. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome <br/><b>Talaschian 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The trial registry was available. <br/>Outcome has different time point listed in the registry. <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> <p><b>Veiga 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: “open label” trial. <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>Cross over: 2/64 (3%) of the control arm received tocilizumab. <br/>Co‐interventions of interest, corticosteroids, and antivirals were reported, but no information on another co‐intervention of interest: biologics. Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis for this outcome. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Broman 2022. Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids. Antivirals were not administered. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention.<br/><b>Broman 2022. Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol and statistical analysis plan were not available, and the registry was retrospective (dated October 8, 2021). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> <p><b>Hermine 2022. Rob 3. Missing outcome data</b>:<br/>Comment: 97 participants randomized; 92 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> </div> </div> <div class="table" id="CD013881-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. All‐cause mortality (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.Randomization</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.Deviations from intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.Missing outcome data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.Measurement of the outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.Selection of the reported results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Hermine 2020.Rob 2. Deviations from intervention</b>:<br/>Quote: “Open‐label study”<br/>Comment: Unblinded study.<br/>Deviations from intended intervention arising because of the study context:<br/>No participant cross over.<br/>Administration of co‐interventions of interest (antivirals, corticosteroids, and biologics) were reported. The proportions of patients receiving antivirals and steroids were imbalanced between two arms (&gt;10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced.<br/>Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect.<br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Derde 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: "Open‐label design" <br/>Comment: Unblinded study (participants and personnel/carers). <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest, antivirals, biologics, and corticosteroids were reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>HMO‐0224‐20 2021</b> . <b>Rob 1. Randomization</b>:<br/>RoB assessment consulted from The WHO Rapid Evidence Appraisal for COVID‐19 Therapies (REACT) Working Group "Association Between Administration of IL‐6 Antagonists and Mortality Among Patients Hospitalized for COVID‐19: A Meta‐analysis." JAMA. 2021;326(6):499–518 due to unavailability of trial details. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b>:<br/>Comment: 97 participants randomized; 92 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> </div> </div> <div class="table" id="CD013881-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Incidence of any adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.Randomization</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.Deviations from intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.Missing outcome data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.Measurement of the outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.Selection of the reported results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>7</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>8</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>9</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sub>10</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Quote: “Open‐label study” Comment: unblinded study. </p> <p>Deviations from intended intervention arising because of the study context: three participants in the treatment group did not receive study drug. Administration of co‐interventions of interest (antivirals, corticosteroids and biologics) were reported. The proportions of participants receiving antivirals and steroids were imbalanced between two arms (&gt; 10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced. Nevertheless, this domain was rated as 'Some Concerns' as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><sup>2</sup> Comment: method of measuring the outcome probably appropriate. Measurement of outcome probably does not differ between groups. Unblinded study. The outcome may contain both clinically‐ and laboratory‐detected events. Assessment of this outcome can be influenced by knowledge of the intervention assignment but is not likely in the context of a pandemic. </p> <p><sup>3</sup> Quote: "the trial was open label" Comment: unblinded study. </p> <p>Deviations from intended intervention arising because of the study context: cross over: 15 (23%) participants in the standard care arm received the study treatment. For 12 (18%) the studied treatment was administered because of clinical worsening as planned in the protocol. Nevertheless, this decision could have been influenced by the trial context. Administration of co‐interventions of interest were reported and not balanced: antivirals (35% vs 47%) and corticosteroids (10% vs 10.6%). These deviations could affect the outcome and were not balanced. Nevertheless, this domain was rated as 'Some Concern' as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><sup>4</sup> Comment: method of measuring the outcome probably appropriate. Measurement of outcome probably does not differ between groups. Unblinded study. The outcome may contain both clinically‐ and laboratory‐detected events. Assessment of this outcome can be influenced by knowledge of the intervention assignment but is not likely in the context of a pandemic. </p> <p><sup>5</sup> Quote: "Randomisation numbers were generated using SAS statistical software package (SAS Institute, Cary, USA). A computer‐ generated 1:1 block randomization scheme was used to assign participants to either treatment group or control one. Each consecutively coded participant was randomly enrolled by the sub‐site investigators until the total number of cases allocated to the site was reached." Comment: Allocation sequence random. Allocation concealment unclear. </p> <p><sup>6</sup> Quote: "One case in the control group aggravated on day three after randomization was transferred to the tocilizumab group according to the rules of the study protocol." Comment: unblinded study. Deviations from intended intervention arising because of the study context: one participant cross‐over. No information on administration of any co‐interventions of interest: antivirals, corticosteroids, biologics. Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. Participants were not analyzed according to their randomized groups for the outcome. Of note, 1 participant randomized to the control group was analyzed in the intervention group. Nevertheless, we considered the analysis to be probably appropriate to estimate the effect of assignment to intervention. </p> <p><sup>7</sup> Comment: method of measuring the outcome probably appropriate. Measurement or ascertainment of outcome probably does not differ between groups. Unblinded study. The outcome contains both clinically‐ and laboratory‐detected events. Assessment of this outcome can be influenced by knowledge of the intervention assignment but is not likely in the context of a pandemic. </p> <p><sup>8</sup> Comment: the protocol and statistical analysis plan were not available. The registry was available. Adverse events were not mentioned in the registry but reported in the paper. No information on whether results were selected from multiple outcome measurements or analyses of the data. </p> <p>9 Quote: “open label” trial. Comment: unblinded study.</p> <p>Deviations from intended intervention arising because of the study context: cross over: 2/64 (3%) of the control arm received tocilizumab. Co‐interventions of interest (corticosteroids and antivirals) were reported, but no information on another co‐intervention of interest: biologics. Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. </p> <p>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><sup>10</sup> Comment: method of measuring the outcome probably appropriate. Measurement of outcome probably does not differ between groups. Unblinded study. The outcome contains both clinically‐ and laboratory‐detected events. Assessment of this outcome can be influenced by knowledge of the intervention assignment but is not likely in the context of a pandemic. </p> <p><b>Soin 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "After randomization, none of the study personnel or patients was masked to treatment assignment in this open‐label trial." Comment: Unblinded study (participants and personnel/carers). <br/>Deviations from intended intervention arising because of the study context. <br/>One patient randomly assigned to the standard care group inadvertently received tocilizumab at baseline and was included in the tocilizumab group for all analyses (one cross‐over) <br/>Information on the administration of co‐interventions of interest was provided: antivirals and corticosteroids. Biologics were not reported. <br/>Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Participants were not analyzed according to their randomized groups for the outcome. <br/>Of note, 1 participant randomized to the control group was analyzed in the intervention group. Nevertheless, we considered the analysis to be probably appropriate to estimate the effect of assignment to intervention. <br/><b>Soin 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor) <br/>The authors reported on adverse events and serious adverse events that may contain both clinically‐ and laboratory‐detected events. All these outcomes can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b> :<br/>Comment: 97 participants randomized; 92 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> </div> </div> <div class="table" id="CD013881-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Incidence of serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Hermine 2020.Rob 2. Deviations from intervention</b> :<br/>Quote: “Open‐label study”<br/>Comment: Unblinded study.<br/>Deviations from intended intervention arising because of the study context:<br/>No participant cross over.<br/>Administration of co‐interventions of interest (antivirals, corticosteroids, and biologics) were reported. The proportions of patients receiving antivirals and steroids were imbalanced between two arms (&gt;10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced.<br/>Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect.<br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention.<br/><b>Hermine 2020.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate.<br/>Measurement or ascertainment of outcome probably does not differ between groups.<br/>Unblinded study (outcome assessor).<br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Salvarani 2020.Rob 2. Deviations from intervention</b> :<br/>Quote: "the trial was open label" <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>Cross over: 15 (23%) patients in the standard care arm received the study treatment. For 12 (18%) the studied treatment was administered because of clinical worsening as planned in the protocol. Nevertheless, this decision could have been influenced by the trial context. <br/>Administration of co‐interventions of interest were reported and not balanced: antivirals (35% vs 47%) and corticosteroids (10% vs 10.6%). These deviations could affect the outcome. Nevertheless, this domain was rated as Some Concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Salvarani 2020.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study. <br/>The outcome contains both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Gordon 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: corticosteroids (252/272 vs 46/48 vs 293/312) were administered and balanced; antivirals (remdesivir: 107/341 vs 21/48 vs 133/389) were reported and imbalanced. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Gordon 2021</b> . <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ among groups. <br/>Unblinded study (outcome assessor) <br/>Outcome may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Soin 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "After randomisation, none of the study personnel or patients was masked to treatment assignment in this open‐label trial." Comment: Unblinded study (participants and personnel/carers). <br/>Deviations from intended intervention arising because of the study context. <br/>One patient randomly assigned to the standard care group inadvertently received tocilizumab at baseline and was included in the tocilizumab group for all analyses (one cross‐over) <br/>Information on the administration of co‐interventions of interest was provided: antivirals and corticosteroids. Biologics were not reported. <br/>Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Participants were not analyzed according to their randomized groups for the outcome. <br/>Of note, 1 participant randomized to the control group was analyzed in the intervention group. Nevertheless, we considered the analysis to be probably appropriate to estimate the effect of assignment to intervention. <br/><b>Soin 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor) <br/>The authors reported on adverse events and serious adverse events that may contain both clinically‐ and laboratory‐detected events. All these outcomes can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Talaschian 2021.Rob 1. Randomization</b> :<br/>Quote: "Eligible patients (one or two days after hospitalization) were randomly distributed to the control and intervention groups by block randomization (1:1 ratio." <br/>Comment: Allocation sequence probably random. Unclear allocation concealment. <br/><b>Talaschian 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "In this study, patients, investigators, and outcome assessors did not inform which group received an intervention. Besides, a placebo was not used in the control group." <br/>Comment: Unclear blinding (unclear if participants and personnel/carers blinded) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Biologics were the intervention. <br/>Corticosteroids reported and balanced between groups. Antivirals reported and not balanced between groups: 35% in the Tocilizumab versus 10% in the standard care arm. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Talaschian 2021.Rob 3. Missing outcome data</b> :<br/>Comment: 40 participants randomized; 36 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>3 participants in the treatment arm and 1 in the standard care arm refused to participate before start of the intervention. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome <br/><b>Talaschian 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The trial registry was available. <br/>Serious adverse events outcomes not pre‐specified. <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> <p><b>Veiga 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open label” trial. <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>Cross over: 2/64 (3%) of the control arm received tocilizumab. <br/>Co‐interventions of interest, corticosteroids, and antivirals were reported, but no information on another co‐intervention of interest: biologics. Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis for this outcome. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Veiga 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study. <br/>Assessment of this outcome requires clinical judgement and can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Wang 2021.Rob 1. Randomization</b> :<br/>Quote: "Randomization numbers were generated using SAS statistical software package (SAS Institute, Cary, USA). A computer‐ generated 1:1 block randomization scheme was used to assign patients to either treatment group or control one. Each consecutively coded patient was randomly enrolled by the sub‐site investigators until the total number of cases allocated to the site was reached." <br/>Allocation sequence random. Allocation concealment unclear. <br/><b>Wang 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "One case in the control group aggravated on day 3 after randomization was transferred to the tocilizumab group according to the rules of the study protocol." <br/>Comment: Unblinded study (participants and personnel/carers). <br/>Deviations from intended intervention arising because of the study context: <br/>One participant cross‐over. <br/>No information on administration of any co‐interventions of interest: antivirals, corticosteroids, biologics. <br/>Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Participants were not analyzed according to their randomized groups for the outcome. <br/>Of note, 1 participant randomized to the control group was analyzed in the intervention group. Nevertheless, we considered the analysis to be probably appropriate to estimate the effect of assignment to intervention. <br/><b>Wang 2021</b> . <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The outcome may contain both clinically‐ and laboratory‐detected events. Assessment of this outcome can be influenced by knowledge of the intervention assignment but is not likely in the context of a pandemic. </p> <p><b>Broman 2022. Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids. Antivirals were not administered. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention <br/><b>Broman 2022.Rob 4. Measurement of the outcome</b> :<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. <br/><b>Broman 2022.Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol and statistical analysis plan were not available, and the registry was retrospective (dated October 8, 2021). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b> :<br/>Comment: 97 participants randomized; 92 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> </div> </div> <div class="table" id="CD013881-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Time to clinical improvement</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Hermine 2020</b> . <b>Rob 2. Deviations from intervention</b>:<br/>Quote: “Open‐label study”<br/>Comment: Unblinded study.<br/>Deviations from intended intervention arising because of the study context:<br/>No participant cross over.<br/>Administration of co‐interventions of interest (antivirals, corticosteroids, and biologics) were reported. The proportions of patients receiving antivirals and steroids were imbalanced between two arms (&gt;10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced.<br/>Nevertheless, this domain was rated as some Concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect.<br/>Participants were analyzed according to their randomized groups for the time‐to‐event outcome. Of note, 1 vs 0 participants were excluded from the analysis because of consent withdrawal which will be assessed in domain 3. Nevertheless, we consider the analysis appropriate to estimate the effect of assignment to intervention. </p> <p><b>Hermine 2020.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate.<br/>Measurement or ascertainment of outcome probably does not differ between groups.<br/>Unblinded study (outcome assessor).<br/>Mortality is an observer‐reported outcome not involving judgement. </p> <p><b>Salama 2020.Rob 2. Deviations from intervention</b>:<br/>Quote: “double‐blind, placebo‐controlled trial” <br/>"A site blinding plan was established at each site to identify which personnel would be blinded or unblinded at a site level. A pharmacy manual and specific training in addition to completion of a site blinding plan was provided to each site. Each site had an unblinded pharmacist that randomised the patient and prepared and labelled study medication in the same method for both tocilizumab and placebo. The remainder of the study team was blinded to treatment assignment. There was no communication during the study between unblinded and blinded members. In addition, there was an unblinded medical monitor available to answer questions from the unblinded site staff. Placebo was not provided and consisted of an unaltered saline infusion bag, the same as would be used to prepare tocilizumab. The volume of tocilizumab diluted in saline appears colorless and matches saline." <br/>Comment: Blinded study. Participants were blinded. Carers were probably blinded. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 10 vs 1 participants were excluded from the analysis post‐randomization because they did not receive the drug. This method was considered inappropriate to estimate the effect of assignment to intervention for this time‐to‐event outcome. There was probably no substantial impact of failure to analyze participants according to their randomized groups. </p> <p><b>Salvarani 2020.Rob 2. Deviations from intervention</b> :<br/>Quote: "the trial was open label" <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>Cross over: 15 (23%) patients in the standard care arm received the study treatment. For 12 (18%) the studied treatment was administered because of clinical worsening as planned in the protocol. Nevertheless, this decision could have been influenced by the trial context. <br/>Administration of co‐interventions of interest were reported and not balanced: antivirals (35% vs 47%) and corticosteroids (10% vs 10.6%). These deviations could affect the outcome. Nevertheless, this domain was rated as Some Concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Salvarani 2020.Rob 4. Measurement of the outcome</b> :<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of time to clinical improvement probably does not differ between groups. <br/>Unblinded study. <br/>Assessment of this outcome requires clinical judgement and can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. <br/><b>Salvarani 2020.Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol and statistical analysis plan were available. <br/>Time to clinical improvement (defined as discharge) is not present in the protocol or registry. <br/>No information on whether the results were selected from multiple outcome measurements or analyses of the data. </p> <p><b>Declercq 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Derde 2021. Rob 2. Deviations from intervention</b> :<br/>Quote: "Open‐label design" <br/>Comment: Unblinded study (participants and personnel/carers). <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest, antivirals, biologics and corticosteroids were reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 9 (tocilizumab), 2 (sarilumab), 8 (anakinra) participants were excluded from the analysis post‐randomization because outcome data were not available which is accounted for in domain 3. <br/>This method was considered appropriate to estimate the effect of assignment to intervention for this outcome. <br/><b>Derde 2021</b> . <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome does not differ among groups. <br/>Unblinded study (outcome assessor) <br/>Clinical improvement (defined as hospital discharge) require clinical judgement and could be affected by knowledge of intervention receipt. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b> :<br/>Comment: 97 participants randomized; 92 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022. Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Rosas 2022.Rob 2. Deviations from intervention</b>:<br/>Quote: "Masking: Double (Participant, Investigator)" <br/>Comment: Blinded study (participants and personnel/carers) <br/>Participants were analyzed according to their randomized groups for the time‐to‐event outcome. <br/>Of note, 2 vs 1 participants were excluded from the (time to clinical improvement) analysis post‐randomization for reasons other than missing data. 1 vs 1 were excluded from the (time to death) analysis post randomization because of a randomization error. 11 vs 12 participants were excluded from the (time to viral negative conversion) analysis post‐randomization because they did not have at least one virology assessment. <br/>This method was considered inappropriate to estimate the effect of assignment to intervention for this outcome. There was probably no substantial impact of failure to analyze participants according to their randomized groups. </p> </div> </div> <div class="table" id="CD013881-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Time to WHO score 7 or above</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.Randomization</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.Deviations from</b> </p> <p><b>intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.Missing outcome</b> </p> <p><b>data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.Measurement of</b> </p> <p><b>the outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.Selection of the</b> </p> <p><b>reported results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns <sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns <sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Quote: “Open‐label study” Comment: unblinded study. </p> <p>Deviations from intended intervention arising because of the study context: 3 participants in the treatment group did not receive study drug. Administration of co‐interventions of interest (antivirals, corticosteroids and biologics) were reported. The proportions of participants receiving antivirals and steroids were imbalanced between 2 arms (&gt; 10% absolute difference between the 2 arms) for steroids. This deviation could affect the outcome and was not balanced. Nevertheless, this domain was rated as Some Concerns as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. Participants were analyzed according to their randomized groups for the outcome. Of note, 1 vs 0 participants were excluded from the analysis because of consent withdrawal. Nevertheless, we consider the analysis appropriate to estimate the effect of assignment to intervention. </p> <p><sup>2</sup> Quote: “double‐blind, placebo‐controlled trial.” “A site blinding plan was established at each site to identify which personnel would be blinded or unblinded at a site level. A pharmacy manual and specific training in addition to completion of a site blinding plan was provided to each site. Each site had an unblinded pharmacist that randomized the participant and prepared and labeled study medication in the same method for both tocilizumab and placebo. The remainder of the study team was blinded to treatment assignment. There was no communication during the study between unblinded and blinded members. In addition, there was an unblinded medical monitor available to answer questions from the unblinded site staff. Placebo was not provided and consisted of an unaltered saline infusion bag, the same as would be used to prepare tocilizumab. The volume of tocilizumab diluted in saline appears colorless and matches saline.” </p> <p>Comment: Blinded study. Participants were blinded. Carers were probably blinded. Participants were analyzed according to their randomized groups for the outcome. Of note, 10 vs 1 participants were excluded from the analysis post‐randomization because they did not receive the drug. This method was considered inappropriate to estimate the effect of assignment to intervention for this time‐to‐event outcome. There was probably no substantial impact of failure to analyze participants according to their randomized groups </p> <p><b>Rutgers 2021.Rob 1. Randomization</b>:<br/>Quote: “Randomization was stratified according to the use of hydroxychloroquine and to (on admission) agreed restrictions for ICU eligibility (ICU eligible or ICU non‐eligible).” <br/>Comment: Allocation sequence probably random. No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. </p> </div> </div> <div class="table" id="CD013881-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Time to death</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Hermine 2020. Rob 2. Deviations from intervention</b>:<br/>Quote: “Open‐label study”<br/>Comment: Unblinded study.<br/>Deviations from intended intervention arising because of the study context:<br/>No participant cross over.<br/>Administration of co‐interventions of interest (antivirals, corticosteroids, and biologics) were reported. The proportions of patients receiving antivirals and steroids were imbalanced between two arms (&gt;10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced.<br/>Nevertheless, this domain was rated as some Concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect.<br/>Participants were analyzed according to their randomized groups for the time‐to‐event outcome. Of note, 1 vs 0 participants were excluded from the analysis because of consent withdrawal which will be assessed in domain 3. Nevertheless, we consider the analysis appropriate to estimate the effect of assignment to intervention. </p> <p><b>Derde 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: "Open‐label design" <br/>Comment: Unblinded study (participants and personnel/carers). </p> <p>No participant cross‐over. <br/>No information on administration of co‐interventions of interest, antivirals, biologics, and corticosteroids were reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 9 (tocilizumab), 2 (sarilumab), 8 (anakinra) participants were excluded from the analysis post‐randomization because outcome data were not available which is accounted for in domain 3. <br/>This method was considered appropriate to estimate the effect of assignment to intervention for this outcome.<br/><b>Rutgers 2021.Rob 1. Randomization</b>:<br/>Quote: “Randomization was stratified according to the use of hydroxychloroquine and to (on admission) agreed restrictions for ICU eligibility (ICU eligible or ICU non‐eligible).” <br/>Comment: Allocation sequence probably random. No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. </p> <p><b>Talaschian 2021.Rob 1. Randomization</b> :<br/>Quote: "Eligible patients (one or two days after hospitalization) were randomly distributed to the control and intervention groups by block randomization (1:1 ratio." <br/>Comment: Allocation sequence probably random. Unclear allocation concealment. <br/><b>Talaschian 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "In this study, patients, investigators, and outcome assessors did not inform which group received an intervention. Besides, a placebo was not used in the control group." <br/>Comment: Unclear blinding (unclear if participants and personnel/carers blinded) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Biologics were the intervention. <br/>Corticosteroids reported and balanced between groups. Antivirals reported and not balanced between groups: 35% in the Tocilizumab versus 10% in the standard care arm. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 3 vs 1 participants were excluded from the analysis post‐randomization due to missing data which is accounted for in domain 3. This method was considered appropriate to estimate the effect of assignment to intervention for this outcome. <br/><b>Talaschian 2021</b> . <b>Rob 3. Missing outcome data</b> :<br/>Comment: 40 participants randomized; 36 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>3 participants in the treatment arm and 1 in the standard care arm refused to participate before start of the intervention. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome <br/><b>Talaschian 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The trial registry was available. <br/>Outcome has different timepoint listed in the registry. <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b>:<br/>Comment: 97 participants randomized; 92 participants analyzed. </p> <p>Data not available for all or nearly all participants randomized.</p> <p>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><b>Rosas 2022.Rob 2. Deviations from intervention</b>:<br/>Quote: "Masking: Double (Participant, Investigator)" <br/>Comment: Blinded study (participants and personnel/carers) <br/>Participants were analyzed according to their randomized groups for the time‐to‐event outcome. <br/>Of note, 2 vs 1 participants were excluded from the (time to clinical improvement) analysis post‐randomization for reasons other than missing data. 1 vs 1 were excluded from the (time to death) analysis post randomization because of a randomization error. 11 vs 12 participants were excluded from the (time to viral negative conversion) analysis post‐randomization beca use they did not have at least one virology assessment. <br/>This method was considered inappropriate to estimate the effect of assignment to intervention for this outcome. There was probably no substantial impact of failure to analyse participants according to their randomized groups. </p> </div> </div> <div class="table" id="CD013881-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC)/placebo. Clinical improvement (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Mariette 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Mariette 2021.Rob 4. Measurement of the outcome</b> :<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. <br/><b>Mariette 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol, statistical analysis plan and registry were available (dated March 27, 2020). <br/>Outcome not pre‐specified (timepoint not reported/different). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial not analyzed as pre‐specified. </p> <p><b>Merchante 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids and biologics. Antivirals (3 vs 7 vs 4) and anticoagulant were reported (37 vs 39 vs 39) and were balanced between groups. <br/>Hence, no sufficient information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Merchante 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unclear blinding (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Sancho‐Lopez 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "Our clinical trial was a national, multicenter, randomized, open label, controlled clinical study". <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Corticosteroids were administered for all patients. Antiviral were provided but no numbers are reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Sancho‐Lopez 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Branch‐Elliman 2022.Rob 4. Measurement of the outcome</b> :<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. <br/><b>Branch‐Elliman 2022.Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol, statistical analysis plan, and registry (submitted April 20, 2020) were available. <br/>Outcome not pre‐specified. <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> <p><b>Garcia‐Vicuna 2022.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: antivirals, corticosteroids and biologics are reported: lopinavir/Ritonavir: 4 vs 1, methylprednisolone bolus: 14 vs 3 and tocilizumab: 0 vs 3. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Garcia‐Vicuna 2022. Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b> :<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022.Rob 4. Measurement of the outcome</b> :<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. <br/><b>Hermine 2022.Rob 5. Selection of the reported results</b>:<br/>Comment: The prospective registry was available (dated March 25th, 2020). <br/>Outcomes not pre‐specified in the registry (timepoint not reported/different).<br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial not analyzed as pre‐specified. </p> </div> </div> <div class="table" id="CD013881-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC)/placebo. Clinical Improvement (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Mariette 2021. Rob 2. Deviations from interventions:</b> </p> <p>Quote: “open‐label study”</p> <p>Comment: Unblinded study (participants and personnel/carers)</p> <p>Deviations from intended intervention arising because of the study context:</p> <p>No participant cross‐over.</p> <p>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). </p> <p>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. </p> <p>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Mariette 2021.Rob 4. Measurement of the outcome</b> :<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. <br/><b>Mariette 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol, statistical analysis plan and registry were available (dated March 27, 2020). <br/>Outcome not pre‐specified (timepoint not reported/different). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial not analyzed as pre‐specified. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b> :<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> </div> </div> <div class="table" id="CD013881-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC)/placebo. WHO Clinical Progression Score level 7 or above (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>a </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Mariette 2021.Rob 2. Deviation from Intervention</b>:<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Sancho‐Lopez 2021.Rob 2. Deviation from Intervention</b>:<br/>Quote: "Our clinical trial was a national, multicenter, randomized, open label, controlled clinical study". <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Corticosteroids were administered for all patients. Antiviral were provided but no numbers are reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Garcia‐Vicuna 2022.Rob 2. Deviation from Intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: antivirals, corticosteroids and biologics are reported: Lopinavir/Ritonavir: 4 vs 1, methylprednisolone bolus: 14 vs 3 and Tocilizumab: 0 vs 3. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Sivapalasingam 2022a.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022a. Rob 3. Missing outcome data</b>:<br/>Comment: 463 participants randomized; 436 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: randomized but not treated (n=6), withdrew consent(n=5), death before start of treatment(n=1) and lost to follow up (n=21). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> </div> </div> <div class="table" id="CD013881-tbl-0020"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). All‐cause mortality (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>a </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>b </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Gordon 2021. Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: corticosteroids (252/272 vs 46/48 vs 293/312) were administered and balanced; antivirals (remdesivir: 107/341 vs 21/48 vs 133/389) were reported and imbalanced. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Mariette 2021.Rob 2. Deviation from Intervention</b>:<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Merchante 2021. Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids and biologics. Antivirals (3 vs 7 vs 4) and anticoagulant were reported (37 vs 39 vs 39) and were balanced between groups. <br/>Hence, no sufficient information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Sancho‐Lopez 2021.Rob 2. Deviation from Intervention</b> :<br/>Quote: "Our clinical trial was a national, multicenter, randomized, open label, controlled clinical study". <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Corticosteroids were administered for all patients. Antiviral were provided but no numbers are reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention.<br/><b>Garcia‐Vicuna 2022.Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: antivirals, corticosteroids and biologics are reported: Lopinavir/Ritonavir: 4 vs 1, methylprednisolone bolus: 14 vs 3 and Tocilizumab: 0 vs 3. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Hermine 2022. Rob 3. Missing outcome data</b>:<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><b>Sivapalasingam 2022a.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022a. Rob 3. Missing outcome data</b>:<br/>Comment: 463 participants randomized; 436 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: randomized but not treated (n=6), withdrew consent(n=5), death before start of treatment(n=1) and lost to follow up (n=21). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><b>Sivapalasingam 2022b.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022b.Rob 3. Missing outcome data</b>:<br/>Comment: 1407 participants randomized; 1330 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons for potential missing data: randomized but not treated (n=42), discontinuation due to investigator/sponsor decision (n=1), withdrawal of consent (n=9) and loss to follow‐up (n=75). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> </div> </div> <div class="table" id="CD013881-tbl-0021"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). All‐cause mortality (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>a </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>b </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Derde 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: "Open‐label design" <br/>Comment: Unblinded study (participants and personnel/carers). <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest, antivirals, biologics and corticosteroids were reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Mariette 2021. Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Garcia‐Vicuna 2022.Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: antivirals, corticosteroids and biologics are reported: Lopinavir/Ritonavir: 4 vs 1, methylprednisolone bolus: 14 vs 3 and Tocilizumab: 0 vs 3. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b>:<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><b>Sivapalasingam 2022a.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022a. Rob 3. Missing outcome data</b>:<br/>Comment: 463 participants randomized; 436 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: randomized but not treated (n=6), withdrew consent(n=5), death before start of treatment(n=1) and lost to follow up (n=21). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><b>Sivapalasingam 2022b.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022b.Rob 3. Missing outcome data</b>:<br/>Comment: 1407 participants randomized; 1330 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons for potential missing data: randomized but not treated (n=42), discontinuation due to investigator/sponsor decision (n=1), withdrawal of consent (n=9) and loss to follow‐up (n=75). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> </div> </div> <div class="table" id="CD013881-tbl-0022"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). Incidence of adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>a </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>b </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Lescure 2021.Rob 5. Selection of the reported results</b>: </p> <p>Comment: The trial registry was available and consulted (up to version dated April 3rd, 2020). <br/>Outcome not pre‐specified <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> <p><b>Mariette 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Mariette 2021.Rob 4. Measurement of the outcome</b> :<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. <br/><b>Sancho‐Lopez 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "Our clinical trial was a national, multicenter, randomized, open label, controlled clinical study". <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Corticosteroids were administered for all patients. Antiviral were provided but no numbers are reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Sancho‐Lopez 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that contains both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b> :<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Sivapalasingam 2022a. Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022a.Rob 3. Missing outcome data</b> :<br/>Comment: 463 participants randomized; 436 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: randomized but not treated (n=6), withdrew consent(n=5), death before start of treatment(n=1) and lost to follow up (n=21). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Sivapalasingam 2022a.Rob 5. Selection of the reported results</b>:<br/>Comment: The trial registry was available and consulted (up to version dated March 26th, 2020). <br/>Outcome not pre‐specified <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> <p><b>Sivapalasingam 2022b.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022b.Rob 3. Missing outcome data</b> :<br/>Comment: 1407 participants randomized; 1330 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons for potential missing data: randomized but not treated (n=42), discontinuation due to investigator/sponsor decision (n=1), withdrawal of consent (n=9) and loss to follow‐up (n=75). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Sivapalasingam 2022b. Rob 5. Selection of the reported results</b>:<br/>Comment: The trial registry was available and consulted (up to version dated March 26th, 2020). <br/>Outcome not pre‐specified <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> </div> </div> <div class="table" id="CD013881-tbl-0023"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). Incidence of serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>a </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>b </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Gordon 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: corticosteroids (252/272 vs 46/48 vs 293/312) were administered and balanced; antivirals (remdesivir: 107/341 vs 21/48 vs 133/389) were reported and imbalanced. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Gordon 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ among groups. <br/>Unblinded study (outcome assessor).<br/>Outcome may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Mariette 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Mariette 2021</b> . <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Sivapalasingam 2022a.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022a.Rob 3. Missing outcome data</b>:<br/>Comment: 463 participants randomized; 436 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: randomized but not treated (n=6), withdrew consent(n=5), death before start of treatment(n=1) and lost to follow up (n=21). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><b>Sivapalasingam 2022b.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022b.Rob 3. Missing outcome data</b>:<br/>Comment: 1407 participants randomized; 1330 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons for potential missing data: randomized but not treated (n=42), discontinuation due to investigator/sponsor decision (n=1), withdrawal of consent (n=9) and loss to follow‐up (n=75). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><b>Garcia‐Vicuna 2022. Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: antivirals, corticosteroids and biologics are reported: lopinavir/Ritonavir: 4 vs 1, methylprednisolone bolus: 14 vs 3 and tocilizumab: 0 vs 3. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Garcia‐Vicuna 2022.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Hermine 2022. Rob 3. Missing outcome data</b> :<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022. Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> </div> </div> <div class="table" id="CD013881-tbl-0024"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). Time to clinical improvement</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Derde 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "Open‐label design" <br/>Comment: Unblinded study (participants and personnel/carers). <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest, antivirals, biologics, and corticosteroids were reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 9 (tocilizumab), 2 (sarilumab), 8 (anakinra) participants were excluded from the analysis post‐randomization because outcome data were not available which is accounted for in domain 3. <br/>This method was considered appropriate to estimate the effect of assignment to intervention for this outcome. <br/><b>Derde 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome does not differ among groups. <br/>Unblinded study (outcome assessor) <br/>Clinical improvement (defined as hospital discharge) require clinical judgement and could be affected by knowledge of intervention receipt. </p> <p><b>Mariette 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 0 vs 4 participants were excluded from the analysis post‐randomization because they withdrew consent which will be taken into account in ROB 3. <br/><b>Mariette 2021. Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Merchante 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids and biologics. Antivirals (3 vs 7 vs 4) and anticoagulant were reported (37 vs 39 vs 39) and were balanced between groups. <br/>Hence, no sufficient information on whether deviations arose because of the trial context. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 1 vs 1 vs 0 participants were excluded from the analysis post‐randomization because [1 in group (sarilumab 200) did not comply with protocol, 1 in group (sarilumab 400) they did not receive the drug. This method was considered inappropriate to estimate the effect of assignment to intervention for this outcome. There was probably no substantial impact of failure to analyse participants according to their randomized groups. <br/><b>Merchante 2021</b> . <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unclear blinding (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Sancho‐Lopez 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "Our clinical trial was a national, multicenter, randomized, open label, controlled clinical study". <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Corticosteroids were administered for all patients. Antiviral were provided but no numbers are reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Sancho‐Lopez 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b> :<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022. Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> </div> </div> <div class="table" id="CD013881-tbl-0025"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC)/placebo. Time to WHO Score 7 or above</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Mariette 2021. Rob 2. Deviations from interventions</b> </p> <p>Quote: “open‐label study”</p> <p>Comment: Unblinded study (participants and personnel/carers)</p> <p>Deviations from intended intervention arising because of the study context:</p> <p>No participant cross‐over.</p> <p>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). </p> <p>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. </p> <p>Participants were analyzed according to their randomized groups for the outcome.</p> <p>Of note, 0 vs 4 participants were excluded from the analysis post‐randomization because they withdrew consent which will be taken into account in ROB 3. </p> <p><b>Mariette 2021. Rob 5. Selection of the reported results</b> </p> <p>Comment: The protocol, statistical analysis plan and registry were available (dated March 27, 2020). </p> <p>Outcomes not pre‐specified.</p> <p>No information on whether the result was selected from multiple outcome measurements or analyses of the data. </p> <p>Trial not analyzed as pre‐specified.</p> <p><b>Sancho‐Lopez 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: "Our clinical trial was a national, multicenter, randomized, open label, controlled clinical study". <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Corticosteroids were administered for all patients. Antiviral were provided but no numbers are reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> </div> </div> <div class="table" id="CD013881-tbl-0026"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). Time to death</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Derde 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: "Open‐label design" <br/>Comment: Unblinded study (participants and personnel/carers). <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest, antivirals, biologics, and corticosteroids were reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 9 (tocilizumab), 2 (sarilumab), 8 (anakinra) participants were excluded from the analysis post‐randomization because outcome data were not available which is accounted for in domain 3. <br/>This method was considered appropriate to estimate the effect of assignment to intervention for this outcome. </p> <p><b>Mariette 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 0 vs 4 participants were excluded from the analysis post‐randomization because they withdrew consent which will be taken into account in ROB 3. </p> <p><b>Merchante 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids and biologics. Antivirals (3 vs 7 vs 4) and anticoagulant were reported (37 vs 39 vs 39) and were balanced between groups. <br/>Hence, no sufficient information on whether deviations arose because of the trial context. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 1 vs 1 vs 0 participants were excluded from the analysis post‐randomization because [1 in group (sarilumab 200) did not comply with protocol, 1 in group (sarilumab 400) they did not receive the drug. This method was considered inappropriate to estimate the effect of assignment to intervention for this outcome. There was probably no substantial impact of failure to analyse participants according to their randomized groups. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b>:<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> </div> </div> <div class="table" id="CD013881-tbl-0027"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">ROB table: clazakizumab vs placebo. Clinical improvement (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Lonze 2022. Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol, statistical analysis plan and retrospective registry were available (dated April 9th, 2020). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </div> <div class="table" id="CD013881-tbl-0028"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 22.</span> <span class="table-title">ROB table: clazakizumab vs placebo. Clinical improvement (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Lonze 2022. Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol, statistical analysis plan and retrospective registry were available (dated April 9th, 2020). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </div> <div class="table" id="CD013881-tbl-0029"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 23.</span> <span class="table-title">ROB table: clazakizumab vs placebo. WHO Score 7 or above (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Lonze 2022. Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol, statistical analysis plan and retrospective registry were available (dated April 9th, 2020).<br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data.<br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </div> <div class="table" id="CD013881-tbl-0030"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 24.</span> <span class="table-title">ROB table: clazakizumab vs placebo. All‐cause mortality (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Jordan 2021.Rob 1. Randomization</b>:<br/>Quote: “Randomized, double‐blind, placebo‐controlled, exploratory phase II study.” <br/>Comment: Allocation sequence probably random. No information on allocation concealment. </p> </div> </div> <div class="table" id="CD013881-tbl-0031"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 25.</span> <span class="table-title">ROB table: clazakizumab vs placebo. All‐cause mortality (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Jordan 2021.Rob 1. Randomization</b>:<br/>Quote: “Randomized, double‐blind, placebo‐controlled, exploratory phase II study.” <br/>Comment: Allocation sequence probably random. No information on allocation concealment. </p> </div> </div> <div class="table" id="CD013881-tbl-0032"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 26.</span> <span class="table-title">ROB table: clazakizumab vs placebo. Incidence of any adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Jordan 2021.Rob 1. Randomization</b>:<br/>Quote: “Randomized, double‐blind, placebo‐controlled, exploratory phase II study.” <br/>Comment: Allocation sequence probably random. No information on allocation concealment. </p> </div> </div> <div class="table" id="CD013881-tbl-0033"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 27.</span> <span class="table-title">ROB table: clazakizumab vs placebo. Incidence of serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Jordan 2021.Rob 1. Randomization</b> :<br/>Quote: “Randomized, double‐blind, placebo‐controlled, exploratory phase II study.” <br/>Comment: Allocation sequence probably random. No information on allocation concealment.<br/><b>Lonze 2022. Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol, statistical analysis plan and retrospective registry were available (dated April 9th, 2020). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </div> <div class="table" id="CD013881-tbl-0034"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 28.</span> <span class="table-title">ROB table: olokizumab vs placebo. Clinical improvement (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Samsonov 2022.Rob 1. Randomization</b> :<br/>Quote: “Eligible patients were randomized to one of three treatment groups" <br/>Comment: Allocation probably random. <br/>No information on allocation concealment <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Samsonov 2022.Rob 2. Deviations from intervention</b>:<br/>Quote: “Masking: Double (Participant, Investigator)” <br/>Comment: Unclear blinding (unclear if personnel/carers blinded) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: antivirals and corticosteroids. Biologics (Tocilizumab and Sarilumab) were reported: 5 (Olokizumab arm) vs 15 (placebo arm). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> </div> </div> <div class="table" id="CD013881-tbl-0035"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 29.</span> <span class="table-title">ROB table: olokizumab vs placebo. All‐cause mortality (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Samsonov 2022.Rob 1. Randomization</b> :<br/>Quote: “Eligible patients were randomized to one of three treatment groups" <br/>Comment: Allocation probably random. <br/>No information on allocation concealment <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Samsonov 2022.Rob 2. Deviations from intervention</b>:<br/>Quote: “Masking: Double (Participant, Investigator)” <br/>Comment: Unclear blinding (unclear if personnel/carers blinded) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: antivirals and corticosteroids. Biologics (Tocilizumab and Sarilumab) were reported:5 (Olokizumab arm) vs 15 (placebo arm). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concerns as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> </div> </div> <div class="table" id="CD013881-tbl-0036"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 30.</span> <span class="table-title">ROB table: olokizumab vs placebo. Incidence of serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Samsonov 2022.Rob 1. Randomization</b> :<br/>Quote: “Eligible patients were randomized to one of three treatment groups" <br/>Comment: Allocation probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Samsonov 2022.Rob 2. Deviations from intervention</b>:<br/>Quote: “Masking: Double (Participant, Investigator)” <br/>Comment: Unclear blinding (unclear if personnel/carers blinded) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: antivirals and corticosteroids. Biologics (Tocilizumab and Sarilumab) were reported: 5 (Olokizumab arm) vs 15 (placebo arm). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> </div> </div> <div class="table" id="CD013881-tbl-0037"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 31.</span> <span class="table-title">ROB table: siltuximab vs placebo. Clinical improvement (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Declercq 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> </div> </div> <div class="table" id="CD013881-tbl-0038"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 32.</span> <span class="table-title">ROB table: siltuximab vs placebo. Clinical Improvement (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Declercq 2021</b> . <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> </div> </div> <div class="table" id="CD013881-tbl-0039"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 33.</span> <span class="table-title">ROB table: siltuximab vs placebo. All‐cause mortality (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013881-tbl-0040"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 34.</span> <span class="table-title">ROB table: siltuximab vs placebo. All‐cause mortality (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013881-tbl-0041"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 35.</span> <span class="table-title">ROB table: siltuximab vs placebo. WHO Score 7 or above (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013881-tbl-0042"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 36.</span> <span class="table-title">ROB table: siltuximab vs placebo. Incidence of serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013881-tbl-0043"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 37.</span> <span class="table-title">ROB table: siltuximab vs placebo. Time to clinical improvement</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Declercq 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> </div> </div> <div class="table" id="CD013881-tbl-0044"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 38.</span> <span class="table-title">ROB table: siltuximab vs placebo. Time to death</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013881-tbl-0045"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 39.</span> <span class="table-title">ROB table: levilimab vs placebo. Clinical improvement (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Lomakin 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The registry was retrospective (dated May 21, 2020). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </div> <div class="table" id="CD013881-tbl-0046"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 40.</span> <span class="table-title">ROB table: levilimab vs placebo. All‐cause mortality (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Lomakin 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The registry was retrospective (dated May 21, 2020). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </div> <div class="table" id="CD013881-tbl-0047"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 41.</span> <span class="table-title">ROB table: levilimab vs placebo. All‐cause mortality (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013881-tbl-0048"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 42.</span> <span class="table-title">ROB table: levilimab vs placebo. Incidence of any adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Lomakin 2021</b> . <b>Rob 5. Selection of the reported results</b>:<br/>Comment: The registry was retrospective (dated May 21, 2020). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </div> <div class="table" id="CD013881-tbl-0049"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 43.</span> <span class="table-title">ROB table: levilimab vs placebo. Incidence of serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Lomakin 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The registry was retrospective (dated May 21, 2020). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </div> <p>Overall, we judged three trials to be at high risk of bias (<a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>). </p> <section id="CD013881-sec-0069"> <h4 class="title">Risk of bias arising from the randomization process </h4> <p>Randomization was described adequately and was appropriate in 25 trials (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2; CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>). There were some concerns in six trials because the method used to conceal treatment allocation was unclear (<a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>). There was no imbalance in baseline data indicative of a problem with the randomization process. We could not assess one trial due to the absence of a publication (<a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>), but considered it to be at high risk of bias based on its assessment in the meta‐analysis published by the WHO REACT Working Group. </p> </section> <section id="CD013881-sec-0070"> <h4 class="title">Risk of bias due to deviations from intended interventions </h4> <p>We judged the risk of bias due to deviation from intended interventions to be low for all outcomes reported in 17 trials (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2; CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>). Of the 17 trials, 10 were not blinded. </p> <p>However, we rated this domain as of some concern for at least one of the outcomes reported in 11 unblinded trials (<a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>) and four blinded trials (<a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>).  </p> <p>At least some of the reported co‐interventions were not balanced in six studies (<a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>); and this could have affected the outcomes.  </p> <p>In <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>, 23% of participants allocated to the standard care arm received tocilizumab, mainly because of clinical worsening. This decision was planned in the protocol. Nevertheless, its administration could have been influenced by the trial context, and this domain was consequently rated as presenting some concerns. These deviations could be responsible for underestimating the treatment effect. Other trials raised some concerns because the co‐interventions were not completely reported (<a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>). </p> <p>Finally, we rated <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> as raising some concerns for important outcomes because participants who did not receive the drug (10 vs 1) were excluded from the analysis post‐randomization.  </p> <p>It should be noted that in <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>, 18% of participants allocated to tocilizumab did not receive the treatment allocated. We considered this deviation probably did not arise because of the trial context and assessed the domain to be low risk. </p> </section> <section id="CD013881-sec-0071"> <h4 class="title">Risk of bias due to missing outcome data </h4> <p>We judged the risk of bias due to incomplete outcome data as low for 28 trials and all outcomes since there was no or a low amount of missing data in the included trials (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>). Reports of preliminary analyses with missing information because follow‐up was not completed were rated at low risk of bias. In four studies, data were unavailable for all or nearly all the participants randomized; however, the reasons for missing data could but were not likely to depend on the true value of the outcomes, and thus we judged the risk of bias to be of some concerns (<a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2, CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>). </p> </section> <section id="CD013881-sec-0072"> <h4 class="title">Risk of bias in the measurement of the outcome </h4> <p>We judged the risk of bias to be low for all outcomes in the 11 blinded trials (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>) and the five open‐label trials (<a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>).  </p> <p>In the other 16 open trials, we considered the risk of bias to be low for observer‐reported outcomes not involving clinical judgment (i.e. mortality, WHO score seven and above, time to death and time to WHO score seven and above). We judged there to be some concerns for the outcomes that could potentially be influenced by knowledge of the intervention assignment (i.e. clinical improvement, time to clinical improvement, adverse events and serious adverse events) (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2, CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>). </p> </section> <section id="CD013881-sec-0073"> <h4 class="title">Risk of bias in the selection of the reported results</h4> <p>The protocol was available for 21 trials (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2; CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>). Neither the protocol nor the statistical analysis plan was available for the other 11 trials (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>).  </p> <p>Overall, we judged 21 trials to be at low risk of bias in this domain for all outcomes (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; REMAP‐CAP (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>); <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>).  </p> <p>This domain was, however, considered to present some concern for 11 trials (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2; CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>).  </p> <p><a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2; CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; and <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> reported some outcomes that had not been prespecified in the registry.  </p> <p>The protocol and statistical analysis plan were not available, and the registry was retrospective for <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> and <a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>. Finally, the outcomes extracted from <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a> for this meta‐analysis were not prespecified.  </p> </section> <section id="CD013881-sec-0074"> <h4 class="title">Bias due to missing results in the synthesis </h4> <p>In <a href="./appendices#CD013881-sec-0166">Appendix 9</a>, we present a matrix indicating the availability of trial results for the critical and important outcomes of each comparison included in the review. Most trials (29/32, 90.6%) reported or provided results for all the review outcomes, as prespecified in the trial registry. Evaluating tocilizumab, <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a> prespecified all‐cause mortality on D28 as an outcome but did not report it. Similarly, <a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>, evaluating olokizumab, prespecified the outcome of time to clinical improvement, but did not report it.  </p> <p>We explored the presence of small‐study effects through funnel plots for outcomes with results from more than 10 trials. For tocilizumab compared to standard care or placebo, funnel plots generally appeared symmetrical with no clear evidence of any small‐study effect (<a href="#CD013881-fig-0002">Figure 2</a>, <a href="#CD013881-fig-0003">Figure 3</a>, <a href="#CD013881-fig-0004">Figure 4</a>, <a href="#CD013881-fig-0005">Figure 5</a>, <a href="#CD013881-fig-0006">Figure 6</a>, <a href="#CD013881-fig-0007">Figure 7</a>).  </p> <div class="figure" id="CD013881-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Funnel plot Tocilizumab vs standard care or placebo. All cause mortality D28" data-id="CD013881-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-02.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot Tocilizumab vs standard care or placebo. All cause mortality D28</p> </div> </div> </div> <div class="figure" id="CD013881-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="8.1.2 Funnel plot Tocilizumab compared to standard care or placebo" data-id="CD013881-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-03.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>8.1.2 Funnel plot Tocilizumab compared to standard care or placebo</p> </div> </div> </div> <div class="figure" id="CD013881-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. Clinical improvement D28" data-id="CD013881-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-04.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. Clinical improvement D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. WHO score 7 D28" data-id="CD013881-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-05.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. WHO score 7 D28</p> </div> </div> </div> <div class="figure" id="CD013881-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. Adverse events" data-id="CD013881-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-06.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. Adverse events</p> </div> </div> </div> <div class="figure" id="CD013881-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. Serious adverse events" data-id="CD013881-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-07.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. Serious adverse events </p> </div> </div> </div> </section> </section> <section id="CD013881-sec-0075"> <h3 class="title" id="CD013881-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD013881-tbl-0001"><b>Summary of findings 1</b> Tociliuzumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</a>; <a href="./full#CD013881-tbl-0002"><b>Summary of findings 2</b> Sarilumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</a>; <a href="./full#CD013881-tbl-0003"><b>Summary of findings 3</b> Clazakizumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</a>; <a href="./full#CD013881-tbl-0004"><b>Summary of findings 4</b> Olokizumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</a>; <a href="./full#CD013881-tbl-0005"><b>Summary of findings 5</b> Siltuximab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</a>; <a href="./full#CD013881-tbl-0006"><b>Summary of findings 6</b> Levilimab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</a> </p> <section id="CD013881-sec-0076"> <h4 class="title">Tocilizumab versus standard care/placebo</h4> <p>We report the certainty of the evidence for critical outcomes in <a href="./full#CD013881-tbl-0001">summary of findings Table 1</a> and for important outcomes in <a href="./appendices#CD013881-sec-0173">Appendix 10</a> ‘Summary of Findings ‐ important outcomes’. The outcome 'WHO progression score (level 7 or above) D60 or more' was not reported in all trials. </p> <section id="CD013881-sec-0077"> <h5 class="title">Critical outcomes</h5> <section id="CD013881-sec-0078"> <h6 class="title">Clinical improvement </h6> <p>Clinical improvement was defined by a score decrease of at least two points on a 7‐category ordinal scale (<a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>), an increase of at least two points on a 6‐category ordinal scale (compared with the worst status the day of randomization) or discharge from the hospital alive (<a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>), or discharge at D28 (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2); <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>). </p> <p>In all, 15 RCTs (6116 participants) reported the proportion of participants meeting these criteria for improvement at D28 (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2); <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>). Tocilizumab probably produces little or no increase in clinical improvement at D28 (RR 1.05, 95% CI 1.00 to 1.11; I<sup>2</sup> = 24.1%; 15 RCTs; 6116 participants; absolute effect: 27 more per 1000 (from 0 fewer to 60 more); moderate‐certainty evidence; <a href="#CD013881-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD013881-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Analysis 1.1.1 Tocilizumab versus placebo or standard care. Outcome: Clinical improvement 28" data-id="CD013881-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-08.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.1 Tocilizumab versus placebo or standard care. Outcome: Clinical improvement 28 </p> </div> </div> </div> <p>One study reported a longer follow‐up of clinical improvement at ≥ D60 (<a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2)). The evidence for an effect of tocilizumab compared to standard care on clinical improvement at ≥ D60 is very uncertain (RR 1.10, 95% CI 0.81 to 1.48; 1 RCT; 97 participants; absolute effect: 61 more per 1000 (from 116 fewer to 292 more); very low‐certainty evidence; <a href="#CD013881-fig-0009">Figure 9</a>).  </p> <div class="figure" id="CD013881-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Analysis 1.1.2 Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D60" data-id="CD013881-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-09.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.2 Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D60 </p> </div> </div> </div> </section> <section id="CD013881-sec-0079"> <h6 class="title">WHO Clinical Progression Score of level 7 or above (i.e. the proportion of participants with mechanical ventilation +/‐ additional organ support or death)  </h6> <p>Thirteen RCTs (2117 participants) reported the proportion of participants with mechanical ventilation or death at D28 (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>). Overall, the evidence is uncertain for the effect of tocilizumab on the proportion of participants with a WHO‐CPS of level 7 or above at D28 (RR 0.90, 95% CI 0.72 to 1.12; I<sup>2</sup> = 19.9 %; 13 RCTs, 2117 participants; absolute effect: 22 fewer per 1000 (from 61 fewer to 26 more); low‐certainty evidence; <a href="#CD013881-fig-0010">Figure 10</a>).  </p> <div class="figure" id="CD013881-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Analysis 1.1.3 Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-10.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.3 Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> </div> <p>We did not obtain data for longer‐term follow‐up (≥ D60).</p> </section> <section id="CD013881-sec-0080"> <h6 class="title">All‐cause mortality </h6> <p>Eighteen RCTs (7428 participants) reported all‐cause mortality at D28 (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2); <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>), and nine RCTs (2775 participants) at ≥ D60 (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2); <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>). One additional study (<a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>), which did not contribute to the pooled effect estimate, also reported on the outcome in 26 participants with zero events in both groups. </p> <p>Tocilizumab reduces all‐cause mortality at D28 compared to standard care alone or to placebo (RR 0.88, 95% CI 0.81 to 0.94; I<sup>2</sup> = 0.0%; 18 RCTs, 7428 participants; absolute effect 34 fewer per 1000 (from 54 fewer to 17 fewer); high‐certainty evidence; <a href="#CD013881-fig-0011">Figure 11</a>).  </p> <div class="figure" id="CD013881-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Analysis 1.1.4 Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-11.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.4 Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> </div> <p>The evidence of an effect of tocilizumab on all‐cause mortality is uncertain at ≥ D60 (RR 0.91, 95% CI 0.80 to 1.04; I<sup>2</sup> = 0.0%; 9 RCTs; 2775 participants; absolute effect: 24 fewer per 1000 (from 53 fewer to 11 more); low‐certainty evidence; <a href="#CD013881-fig-0012">Figure 12</a>).  </p> <div class="figure" id="CD013881-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Analysis 1.1.5 Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-12.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.5 Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> </div> </section> <section id="CD013881-sec-0081"> <h6 class="title">Adverse events (AEs)</h6> <p>AEs were assessed by spontaneous reporting (<a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>), active monitoring (<a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>), both methods (<a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2); <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>) and by unknown methods in three RCTs (<a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>).  </p> <p>AEs were reported in nine RCTs (1811 participants) (<a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2); <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>). Tocilizumab probably results in little to no difference in the risk of adverse events (RR 1.03, 95% CI 0.95 to 1.12; I<sup>2</sup> = 0.0%; 9 RCTs, 1811 participants; absolute effect: 13 more per 1000 (from 22 fewer to 53 more); moderate‐certainty evidence; <a href="#CD013881-fig-0013">Figure 13</a>).  </p> <div class="figure" id="CD013881-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Analysis 1.1.6 Tocilizumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-13.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.6 Tocilizumab versus placebo or standard care. Outcome: Adverse events</p> </div> </div> </div> </section> <section id="CD013881-sec-0082"> <h6 class="title">Serious adverse events (SAEs)</h6> <p>SAEs were reported in 16 RCTs (2974 participants) (<a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2); <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a>). Another study (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>), which did not contribute to the pooled effect estimate, also reported on the outcome in 21 participants with zero events in both groups. </p> <p>The evidence comparing tocilizumab to standard care alone or to placebo on serious adverse events is very uncertain (RR 0.93, 95% CI 0.81 to 1.07; I<sup>2</sup> = 0.0%; 16 RCTs, 2974 participants; absolute effect: 12 fewer per 1000 (from 32 fewer to 12 more); very low‐certainty evidence; <a href="#CD013881-fig-0014">Figure 14</a>). </p> <div class="figure" id="CD013881-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Analysis 1.1.7 Tocilizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-14.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1.7 Tocilizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> </div> </section> </section> <section id="CD013881-sec-0083"> <h5 class="title">Important outcomes</h5> <p>We report the certainty of evidence for the important outcomes in <a href="./appendices#CD013881-sec-0173">Appendix 10</a>. </p> <section id="CD013881-sec-0084"> <h6 class="title">Time to clinical improvement</h6> <p>This outcome was reported in seven RCTs (2827 participants) (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2); <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>). The time of follow‐up ranged between 28 days and 90 days. The evidence of the effect of tocilizumab on time to clinical improvement compared to standard care alone or to placebo is uncertain (HR 1.22, 95% CI 1.10 to 1.34; I<sup>2</sup> = 0.0%; 7 RCTs, 2827 participants; absolute effect: 72 more per 1000 (from 35 more to 105 more); low‐certainty evidence; <a href="#CD013881-fig-0015">Figure 15</a>).  </p> <div class="figure" id="CD013881-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Analysis 1.2.1 Tocilizumab versus placebo or standard care. Outcome: Time to clinical improvement" data-id="CD013881-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-15.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.2.1 Tocilizumab versus placebo or standard care. Outcome: Time to clinical improvement </p> </div> </div> </div> </section> <section id="CD013881-sec-0085"> <h6 class="title">Time to WHO Clinical Progression Score of level 7 or above</h6> <p>This outcome was reported in four RCTs (1116 participants) (<a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>). Tocilizumab reduces the probability that an individual would reach the WHO‐CPS of level 7 or above compared to standard care alone or to placebo at a specific time point (D28 up to D90) (HR 0.63, 95% CI 0.48 to 0.84; I<sup>2</sup> = 0.0%; 4 RCTs, 1116 participants; absolute effect: 73 fewer per 1000 (from 104 fewer to 31 fewer); high‐certainty evidence; <a href="#CD013881-fig-0016">Figure 16</a>). </p> <div class="figure" id="CD013881-fig-0016"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 16</div> </div> <hr class="top"/><img alt="Analysis 1.2.2 Tocilizumab versus placebo or standard care. Outcome: Time to WHO progression score (level 7 and above)" data-id="CD013881-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-16.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.2.2 Tocilizumab versus placebo or standard care. Outcome: Time to WHO progression score (level 7 and above) </p> </div> </div> </div> </section> <section id="CD013881-sec-0086"> <h6 class="title">Time to death</h6> <p>This outcome was reported in nine RCTs (2949 participants) (<a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐TOCI‐2); <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>). Tocilizumab probably reduces the probability that an individual would die compared to standard care alone at a specific time point (D28 up to D90) (HR 0.77, 95% CI 0.65 to 0.91; I<sup>2</sup> = 0.0%; 9 RCTs; 2949 participants; absolute effect: 50 fewer per 1000 (from 78 fewer to 19 fewer); moderate‐certainty evidence; <a href="#CD013881-fig-0017">Figure 17</a>).  </p> <div class="figure" id="CD013881-fig-0017"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 17</div> </div> <hr class="top"/><img alt="Analysis 1.2.3 Tocilizumab versus placebo or standard care. Outcome: Time to death" data-id="CD013881-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-17.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.2.3 Tocilizumab versus placebo or standard care. Outcome: Time to death</p> </div> </div> </div> </section> </section> </section> <section id="CD013881-sec-0087"> <h4 class="title">Sarilumab versus standard care/placebo</h4> <p>We have included results from nine trials and merged the results reporting on different doses of sarilumab in our analysis (<a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (reporting results of phase 2 and 3 analysis populations)). We report the certainty of the evidence for critical outcomes in <a href="./full#CD013881-tbl-0002">summary of findings Table 2</a> and for important outcomes in <a href="./appendices#CD013881-sec-0175">Appendix 11</a> ‘Summary of Findings 8 ‐ important outcomes’. The outcome WHO progression score (level 7 or above) at D60 or more was not reported. </p> <section id="CD013881-sec-0088"> <h5 class="title">Critical outcomes</h5> <section id="CD013881-sec-0089"> <h6 class="title">Clinical improvement </h6> <p>Clinical improvement was defined as discharge at day 28 (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>); as a 2‐point rise in a 7‐category ordinal scale or hospital discharge, whichever occurred first (<a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>), or as the proportion with a 1‐point improvement in clinical status using a 7‐point ordinal scale on day 22 (<a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>). <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> reported results from phase 2 and phase 3 datasets.  </p> <p>Seven RCTS (2425 participants) reported the proportion of participants achieving clinical improvement at D28 (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (<a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>.1 results from phase 2; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>.2 results from phase 3)). Sarilumab probably results in little or no increase in clinical improvement at D28 compared to standard care alone or placebo (RR 0.99, 95% CI 0.94 to 1.05; I<sup>2</sup> = 0.0%; 7 RCTs; 2425 participants; absolute effect: 6 fewer per 1000 (from 39 fewer to 32 more); moderate‐certainty evidence; <a href="#CD013881-fig-0018">Figure 18</a>).  </p> <div class="figure" id="CD013881-fig-0018"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 18</div> </div> <hr class="top"/><img alt="Analysis 2.1.1 Sarilumab versus placebo or standard care. Outcome: Clinical improvement D28Sivapalasingam 2022: Sivapalasingam 2022.1 refers to the phase 2 results; Sivapalasingam 2022.2 refers to the phase 3 results." data-id="CD013881-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-18.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.1 Sarilumab versus placebo or standard care. Outcome: Clinical improvement D28 </p> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>: <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>.1 refers to the phase 2 results; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>.2 refers to the phase 3 results. </p> </div> </div> </div> <p>Two studies (239 participants) reported a longer follow‐up of clinical improvement, defined as hospital discharge at ≥ D60 (<a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>). The evidence of an effect of sarilumab on clinical improvement, compared to standard care alone, at ≥ D60 is very uncertain (RR 1.22, 95% CI 0.91 to 1.63; 2 RCTs; 239 participants; absolute effect: 138 more per 1000 (from 57 fewer to 396 more); very low‐certainty evidence; <a href="#CD013881-fig-0019">Figure 19</a>). </p> <div class="figure" id="CD013881-fig-0019"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 19</div> </div> <hr class="top"/><img alt="Analysis 2.1.2 Sarilumab versus placebo or standard care. Outcome: Clinical improvement D60" data-id="CD013881-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-19.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.2 Sarilumab versus placebo or standard care. Outcome: Clinical improvement D60 </p> </div> </div> </div> </section> <section id="CD013881-sec-0090"> <h6 class="title">WHO Clinical Progression Score of level 7 or above (i.e. the proportion of participants with mechanical ventilation +/‐ additional organ support or death)  </h6> <p>Five RCTs (886 participants) reported the proportion of participants with mechanical ventilation or death at D28 (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (phase 2)). The evidence of the effect of sarilumab on the proportion of participants with a WHO‐CPS of level 7 or above at D28 is very uncertain (RR 1.10, 95% CI 0.90 to 1.33; I<sup>2</sup> = 0.0 %; 5 RCTs, 886 participants; absolute effect: 25 more per 1000 (from 25 fewer to 83 more); very low‐certainty evidence; <a href="#CD013881-fig-0020">Figure 20</a>). We did not obtain data for longer‐term follow‐up (≥ D60). </p> <div class="figure" id="CD013881-fig-0020"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 20</div> </div> <hr class="top"/><img alt="Analysis 2.1.3 Sarilumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-20.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.3 Sarilumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> </div> </section> <section id="CD013881-sec-0091"> <h6 class="title">All‐cause mortality </h6> <p>Nine RCTs (3305 participants) reported all‐cause mortality at D28 (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (<a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>.1 results from phase 2; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>.2 results from phase 3)). The evidence for an effect of sarilumab compared to standard care alone or placebo on all‐cause mortality at D28 is very uncertain (RR 1.06, 95% CI 0.86 to 1.30; I<sup>2</sup> = 10.3%; 9 RCTs, 3305 participants; absolute effect: 13 more per 1000 (from 31 fewer to 67 more); very low‐certainty evidence; <a href="#CD013881-fig-0021">Figure 21</a>). </p> <div class="figure" id="CD013881-fig-0021"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 21</div> </div> <hr class="top"/><img alt="Analysis 2.1.4 Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-21.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.4 Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> </div> <p>Six RCTs (3379 participants) reported all‐cause mortality at ≥ D60 (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (<a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>.1 results from phase 2; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>.2 results from phase 3)). The evidence for an effect of sarilumab compared to standard care alone or placebo on all‐cause mortality at ≥ D60 is very uncertain (RR 0.95, 95% CI 0.84 to 1.07; I<sup>2</sup> = 0.0%; 6 RCTs, 3379 participants; absolute effect: 15 fewer per 1000 (from 47 fewer to 21 more); very low‐certainty evidence; <a href="#CD013881-fig-0022">Figure 22</a>). </p> <div class="figure" id="CD013881-fig-0022"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 22</div> </div> <hr class="top"/><img alt="Analysis 2.1.5 Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-22.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.5 Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> </div> </section> <section id="CD013881-sec-0092"> <h6 class="title">Adverse events</h6> <p>Two trials assessed AEs with active monitoring (<a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>), and two trials used active monitoring and spontaneous reporting (<a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>).  </p> <p>Four trials (860 participants) reported adverse events (<a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>). The evidence for an effect of sarilumab compared to standard care alone or placebo on adverse events is uncertain (RR 1.12, 95% CI 0.97 to 1.28; I<sup>2</sup> = 0.0%; 4 RCTs, 860 participants; absolute effect 49 more per 1000 (from 12 fewer to 51 more); low‐certainty evidence; <a href="#CD013881-fig-0023">Figure 23</a>).  </p> <div class="figure" id="CD013881-fig-0023"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 23</div> </div> <hr class="top"/><img alt="Analysis 2.1.6 Sarilumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-23.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.6 Sarilumab versus placebo or standard care. Outcome: Adverse events</p> </div> </div> </div> </section> <section id="CD013881-sec-0093"> <h6 class="title">Serious adverse events</h6> <p>Six trials (2936 participants) reported serious adverse events (<a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (<a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>.1 results from phase 2; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>.2 results from phase 3)). The evidence for an effect of sarilumab compared to standard care alone or placebo on serious adverse events is uncertain (RR 1.09, 95% CI 0.97 to 1.21; I<sup>2</sup> = 0.0%; 6 RCTs, 2936 participants; absolute effect 22 more per 1000 (from 7 fewer to 51 more); low‐certainty evidence; <a href="#CD013881-fig-0024">Figure 24</a>).  </p> <div class="figure" id="CD013881-fig-0024"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 24</div> </div> <hr class="top"/><img alt="Analysis 2.1.7 Sarilumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-24.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.1.7 Sarilumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> </div> </section> </section> <section id="CD013881-sec-0094"> <h5 class="title">Important outcomes</h5> <section id="CD013881-sec-0095"> <h6 class="title">Time to clinical improvement</h6> <p>Six trials (1881 participants) reported on time to clinical improvement (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>). The evidence for an effect of sarilumab compared to standard care alone or placebo on time to clinical improvement is uncertain (HR 1.13, 95% CI 1.00 to 1.29; I<sup>2</sup> = 13.4%; 6 RCTs, 1881 participants; absolute effect 41 more per 1000 (from 0 to 82 more); low‐certainty evidence; <a href="#CD013881-fig-0025">Figure 25</a>).  </p> <div class="figure" id="CD013881-fig-0025"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 25</div> </div> <hr class="top"/><img alt="Analysis 2.2.1 Sarilumab versus placebo or standard care. Outcome: Time to clinical improvement" data-id="CD013881-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-25.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.2.1 Sarilumab versus placebo or standard care. Outcome: Time to clinical improvement </p> </div> </div> </div> </section> <section id="CD013881-sec-0096"> <h6 class="title">Time to WHO Clinical Progression Score of level 7 or above</h6> <p>Two trials (349 participants) reported on time to WHO‐CPS of level 7 or above with 28 days follow‐up (<a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>). The evidence for an effect of sarilumab compared to standard care alone on time to WHO‐CPS of level 7 is very uncertain (HR 0.90, 95% CI 0.29 to 2.86; 2 RCTs, 349 participants; absolute effect 15 fewer per 1000 (from 110 fewer to 232 more); very low‐certainty evidence; <a href="#CD013881-fig-0026">Figure 26</a>). </p> <div class="figure" id="CD013881-fig-0026"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 26</div> </div> <hr class="top"/><img alt="Analysis 2.2.2 Sarilumab versus placebo or standard care. Time to WHO Clinical Progression Score of level 7 or above" data-id="CD013881-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-26.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.2.2 Sarilumab versus placebo or standard care. Time to WHO Clinical Progression Score of level 7 or above </p> </div> </div> </div> </section> <section id="CD013881-sec-0097"> <h6 class="title">Time to death</h6> <p>Four trials (1260) reported time to death with a follow‐up ranging from 28 to 90 days (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> (CORIMUNO‐SARI‐2); <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>).  </p> <p>Sarilumab reduces the probability that an individual would die compared to standard care alone at a specific time point D28 up to 90 (HR 0.71, 95% CI 0.56 to 0.90; I<sup>2</sup> = 0.0%; 4 RCTs, 1260 participants; absolute effect 80 fewer per 1000 (from 124 fewer to 26 fewer); high‐certainty evidence; <a href="#CD013881-fig-0027">Figure 27</a>). </p> <div class="figure" id="CD013881-fig-0027"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 27</div> </div> <hr class="top"/><img alt="Analysis 2.2.3 Sarilumab versus placebo or standard care. Outcome: Time to death" data-id="CD013881-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-27.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 2.2.3 Sarilumab versus placebo or standard care. Outcome: Time to death</p> </div> </div> </div> </section> </section> </section> <section id="CD013881-sec-0098"> <h4 class="title">Clazakizumab versus placebo</h4> <p>We identified two trials evaluating the effect of clazakizumab versus placebo: one has been published (<a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>), while the other posted results concerning only 28% of its target sample size (17 recruited/60 planned) (<a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>). </p> <p>We report the certainty of the evidence for critical outcomes in <a href="./full#CD013881-tbl-0003">summary of findings Table 3</a>. The important outcomes were not reported. </p> <section id="CD013881-sec-0099"> <h5 class="title">Critical outcomes</h5> <section id="CD013881-sec-0100"> <h6 class="title">Clinical improvement </h6> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> reported clinical improvement on D28, defined as an improvement from baseline by at least two points on the WHO 11‐point ordinal scale.  </p> <p>The evidence of an effect of clazakizumab on clinical improvement at D28, compared to placebo, is very uncertain (RR 1.28, 95% CI 0.97 to 1.70; 1 RCT; 152 participants; absolute effect: 140 more per 1000 (from 15 fewer to 350 more); very low‐certainty evidence; <a href="#CD013881-fig-0028">Figure 28</a>).  </p> <div class="figure" id="CD013881-fig-0028"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 28</div> </div> <hr class="top"/><img alt="Analysis 3.1.1 Clazakizumab versus placebo or standard care. Outcome: Clinical improvement 28" data-id="CD013881-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-28.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.1 Clazakizumab versus placebo or standard care. Outcome: Clinical improvement 28 </p> </div> </div> </div> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> also reported on a longer‐term follow‐up for clinical improvement (≥ D60). The evidence of clazakizumab effect on clinical improvement at D ≥ 60, compared to placebo, is very uncertain (RR 1.28, 95% CI 0.99 to 1.66; 1 RCT; 152 participants; absolute effect: 151 more per 1000 (from 5 fewer to 357 more); very low‐certainty evidence; <a href="#CD013881-fig-0029">Figure 29</a>). </p> <div class="figure" id="CD013881-fig-0029"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 29</div> </div> <hr class="top"/><img alt="Analysis 3.1.2 Clazakizumab versus placebo or standard care. Outcome: Clinical improvement D60" data-id="CD013881-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-29.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.2 Clazakizumab versus placebo or standard care. Outcome: Clinical improvement D60 </p> </div> </div> </div> </section> <section id="CD013881-sec-0101"> <h6 class="title">WHO Clinical Progression Score of level 7 or above (i.e. the proportion of participants with mechanical ventilation +/‐ additional organ support or death)  </h6> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> reported on the proportion of participants with mechanical ventilation or death. The evidence of the effect of clazakizumab on the proportion of participants with a WHO‐CPS of level 7 or above at D28 is very uncertain (RR 0.66, 95% CI 0.43 to 1.01; 1 RCT, 152 participants; absolute effect: 152 more per 1000 (from 254 fewer to 4 more); very low‐certainty evidence; <a href="#CD013881-fig-0030">Figure 30</a>). We did not obtain data for longer‐term follow‐up (≥ D60). </p> <div class="figure" id="CD013881-fig-0030"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 30</div> </div> <hr class="top"/><img alt="Analysis 3.1.3 Clazakizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-30.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.3 Clazakizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> </div> </section> <section id="CD013881-sec-0102"> <h6 class="title">All‐cause mortality </h6> <p>Two RCTs (169 participants) reported all‐cause mortality at D28 and ≥ D60 (<a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a>). The evidence for an effect of clazakizumab compared to placebo on all‐cause mortality at D28 is very uncertain (RR 0.91, 95% CI 0.54 to 1.55; I<sup>2</sup> = 0.0 %; 2 RCTs, 169 participants; absolute effect: 23 fewer per 1000 (from 116 fewer to 139 more); very low‐certainty evidence; <a href="#CD013881-fig-0031">Figure 31</a>). </p> <div class="figure" id="CD013881-fig-0031"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 31</div> </div> <hr class="top"/><img alt="Analysis 3.1.4 Clazakizumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-31.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.4 Clazakizumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> </div> <p>The evidence for an effect of clazakizumab compared to placebo on all‐cause mortality at ≥ D60 is also very uncertain (RR 0.77, 95% CI 0.49 to 1.19; I<sup>2</sup> = 0.0%; 2 RCTs, 169 participants; absolute effect: 83 fewer per 1000 (from 184 fewer to 69 more); very low‐certainty evidence; <a href="#CD013881-fig-0032">Figure 32</a>). </p> <div class="figure" id="CD013881-fig-0032"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 32</div> </div> <hr class="top"/><img alt="Analysis 3.1.5 Clazakizumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-32.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.5 Clazakizumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> </div> </section> <section id="CD013881-sec-0103"> <h6 class="title">Adverse events</h6> <p><a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a> reported adverse events assessed by active monitoring for 17 included participants. The evidence of clazakizumab effect on adverse events, compared to standard care alone, is uncertain (RR 1.12, 95% CI 0.20 to 6.24; 1 RCT, 17 participants; absolute effect 29 more per 1000 (from 178 fewer to 1000 more); low‐certainty evidence; <a href="#CD013881-fig-0033">Figure 33</a>).  </p> <div class="figure" id="CD013881-fig-0033"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 33</div> </div> <hr class="top"/><img alt="Analysis 3.1.6 Clazakizumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-33.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.6 Clazakizumab versus placebo or standard care. Outcome: Adverse events</p> </div> </div> </div> </section> <section id="CD013881-sec-0104"> <h6 class="title">Serious adverse events</h6> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> and <a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a> (169 participants) reported serious adverse events. The evidence of clazakizumab's effect on serious adverse events, compared to placebo alone, is uncertain (RR 0.69, 95% CI 0.46 to 1.04; I<sup>2</sup>= 0.0%; 2 RCTs, 169 participants; absolute effect 134 fewer per 1000 (from 234 fewer to 17 more); low‐certainty evidence; <a href="#CD013881-fig-0034">Figure 34</a>). </p> <div class="figure" id="CD013881-fig-0034"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 34</div> </div> <hr class="top"/><img alt="Analysis 3.1.7 Clazakizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-34.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 3.1.7 Clazakizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> </div> </section> </section> <section id="CD013881-sec-0105"> <h5 class="title">Important outcomes</h5> <p>None of the studies included reported results for any of the important outcomes, namely, time to clinical improvement, time to WHO score seven, and above and time to death.  </p> </section> </section> <section id="CD013881-sec-0106"> <h4 class="title">Olokizumab versus placebo</h4> <p>We have identified and included results from a three‐arm trial evaluating the effect of olokizumab (n = 124) versus placebo (n = 124) (<a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a>). As the trial is not yet published, we considered the results posted on clinicaltrials.gov under registration number NCT04380519. We report the evidence of certainty for critical outcomes in <a href="./full#CD013881-tbl-0004">summary of findings Table 4</a>. The WHO progression score (level 7 or above) at D60 or more and important outcomes were not reported. </p> <section id="CD013881-sec-0107"> <h5 class="title">Critical outcomes</h5> <p>No data are available for clinical improvement (≥ D60), WHO‐CPS of level 7 or above (D28, ≥ D60), all‐cause mortality (≥ D60) and adverse events. </p> <section id="CD013881-sec-0108"> <h6 class="title">Clinical improvement </h6> <p><a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a> reported on clinical improvement at D28, defined as an improvement from baseline by at least two points on a 6‐point ordinal scale. </p> <p>The evidence for an effect of olokizumab on clinical improvement, compared to placebo at D28 is very uncertain (RR 1.10, 95% CI 0.96 to 1.24; 1 RCT, 248 participants; absolute effect: 76 more per 1000 (from 30 fewer to 182 more); very low‐certainty evidence; <a href="#CD013881-fig-0035">Figure 35</a>).  </p> <div class="figure" id="CD013881-fig-0035"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 35</div> </div> <hr class="top"/><img alt="Analysis 4.1.1 Olokizumab versus placebo or standard care. Outcome: Clinical improvement 28" data-id="CD013881-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-35.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 4.1.1 Olokizumab versus placebo or standard care. Outcome: Clinical improvement 28 </p> </div> </div> </div> </section> <section id="CD013881-sec-0109"> <h6 class="title">All‐cause mortality </h6> <p><a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a> reported all‐cause mortality at D28. </p> <p>The evidence for an effect of olokizumab compared with all‐cause mortality at D28 is very uncertain (RR 1.50, 95% CI 0.55 to 4.09; 1 RCT, 248 participants; absolute effect: 24 more per 1000 (from 22 fewer to 150 more); very low‐certainty evidence; <a href="#CD013881-fig-0036">Figure 36</a>). </p> <div class="figure" id="CD013881-fig-0036"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 36</div> </div> <hr class="top"/><img alt="Analysis 4.1.2 Olokizumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-36.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 4.1.2 Olokizumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> </div> </section> </section> <section id="CD013881-sec-0110"> <h5 class="title">Serious adverse events</h5> <p><a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a> (248 participants) reported serious adverse events. The evidence for an effect of olokizumab compared to placebo on serious adverse events is very uncertain (RR 1.25, 95% CI 0.51 to 3.06; 1 RCT, 248 participants; absolute effect: 16 more per 1000 (from 32 fewer to 133 more); very low‐certainty evidence; <a href="#CD013881-fig-0037">Figure 37</a>). </p> <div class="figure" id="CD013881-fig-0037"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 37</div> </div> <hr class="top"/><img alt="Analysis 4.1.3 Olokizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-37.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 4.1.3 Olokizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> </div> </section> <section id="CD013881-sec-0111"> <h5 class="title">Important outcomes</h5> <p>No data are available for any important outcomes; time to clinical improvement, time to WHO‐CPS of level 7 or above, and time to death.  </p> </section> </section> <section id="CD013881-sec-0112"> <h4 class="title">Siltuximab versus standard care</h4> <p>We have identified and included results from one 2 × 2 factorial design trial evaluating the effect of siltuximab versus standard care (<a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>). We report the certainty of the evidence for critical outcomes in <a href="./full#CD013881-tbl-0005">summary of findings Table 5</a>. Also see <a href="./appendices#CD013881-sec-0177">Appendix 12</a> ‘Summary of Findings 9 ‐ important outcomes’. WHO progression score (level 7 or above) at D60 or more was not reported. </p> <section id="CD013881-sec-0113"> <h5 class="title">Critical outcomes</h5> <section id="CD013881-sec-0114"> <h6 class="title">Clinical improvement </h6> <p>The definition of clinical improvement extracted is "an increase of at least two points on a 6‐category ordinal scale (compared with the worst status at the day of randomization) or discharge from the hospital alive" (<a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>). </p> <p>The evidence for an effect of siltuximab compared to standard care alone or placebo on clinical improvement at D28 is very uncertain (RR 0.97, 95% CI 0.79 to 1.18; 1 RCT, 148 participants; absolute effect: 22 fewer per 1000 (from 155 fewer to 132 more); very low‐certainty evidence; <a href="#CD013881-fig-0038">Figure 38</a>).  </p> <div class="figure" id="CD013881-fig-0038"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 38</div> </div> <hr class="top"/><img alt="Analysis 5.1.1 Siltuximab versus placebo or standard care. Outcome: Clinical improvement 28" data-id="CD013881-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-38.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 5.1.1 Siltuximab versus placebo or standard care. Outcome: Clinical improvement 28 </p> </div> </div> </div> <p>No data are available for longer‐term clinical improvement (≥ D60).</p> </section> <section id="CD013881-sec-0115"> <h6 class="title">WHO Clinical Progression Score of level 7 or above (i.e. the proportion of participants with mechanical ventilation +/‐ additional organ support or death)  </h6> <p>The evidence is uncertain for the effect of siltuximabon on the proportion of participants with a WHO‐CPS of level 7 or above at D28 (RR 1.97, 95% CI 1.07 to 3.36; 1 RCT, 148 participants; absolute effect: 162 more per 1000 (from 12 more to 438 more); low‐certainty evidence; <a href="#CD013881-fig-0039">Figure 39</a>). We did not obtain data for longer‐term follow‐up (≥ D60). </p> <div class="figure" id="CD013881-fig-0039"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 39</div> </div> <hr class="top"/><img alt="Analysis 5.1.2 Siltuximab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-39.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 5.1.2 Siltuximab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> </div> </section> <section id="CD013881-sec-0116"> <h6 class="title">All‐cause mortality </h6> <p>The evidence for an effect of siltuximab compared to standard care on all‐cause mortality at D28 is very uncertain (RR 1.35, 95% CI 0.54 to 3.36; 1 RCT, 148 participants; absolute effect: 34 fewer per 1000 (from 45 fewer to 229 more); very low‐certainty evidence; <a href="#CD013881-fig-0040">Figure 40</a>). </p> <div class="figure" id="CD013881-fig-0040"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 40</div> </div> <hr class="top"/><img alt="Analysis 5.1.3 Siltuximab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-40.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 5.1.3 Siltuximab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> </div> <p>Similarly, the evidence of its effect on all‐cause mortality at ≥ D60, compared to placebo alone, is very uncertain (RR 1.58, 95% CI 0.74 to 3.38; 1 RCT, 148 participants; absolute effect 73 more per 1000 (from 33 fewer to 298 more); very low‐certainty evidence; <a href="#CD013881-fig-0041">Figure 41</a>). </p> <div class="figure" id="CD013881-fig-0041"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 41</div> </div> <hr class="top"/><img alt="Analysis 5.1.4 Siltuximab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-41.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 5.1.4 Siltuximab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> </div> </section> <section id="CD013881-sec-0117"> <h6 class="title">Adverse events</h6> <p>We did not obtain results on adverse events.</p> </section> <section id="CD013881-sec-0118"> <h6 class="title">Serious adverse events</h6> <p>The evidence for an effect of siltuximab compared to placebo alone at ≥ D60 is uncertain (RR 1.29, 95% CI 0.64 to 2.62; 1 RCT, 148 participants; absolute effect 44 more per 1000 (from 55 fewer to 248 more); low‐certainty evidence; <a href="#CD013881-fig-0042">Figure 42</a>). </p> <div class="figure" id="CD013881-fig-0042"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 42</div> </div> <hr class="top"/><img alt="Analysis 5.1.5 Siltuximab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-42.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 5.1.5 Siltuximab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> </div> </section> </section> <section id="CD013881-sec-0119"> <h5 class="title">Important outcomes</h5> <p>No data are available for any important outcomes; time to clinical improvement, time to WHO‐CPS level 7 or above.  </p> <section id="CD013881-sec-0120"> <h6 class="title">Time to death</h6> <p>The evidence for an effect of siltuximab compared to standard care alone or placebo on time to death is very uncertain (HR 1.51, 95% CI 0.65 to 3.50; 1 RCT, 148 participants; absolute effect: 58 more per 1000 (from 42 fewer to 248 more; very low‐certainty evidence; <a href="#CD013881-fig-0043">Figure 43</a>). </p> <div class="figure" id="CD013881-fig-0043"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 43</div> </div> <hr class="top"/><img alt="Analysis 5.2.1 Siltuximab versus placebo or standard care. Outcome: Time to death" data-id="CD013881-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-43.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 5.2.1 Siltuximab versus placebo or standard care. Outcome: Time to death</p> </div> </div> </div> </section> </section> </section> <section id="CD013881-sec-0121"> <h4 class="title">Levilimab versus placebo</h4> <p>We have identified and included results from one trial evaluating the effect of levilimab versus placebo (<a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a>). We report the certainty of the evidence for critical outcomes in <a href="./full#CD013881-tbl-0006">summary of findings Table 6</a>. The WHO progression score (level 7 or above) at D60 or more and the important outcomes were not reported. </p> <section id="CD013881-sec-0122"> <h5 class="title">Critical outcomes</h5> <section id="CD013881-sec-0123"> <h6 class="title">Clinical improvement </h6> <p>The evidence of levilimab's effect, compared to placebo, on clinical improvement at D28 is uncertain (RR 1.53, 95% CI 1.26 to 1.85; 1 RCT, 206 participants; absolute effect: 293 more per 1000 (from 144 more to 470 more); low‐certainty evidence; <a href="#CD013881-fig-0044">Figure 44</a>). Clinical improvement was defined as an improvement of two or more points from baseline on the 7‐category ordinal scale of clinical status, or reaching categories 1 or 2 on Day 14.  </p> <div class="figure" id="CD013881-fig-0044"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 44</div> </div> <hr class="top"/><img alt="Analysis 6.1.1 Levilimab versus placebo or standard care. Outcome: Clinical improvement 28" data-id="CD013881-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-44.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 6.1.1 Levilimab versus placebo or standard care. Outcome: Clinical improvement 28 </p> </div> </div> </div> <p>No available information was obtained about clinical improvement at D60 or more. </p> </section> <section id="CD013881-sec-0124"> <h6 class="title">WHO Clinical Progression Score of level 7 or above (i.e. the proportion of participants with mechanical ventilation +/‐ additional organ support or death)  </h6> <p>We did not obtain data on WHO‐CPS of level 7 or above around D28, or for longer‐term follow‐up (≥ D60). </p> </section> <section id="CD013881-sec-0125"> <h6 class="title">All‐cause mortality </h6> <p>The evidence for an effect of levilimab compared to placebo on all‐cause mortality at D28 is very uncertain (RR 1.00, 95% CI 0.26 to 3.89; 1 RCT, 206 participants; absolute effect: 0 fewer per 1000 (from 29 fewer to 112 more); very low‐certainty evidence; <a href="#CD013881-fig-0045">Figure 45</a>). </p> <div class="figure" id="CD013881-fig-0045"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 45</div> </div> <hr class="top"/><img alt="Analysis 6.1.2 Levilimab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-45.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 6.1.2 Levilimab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> </div> <p>The evidence of levilimab's effect, compared to placebo, on all‐cause mortality at ≥ D60 is also very uncertain (RR 1.00, 95% CI 0.26 to 3.89; 1 RCT, 206 participants; absolute effect: 0 fewer per 1000 (from 29 fewer to 112 more); very low‐certainty evidence; <a href="#CD013881-fig-0046">Figure 46</a>). </p> <div class="figure" id="CD013881-fig-0046"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 46</div> </div> <hr class="top"/><img alt="Analysis 6.1.3 Levilimab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-46.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 6.1.3 Levilimab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> </div> </section> <section id="CD013881-sec-0126"> <h6 class="title">Adverse events</h6> <p>Adverse events were assessed by spontaneous reporting and active monitoring.</p> <p>The evidence for an effect of levilimab compared to placebo on adverse events is uncertain (RR 1.17, 95% CI 0.73 to 1.87; 1 RCT, 206 participants; absolute effect 40 more per 1000 (from 63 fewer to 203 more); low‐certainty evidence; <a href="#CD013881-fig-0047">Figure 47</a>). </p> <div class="figure" id="CD013881-fig-0047"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 47</div> </div> <hr class="top"/><img alt="Analysis 6.1.4 Levilimab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-47.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 6.1.4 Levilimab versus placebo or standard care. Outcome: Adverse events</p> </div> </div> </div> </section> <section id="CD013881-sec-0127"> <h6 class="title">Serious adverse events</h6> <p>The evidence for an effect of levilimab compared to placebo on serious adverse events is uncertain (RR 0.50, 95% CI 0.05 to 5.43; 1 RCT, 206 participants; absolute effect 10 fewer per 1000 (from 18 fewer to 86 more); low‐certainty evidence; <a href="#CD013881-fig-0048">Figure 48</a>). </p> <div class="figure" id="CD013881-fig-0048"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 48</div> </div> <hr class="top"/><img alt="Analysis 6.1.5 Levilimab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0048" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-48.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 6.1.5 Levilimab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> </div> </section> </section> </section> <section id="CD013881-sec-0128"> <h4 class="title">Important outcomes</h4> <p>None of the included studies reported any of the important outcomes, namely time to clinical improvement, time to WHO score level 7 and above and time to death.  </p> </section> <section id="CD013881-sec-0129"> <h4 class="title">Investigation of heterogeneity </h4> <p>The limited number of RCTs that provided results and the absence of variation across trials in some variables such as age and gender prevented us from performing all the preplanned subgroup analyses (see <a href="#CD013881-sec-0187">Differences between protocol and review</a>). We also considered two post hoc subgroup analyses based on the type of funding and the presence of conflicts of interest. </p> <p>Overall, subgroup analyses were possible only for the following comparisons.</p> <p> <ul id="CD013881-list-0014"> <li> <p>Tocilizumab</p> <ul id="CD013881-list-0015"> <li> <p>Analysis by type of funding: see <a href="#CD013881-fig-0049">Figure 49</a>, <a href="#CD013881-fig-0050">Figure 50</a>, <a href="#CD013881-fig-0051">Figure 51</a>, <a href="#CD013881-fig-0052">Figure 52</a>, <a href="#CD013881-fig-0053">Figure 53</a>, and <a href="#CD013881-fig-0054">Figure 54</a>. </p> </li> <li> <p>Analysis by type of location: see <a href="#CD013881-fig-0055">Figure 55</a>, <a href="#CD013881-fig-0056">Figure 56</a>, <a href="#CD013881-fig-0057">Figure 57</a>,<a href="#CD013881-fig-0058">Figure 58</a>, <a href="#CD013881-fig-0059">Figure 59</a>, and <a href="#CD013881-fig-0060">Figure 60</a>. </p> </li> <li> <p>Analysis by conflict of interests see: <a href="#CD013881-fig-0061">Figure 61</a>, <a href="#CD013881-fig-0062">Figure 62</a>, <a href="#CD013881-fig-0063">Figure 63</a>, <a href="#CD013881-fig-0064">Figure 64</a>, <a href="#CD013881-fig-0065">Figure 65</a>, and <a href="#CD013881-fig-0066">Figure 66</a>. </p> </li> <li> <p>Analysis by patient severity see: <a href="#CD013881-fig-0067">Figure 67</a>, <a href="#CD013881-fig-0068">Figure 68</a>, <a href="#CD013881-fig-0069">Figure 69</a>, <a href="#CD013881-fig-0070">Figure 70</a>, and <a href="#CD013881-fig-0071">Figure 71</a>. </p> </li> </ul> </li> <li> <p>Sarilumab</p> <ul id="CD013881-list-0016"> <li> <p>Analysis by type of funding see: <a href="#CD013881-fig-0072">Figure 72</a>, <a href="#CD013881-fig-0073">Figure 73</a>, <a href="#CD013881-fig-0074">Figure 74</a>, <a href="#CD013881-fig-0075">Figure 75</a>, <a href="#CD013881-fig-0076">Figure 76</a>, and <a href="#CD013881-fig-0077">Figure 77</a>. </p> </li> <li> <p>Analysis by type of location see: <a href="#CD013881-fig-0078">Figure 78</a>, <a href="#CD013881-fig-0079">Figure 79</a>, <a href="#CD013881-fig-0080">Figure 80</a>, and <a href="#CD013881-fig-0081">Figure 81</a>. </p> </li> <li> <p>Analysis by conflict of interests see: <a href="#CD013881-fig-0082">Figure 82</a>, <a href="#CD013881-fig-0083">Figure 83</a>, <a href="#CD013881-fig-0084">Figure 84</a>, <a href="#CD013881-fig-0085">Figure 85</a>, <a href="#CD013881-fig-0086">Figure 86</a>, and <a href="#CD013881-fig-0087">Figure 87</a>. </p> </li> </ul> </li> <li> <p>Clazakizumab</p> <ul id="CD013881-list-0017"> <li> <p>Analysis by conflict of interests: see <a href="#CD013881-fig-0088">Figure 88</a>, <a href="#CD013881-fig-0089">Figure 89</a>, and <a href="#CD013881-fig-0090">Figure 90</a>. </p> </li> </ul> </li> </ul> </p> <div class="figure" id="CD013881-fig-0049"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 49</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.3.1 Funding. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28" data-id="CD013881-fig-0049" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-49.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.3.1 Funding. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0050"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 50</div> </div> <hr class="top"/><img alt="Subgroup analysis.1.3.2 Funding. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0050" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-50.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis.1.3.2 Funding. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0051"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 51</div> </div> <hr class="top"/><img alt="Subgroup analysis.1.3.3 Funding. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0051" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-51.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis.1.3.3 Funding. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0052"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 52</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.3.4 Funding. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0052" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-52.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.3.4 Funding. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0053"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 53</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.3.5 Funding. Tocilizumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0053" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-53.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.3.5 Funding. Tocilizumab versus placebo or standard care. Outcome: Adverse events </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0054"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 54</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.3.6 Funding. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0054" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-54.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.3.6 Funding. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0055"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 55</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.4.1 Location. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28" data-id="CD013881-fig-0055" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-55.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.4.1 Location. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0056"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 56</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.4.2 Location. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0056" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-56.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.4.2 Location. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0057"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 57</div> </div> <hr class="top"/><img alt="Subgroup analysis.1.4.3 Location. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0057" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-57.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis.1.4.3 Location. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0058"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 58</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.4.4 Location. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0058" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-58.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.4.4 Location. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0059"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 59</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.4.5 Location. Tocilizumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0059" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-59.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.4.5 Location. Tocilizumab versus placebo or standard care. Outcome: Adverse events </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0060"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 60</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.4.6 Location. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0060" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-60.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.4.6 Location. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0061"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 61</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.5.1 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28" data-id="CD013881-fig-0061" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-61.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.5.1 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0062"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 62</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.5.2 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0062" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-62.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.5.2 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0063"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 63</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.5.3 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0063" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-63.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.5.3 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0064"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 64</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.5.4 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0064" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-64.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.5.4 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0065"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 65</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.5.5 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0065" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-65.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.5.5 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Adverse events </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0066"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 66</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.5.6 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0066" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-66.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.5.6 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0067"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 67</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.6.1 Severity. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28" data-id="CD013881-fig-0067" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-67.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.6.1 Severity. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0068"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 68</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.6.2 Severity. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0068" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-68.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.6.2 Severity. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0069"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 69</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.6.3 Severity. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0069" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-69.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.6.3 Severity. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0070"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 70</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.6.4 Severity. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0070" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-70.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.6.4 Severity. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0071"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 71</div> </div> <hr class="top"/><img alt="Subgroup analysis. 1.6.5 Severity. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0071" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-71.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 1.6.5 Severity. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0072"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 72</div> </div> <hr class="top"/><img alt="Subgroup analysis. 2.3.1 Funding. Sarilumab versus placebo or standard care. Outcome: Clinical improvement D28" data-id="CD013881-fig-0072" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-72.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 2.3.1 Funding. Sarilumab versus placebo or standard care. Outcome: Clinical improvement D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0073"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 73</div> </div> <hr class="top"/><img alt="Subgroup analysis.2.3.3 Funding. Sarilumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0073" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-73.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis.2.3.3 Funding. Sarilumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0074"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 74</div> </div> <hr class="top"/><img alt="Subgroup analysis.2.3.4 Funding. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0074" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-74.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis.2.3.4 Funding. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0075"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 75</div> </div> <hr class="top"/><img alt="Subgroup analysis. 2.3.5 Funding. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0075" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-75.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 2.3.5 Funding. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0076"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 76</div> </div> <hr class="top"/><img alt="Subgroup analysis. 2.3.6 Funding. Sarilumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0076" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-76.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 2.3.6 Funding. Sarilumab versus placebo or standard care. Outcome: Adverse events </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0077"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 77</div> </div> <hr class="top"/><img alt="Subgroup analysis. 2.3.7 Funding. Sarilumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0077" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-77.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 2.3.7 Funding. Sarilumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0078"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 78</div> </div> <hr class="top"/><img alt="Subgroup analysis.2.4.1 Location. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0078" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-78.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis.2.4.1 Location. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0079"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 79</div> </div> <hr class="top"/><img alt="Subgroup analysis. 2.4.2 Location. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0079" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-79.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 2.4.2 Location. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0080"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 80</div> </div> <hr class="top"/><img alt="Subgroup analysis. 2.4.3 Location. Sarilumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0080" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-80.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 2.4.3 Location. Sarilumab versus placebo or standard care. Outcome: Adverse events </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0081"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 81</div> </div> <hr class="top"/><img alt="Subgroup analysis. 2.4.4 Location. Sarilumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0081" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-81.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 2.4.4 Location. Sarilumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0082"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 82</div> </div> <hr class="top"/><img alt="Subgroup analysis. 2.5.1 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: Clinical improvement D28" data-id="CD013881-fig-0082" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-82.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 2.5.1 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: Clinical improvement D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0083"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 83</div> </div> <hr class="top"/><img alt="Subgroup analysis. 2.5.2 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0083" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-83.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 2.5.2 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0084"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 84</div> </div> <hr class="top"/><img alt="Subgroup analysis. 2.5.3 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0084" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-84.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 2.5.3 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0085"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 85</div> </div> <hr class="top"/><img alt="Subgroup analysis. 2.5.4 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0085" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-85.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 2.5.4 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0086"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 86</div> </div> <hr class="top"/><img alt="Subgroup analysis. 2.5.5 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0086" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-86.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 2.5.5 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: Adverse events </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0087"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 87</div> </div> <hr class="top"/><img alt="Subgroup analysis. 2.5.6 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0087" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-87.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 2.5.6 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0088"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 88</div> </div> <hr class="top"/><img alt="Subgroup analysis. 3.3.1 Conflict of interest. Clazakizumab versus placebo. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0088" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-88.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 3.3.1 Conflict of interest. Clazakizumab versus placebo. Outcome: All‐cause mortality D28 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0089"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 89</div> </div> <hr class="top"/><img alt="Subgroup analysis. 3.3.2 Conflict of interest. Clazakizumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0089" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-89.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 3.3.2 Conflict of interest. Clazakizumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> </div> <div class="figure" id="CD013881-fig-0090"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 90</div> </div> <hr class="top"/><img alt="Subgroup analysis. 3.3.3 Conflict of interest. Clazakizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0090" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-90.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Subgroup analysis. 3.3.3 Conflict of interest. Clazakizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> </div> <p>None of the characteristics explored explained any heterogeneity.</p> </section> <section id="CD013881-sec-0130"> <h4 class="title">Sensitivity analysis </h4> <p>Details of the sensitivity analyses are available in <a href="./appendices#CD013881-sec-0179">Appendix 13</a>. </p> <p>We performed sensitivity analyses for all comparisons versus controls for available case analysis. No important discrepancies in the summary results were observed when we used the number analyzed in the RCTs instead of the number randomized as the denominator. </p> <p>Sensitivity analyses excluding high‐risk studies were possible only for tocilizumab, with two high‐risk of bias studies included; the exclusion of these high‐risk of bias trials (<a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>) did not change the results.  </p> <p>Sensitivity analyses excluding preprint and unpublished results were possible for some outcomes for tocilizumab, sarilumab and clazakizumab. Results were consistent when considering only trials reported as peer‐reviewed articles. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013881-sec-0131" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013881-sec-0131"></div> <section id="CD013881-sec-0132"> <h3 class="title" id="CD013881-sec-0132">Summary of main results</h3> <p>This review provides an updated assessment of the efficacy and safety of IL‐6 blocking agents for people with COVID‐19 disease. We now include 32 RCTs (involving 12,160 participants) with reported results; 22 of them are newly identified for this update. The majority of the trial participants had moderate to critical disease with a mean age ranging from 56 to 65 years. When compared to placebo or standard care, tocilizumab reduces all‐cause mortality at D28 (high‐certainty evidence). The evidence is very uncertain about the effect of sarilumab on all‐cause mortality at D28. The evidence is uncertain for all cause‐mortality at ≥ D60 for tocilizumab and very uncertain for sarilumab. Nevertheless, tocilizumab and sarilumab probably result in little or no increase in clinical improvement at D28 (moderate‐certainty evidence). The effect on the proportion of participants with a WHO‐CPS level of 7 or above remains uncertain at D28 for tocilizumab and the evidence is very uncertain about the effect of sarilumab. Tocilizumab probably results in little or no difference in the risk of adverse events (moderate‐certainty evidence). The evidence on serious adverse events is very uncertain for tocilizumab and uncertain for sarilumab. </p> <p>With respect to important outcomes, we conclude that tocilizumab reduces the probability that an individual would reach the WHO‐CPS of level 7 or above compared to standard care alone or to placebo at a specific time point D28 up to D90. It probably reduces the probability that an individual would die compared to standard care alone at a specific time point D28 up to D90. Finally, sarilumab reduces the probability that an individual would die compared to standard care alone at a specific time point of D28 up to D90. </p> <p>For the other IL‐6 blocking agents evaluated in this meta‐analysis, the evidence of their effects was uncertain or very uncertain, mainly due to the very small number of studies evaluating them. </p> <p>Due to insufficient data, we could not provide information on immunocompromised people and the most clinically vulnerable people, and could not present the results disaggregated by gender. </p> <p>Finally, most of the studies included in this review took place during infection with the wild‐type strain, before the emergence of variants of concern. Only four studies were conducted during a period that included infections by both the wild type and the alpha variant. Most of the trials included in this review update were conducted before COVID‐19 vaccines against SARS‐CoV‐2 infections were rolled out on a large scale. </p> </section> <section id="CD013881-sec-0133"> <h3 class="title" id="CD013881-sec-0133">Overall completeness and applicability of evidence</h3> <p>We identified 49 registered RCTs evaluating IL‐6 blocking agents; two‐thirds of these registered trials reported results included in this meta‐analysis. This quantity of evidence was adequate to judge the effectiveness and safety of IL‐6 blocking agents — mainly tocilizumab and sarilumab. Of the 17 registered trials with no published results, only one trial evaluating tocilizumab, with 200 participants, was completed by December 2020 and its results have not been published. Three other trials of tocilizumab, conducted in Iran, were stated in the registry to have completed recruitment based on the expected completion date. We cannot, however, be sure that the study was actually completed since the investigators did not update the information on the registry (Iranian registry) since registration. No further completed studies of IL‐6 blocking agents are expected. Unpublished results of registered trials could produce evidence from six trials with only around 730 participants planned, 294 of them for tocilizumab and 171 for sarilumab. </p> <p>Accordingly, the information for tocilizumab collected in this review covers most of the critical and important outcomes, thus allowing a clear judgment of its efficacy and safety. This calls into question the need to continue updating this review unless we find evidence justifying a major change in our conclusions. </p> <p>All ongoing and not recruiting studies were registered between April and December 2020, except for one registered in January 2022 evaluating olokizumab. For the other drugs, one ongoing trial with a small sample size has not reported results for olokizumab or clazakizumab, and there are no other ongoing registered trials for levilimab and siltuximab. </p> <p>Most of the trials included (26/32, 81.25%) were multicenter trials; and four were multinational. </p> <p>Moreover, the studies defined the outcome of clinical improvement differently. Definitions included at least one or two points on the WHO severity score or hospital discharge. We considered all the definitions of clinical improvement. </p> <p>It is worth mentioning that many jurisdictions outside the USA have suffered from ongoing shortages of tocilizumab (<a href="./references#CD013881-bbs2-0064" title="COVID-19 use causes tocilizumab shortage. Cancer Discovery2021;11(12):2950. [DOI: doi.org/10.1158/2159-8290.CD-NB2021-0386]">Cancer Discov 2021</a>; <a href="./references#CD013881-bbs2-0116" title="VermaAA , PaiM , SahaS , BeanS , FralickM , GibsonJL , et al. Managing drug shortages during a pandemic: tocilizumab and COVID-19. CMAJ2021;193(21):E771-6.">Verma 2021</a>). As a result, some centers resorted to using lower doses of tocilizumab due to shortages (<a href="./references#CD013881-bbs2-0112" title="StukasS , GoshuaG , KinkadeA , GreyR , MahG , BiggsCM , et al. Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study. Lancet Regional Health – Americas2022;11:100228.">Stukas 2022</a>), and at least one small RCT has shown comparable biochemical and clinical outcomes between lower dose and standard dose tocilizumab (<a href="./references#CD013881-bbs2-0088" title="KumarPN , Hernández-SánchezJ , NagelS , FengY , CaiF , RabinJ , et al. Safety and efficacy of Tocilizumab 4 or 8 mg/kg in hospitalized patients with moderate to severe Coronavirus disease 2019 pneumonia: A randomized clinical trial. Open Forum Infectious Diseases2022;9(1):ofab608.">Kumar 2022</a>). </p> </section> <section id="CD013881-sec-0134"> <h3 class="title" id="CD013881-sec-0134">Quality of the evidence</h3> <p>Overall for tocilizumab, the certainty of the evidence was very low for clinical improvement at D60 or later and for serious adverse events due to imprecision, indirectness and risk of bias. The level of certainty was low for the WHO‐CPS score (level 7 or higher) at D28 and all‐cause mortality at D60 or later because of very serious imprecision; it was moderate for clinical improvement at D28 and for adverse events, due to serious imprecision. Finally, the certainty of the evidence for all‐cause mortality at D28 was high. </p> <p>For sarilumab, the certainty of evidence was very low for four critical outcomes (clinical improvement on D60 or later, the WHO‐CPS score (7 or higher) at D28, all‐cause mortality at D28, all‐cause mortality at D60 or later), mainly because of serious risk of bias and very serious imprecision, and low for adverse events and serious adverse events because of serious risk of bias and imprecision. Despite the serious risk of bias, which we downgraded by one level for the clinical improvement outcome around D28, we assessed the certainty to be moderate, as we had no other concerns regarding imprecision, inconsistency, or indirectness for this particular outcome. </p> <p>For clazakizumab, olokizumab, siltuximab, and levilimab, the certainty of evidence was low or very low for all reported outcomes. </p> <p>Reasons for downgrading the certainty were mainly because of serious indirectness, and very serious imprecision. More details are given in the summary of finding tables. </p> </section> <section id="CD013881-sec-0135"> <h3 class="title" id="CD013881-sec-0135">Potential biases in the review process</h3> <p>To minimize potential bias in the review, we complied with the guidance of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013881-bbs2-0079" title="Higgins, JPT Thomas, J Chandler, J Cumpston, M Li, T Page, MJ Welch, VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook2021.">Higgins 2021</a>), and assessed the effects of potential biases in sensitivity analyses. First, we continue to use the L‐OVE platform and the Cochrane clinical trial registry to search for new trials and inclusions. The search strategy has been peer‐reviewed and provided 100% sensitivity on the identification of COVID‐19 RCTs, thus considerably reducing the workload (<a href="./references#CD013881-bbs2-0102" title="PierreO , RiverosC , CharpyS , BoutronI . Secondary electronic sources demonstrated very good sensitivity for identifying studies evaluating interventions for COVID-19. Journal of Clinical Epidemiology2022;141:46-53.">Pierre 2022</a>). The platform also retrieved results posted on the <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> registry and included in the analysis of this review, either as an update for an already published article or as the only available results for an unpublished study. Second, to increase our review’s informative value, we continue to search and track all registered trials in a living mapping of registered trials. Third, two reviewers both screen studies, extract information, and perform risk of bias assessments. They then reach a consensus, conduct quality control after analysis, and grade the evidence. The project life cycle has a duration of two weeks and now runs on a daily basis for extraction and risk of bias assessment, weekly for screening, and every two weeks for updating analyses, grades, and quality control. The process is continuous and all updates of this review using the latest COVID‐NMA database are publicly available on the COVID‐NMA platform (<a href="http://covid-nma.com" target="_blank">covid-nma.com</a>). Furthermore, analyses can be performed with the metaCOVID tool (<a href="http://covid-nma.com/metacovid/" target="_blank">covid-nma.com/metacovid/</a>). </p> <p>Moreover, we included data from preprints, posted results, and other meta‐analyses to ensure inclusion of the best available evidence. These publications have potentially differing quality, and results may change once peer‐reviewed journal publications are available (<a href="./references#CD013881-bbs2-0097" title="OikonomidiT , BoutronI , PierreO , CabanacG , RavaudP , COVID-19 NMA Consortium. Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study. BMC Medicine2020;18(1):402. [DOI: 10.1186/s12916-020-01880-8] [PMID: 33334338]">Oikonomidi 2020</a>). To overcome this issue, we have developed a preprint tracker to be informed of updates so that we can update data collection and data analysis when a preprint is modified or published. We also explored the effect later through a sensitivity analysis that showed consistent results when we considered only trials reported as peer‐reviewed articles (thus excluding preprints). </p> <p>Finally, we decided not to pool different IL‐6 blocking agents because we have no evidence that their effects are sufficiently similar. We have also been unable to assess the variation in effects due to changes in the standard care provided. </p> </section> <section id="CD013881-sec-0136"> <h3 class="title" id="CD013881-sec-0136">Agreements and disagreements with other studies or reviews</h3> <p>We identified 19 systematic reviews focusing on IL‐6 blocking agents for COVID‐19 published in 2022; three were updated after June 2021 (<a href="./references#CD013881-bbs2-0060" title="BoppanaTK , MittalS , MadanK , MohanA , HaddaV , GuleriaR . Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Monaldi Archives for Chest Disease2022;92(4):2136.">Boppana 2022</a>; <a href="./references#CD013881-bbs2-0101" title="PengJ , SheX , MeiH , ZhengH , FuM , LiangG , et al. Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis. Aging2022;14(2):557-71.">Peng 2022</a>; <a href="./references#CD013881-bbs2-0125" title="YuSY , KohDH , ChoiM , RyooS , HuhK , YeomJS , et al. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis. Emerging Microbes &amp; Infections2022;11(1):1154-65.">Yu 2022</a>). Among them, two assessed tocilizumab (<a href="./references#CD013881-bbs2-0060" title="BoppanaTK , MittalS , MadanK , MohanA , HaddaV , GuleriaR . Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Monaldi Archives for Chest Disease2022;92(4):2136.">Boppana 2022</a>; <a href="./references#CD013881-bbs2-0101" title="PengJ , SheX , MeiH , ZhengH , FuM , LiangG , et al. Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis. Aging2022;14(2):557-71.">Peng 2022</a>) and the third assessed tocilizumab and sarilumab (<a href="./references#CD013881-bbs2-0125" title="YuSY , KohDH , ChoiM , RyooS , HuhK , YeomJS , et al. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis. Emerging Microbes &amp; Infections2022;11(1):1154-65.">Yu 2022</a>). All included RCTs only. In most outcomes in those reviews that overlapped with ours, the results were consistent. </p> <p>Among the living systematic reviews that we are aware of (<a href="./references#CD013881-bbs2-0070" title="CrucianiF , AmatoL , De CrescenzoF , MitrovaZ , SaulleR , VecchiS , DavoliM . [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.]. Recenti Progressi in Medicina2021;112(3):195-206.">Cruciani 2021</a>; <a href="./references#CD013881-bbs2-0082" title="JuulS , NielsenEE , FeinbergJ , SiddiquiF , JørgensenCK , BarotE , et al. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS One2021;16(3):e0248132.">Juul 2021</a>; <a href="./references#CD013881-bbs2-0085" title="KhanF , StewartI , FabbriL , MossS , RobinsonKA , SmythA , et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax2021;Feb 2021:Epub ahead of print. [DOI: 10.1136/thoraxjnl-2020-215266] [PMID: 33579777]">Khan 2021</a>; <a href="./references#CD013881-bbs2-0099" title="Pan American Health Organization. Ongoing living update of potential COVID-19 therapeutics options: summary of evidence: rapid review. Available at iris.paho.org/handle/10665.2/52719..">PAHO 2022</a>; <a href="./references#CD013881-bbs2-0107" title="SiemieniukRA , BartoszkoJJ , GeL , ZeraatkarD , IzcovichA , KumE , et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ2020;370:m2980. [DOI: 10.1136/bmj.m2980] [PMID: 32732190]">Siemieniuk 2020</a>; <a href="./references#CD013881-bbs2-0114" title="TleyjehIM , KashourZ , DamlajM , RiazM , TlayjehH , AltannirM , et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clinical Microbiology and Infection2021;27(2):215-27. [DOI: 10.1016/j.cmi.2020.10.036] [PMID: 33161150]">Tleyjeh 2021</a>), only the one by the Pan American Health Organization has been updated since June 2021 (<a href="./references#CD013881-bbs2-0099" title="Pan American Health Organization. Ongoing living update of potential COVID-19 therapeutics options: summary of evidence: rapid review. Available at iris.paho.org/handle/10665.2/52719..">PAHO 2022</a>); it has in fact been publishing monthly updates since September 2020. Their results are consistent with ours regarding the effects of tocilizumab, sarilumab, clazakizumab, siltuximab, and levilimab on mortality, clinical improvement, and serious adverse events, with only a few discrepancies regarding the GRADE assessment (likely due to the use of different criteria to downgrade for imprecision). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013881-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flowchart of included randomized controlled trials (RCTs) of interleukin 6 (IL‐6) blocking agents (last search date: 7 June 2022)ICTRP: World Health Organization (WHO) International Clinical Trials Registry Platforma Multiple arm RCTs evaluated both tocilizumab and sarilumab (one published and one unpublished result),b One factorial RCT evaluated tocilizumab and siltuximab, and consequently, they appear twice." data-id="CD013881-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_t/tCD013881-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flowchart of included randomized controlled trials (RCTs) of interleukin 6 (IL‐6) blocking agents (last search date: 7 June 2022) </p> <p>ICTRP: World Health Organization (WHO) International Clinical Trials Registry Platform</p> <p><sup>a</sup> Multiple arm RCTs evaluated both tocilizumab and sarilumab (one published and one unpublished result), </p> <p><sup>b</sup> One factorial RCT evaluated tocilizumab and siltuximab, and consequently, they appear twice. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Funnel plot Tocilizumab vs standard care or placebo. All cause mortality D28" data-id="CD013881-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-02.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Funnel plot Tocilizumab vs standard care or placebo. All cause mortality D28</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-02.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-03" target="_blank"><b></b></a></p> </div><img alt="8.1.2 Funnel plot Tocilizumab compared to standard care or placebo" data-id="CD013881-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-03.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>8.1.2 Funnel plot Tocilizumab compared to standard care or placebo</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-03.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-04" target="_blank"><b></b></a></p> </div><img alt="8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. Clinical improvement D28" data-id="CD013881-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-04.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. Clinical improvement D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-04.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-05" target="_blank"><b></b></a></p> </div><img alt="8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. WHO score 7 D28" data-id="CD013881-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-05.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. WHO score 7 D28</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-05.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-06" target="_blank"><b></b></a></p> </div><img alt="8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. Adverse events" data-id="CD013881-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-06.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-06.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-07" target="_blank"><b></b></a></p> </div><img alt="8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. Serious adverse events" data-id="CD013881-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-07.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>8.1.2 Funnel plot Tocilizumab compared to standard care or placebo. Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-07.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.1 Tocilizumab versus placebo or standard care. Outcome: Clinical improvement 28" data-id="CD013881-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-08.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Analysis 1.1.1 Tocilizumab versus placebo or standard care. Outcome: Clinical improvement 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-08.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.2 Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D60" data-id="CD013881-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-09.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Analysis 1.1.2 Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-09.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.3 Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-10.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Analysis 1.1.3 Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-10.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.4 Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-11.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Analysis 1.1.4 Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-11.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.5 Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-12.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Analysis 1.1.5 Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-12.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-13" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.6 Tocilizumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-13.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Analysis 1.1.6 Tocilizumab versus placebo or standard care. Outcome: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-13.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-14" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1.7 Tocilizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-14.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Analysis 1.1.7 Tocilizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-14.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-15" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.2.1 Tocilizumab versus placebo or standard care. Outcome: Time to clinical improvement" data-id="CD013881-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-15.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Analysis 1.2.1 Tocilizumab versus placebo or standard care. Outcome: Time to clinical improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-15.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-16" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.2.2 Tocilizumab versus placebo or standard care. Outcome: Time to WHO progression score (level 7 and above)" data-id="CD013881-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-16.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p>Analysis 1.2.2 Tocilizumab versus placebo or standard care. Outcome: Time to WHO progression score (level 7 and above) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-16.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-17" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.2.3 Tocilizumab versus placebo or standard care. Outcome: Time to death" data-id="CD013881-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-17.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 17</div> <div class="figure-caption"> <p>Analysis 1.2.3 Tocilizumab versus placebo or standard care. Outcome: Time to death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-17.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-18" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.1 Sarilumab versus placebo or standard care. Outcome: Clinical improvement D28Sivapalasingam 2022: Sivapalasingam 2022.1 refers to the phase 2 results; Sivapalasingam 2022.2 refers to the phase 3 results." data-id="CD013881-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-18.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 18</div> <div class="figure-caption"> <p>Analysis 2.1.1 Sarilumab versus placebo or standard care. Outcome: Clinical improvement D28 </p> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>: <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>.1 refers to the phase 2 results; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>.2 refers to the phase 3 results. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-18.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-19" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.2 Sarilumab versus placebo or standard care. Outcome: Clinical improvement D60" data-id="CD013881-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-19.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 19</div> <div class="figure-caption"> <p>Analysis 2.1.2 Sarilumab versus placebo or standard care. Outcome: Clinical improvement D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-19.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-20" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.3 Sarilumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-20.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 20</div> <div class="figure-caption"> <p>Analysis 2.1.3 Sarilumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-20.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-21" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.4 Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-21.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 21</div> <div class="figure-caption"> <p>Analysis 2.1.4 Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-21.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-22" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.5 Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-22.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 22</div> <div class="figure-caption"> <p>Analysis 2.1.5 Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-22.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-23" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.6 Sarilumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-23.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 23</div> <div class="figure-caption"> <p>Analysis 2.1.6 Sarilumab versus placebo or standard care. Outcome: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-23.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-24" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.1.7 Sarilumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-24.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 24</div> <div class="figure-caption"> <p>Analysis 2.1.7 Sarilumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-24.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-25" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.2.1 Sarilumab versus placebo or standard care. Outcome: Time to clinical improvement" data-id="CD013881-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-25.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 25</div> <div class="figure-caption"> <p>Analysis 2.2.1 Sarilumab versus placebo or standard care. Outcome: Time to clinical improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-25.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-26" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.2.2 Sarilumab versus placebo or standard care. Time to WHO Clinical Progression Score of level 7 or above" data-id="CD013881-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-26.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 26</div> <div class="figure-caption"> <p>Analysis 2.2.2 Sarilumab versus placebo or standard care. Time to WHO Clinical Progression Score of level 7 or above </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-26.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-27" target="_blank"><b></b></a></p> </div><img alt="Analysis 2.2.3 Sarilumab versus placebo or standard care. Outcome: Time to death" data-id="CD013881-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-27.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 27</div> <div class="figure-caption"> <p>Analysis 2.2.3 Sarilumab versus placebo or standard care. Outcome: Time to death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-27.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-28" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.1 Clazakizumab versus placebo or standard care. Outcome: Clinical improvement 28" data-id="CD013881-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-28.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 28</div> <div class="figure-caption"> <p>Analysis 3.1.1 Clazakizumab versus placebo or standard care. Outcome: Clinical improvement 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-28.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-29" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.2 Clazakizumab versus placebo or standard care. Outcome: Clinical improvement D60" data-id="CD013881-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-29.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 29</div> <div class="figure-caption"> <p>Analysis 3.1.2 Clazakizumab versus placebo or standard care. Outcome: Clinical improvement D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-29.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-30" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.3 Clazakizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-30.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 30</div> <div class="figure-caption"> <p>Analysis 3.1.3 Clazakizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-30.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-31" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.4 Clazakizumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-31.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 31</div> <div class="figure-caption"> <p>Analysis 3.1.4 Clazakizumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-31.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-32" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.5 Clazakizumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-32.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 32</div> <div class="figure-caption"> <p>Analysis 3.1.5 Clazakizumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-32.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-33" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.6 Clazakizumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-33.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 33</div> <div class="figure-caption"> <p>Analysis 3.1.6 Clazakizumab versus placebo or standard care. Outcome: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-33.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-34" target="_blank"><b></b></a></p> </div><img alt="Analysis 3.1.7 Clazakizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-34.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 34</div> <div class="figure-caption"> <p>Analysis 3.1.7 Clazakizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-34.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-35" target="_blank"><b></b></a></p> </div><img alt="Analysis 4.1.1 Olokizumab versus placebo or standard care. Outcome: Clinical improvement 28" data-id="CD013881-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-35.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 35</div> <div class="figure-caption"> <p>Analysis 4.1.1 Olokizumab versus placebo or standard care. Outcome: Clinical improvement 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-35.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-36" target="_blank"><b></b></a></p> </div><img alt="Analysis 4.1.2 Olokizumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-36.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 36</div> <div class="figure-caption"> <p>Analysis 4.1.2 Olokizumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-36.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-37" target="_blank"><b></b></a></p> </div><img alt="Analysis 4.1.3 Olokizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-37.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 37</div> <div class="figure-caption"> <p>Analysis 4.1.3 Olokizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-37.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-38" target="_blank"><b></b></a></p> </div><img alt="Analysis 5.1.1 Siltuximab versus placebo or standard care. Outcome: Clinical improvement 28" data-id="CD013881-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-38.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 38</div> <div class="figure-caption"> <p>Analysis 5.1.1 Siltuximab versus placebo or standard care. Outcome: Clinical improvement 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-38.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-39" target="_blank"><b></b></a></p> </div><img alt="Analysis 5.1.2 Siltuximab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-39.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 39</div> <div class="figure-caption"> <p>Analysis 5.1.2 Siltuximab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-39.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-40" target="_blank"><b></b></a></p> </div><img alt="Analysis 5.1.3 Siltuximab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-40.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 40</div> <div class="figure-caption"> <p>Analysis 5.1.3 Siltuximab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-40.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-41" target="_blank"><b></b></a></p> </div><img alt="Analysis 5.1.4 Siltuximab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-41.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 41</div> <div class="figure-caption"> <p>Analysis 5.1.4 Siltuximab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-41.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-42" target="_blank"><b></b></a></p> </div><img alt="Analysis 5.1.5 Siltuximab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-42.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 42</div> <div class="figure-caption"> <p>Analysis 5.1.5 Siltuximab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-42.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-43" target="_blank"><b></b></a></p> </div><img alt="Analysis 5.2.1 Siltuximab versus placebo or standard care. Outcome: Time to death" data-id="CD013881-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-43.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 43</div> <div class="figure-caption"> <p>Analysis 5.2.1 Siltuximab versus placebo or standard care. Outcome: Time to death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-43.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-44" target="_blank"><b></b></a></p> </div><img alt="Analysis 6.1.1 Levilimab versus placebo or standard care. Outcome: Clinical improvement 28" data-id="CD013881-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-44.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 44</div> <div class="figure-caption"> <p>Analysis 6.1.1 Levilimab versus placebo or standard care. Outcome: Clinical improvement 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-44.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-45" target="_blank"><b></b></a></p> </div><img alt="Analysis 6.1.2 Levilimab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-45.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 45</div> <div class="figure-caption"> <p>Analysis 6.1.2 Levilimab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-45.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-46" target="_blank"><b></b></a></p> </div><img alt="Analysis 6.1.3 Levilimab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-46.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 46</div> <div class="figure-caption"> <p>Analysis 6.1.3 Levilimab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-46.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-47" target="_blank"><b></b></a></p> </div><img alt="Analysis 6.1.4 Levilimab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-47.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 47</div> <div class="figure-caption"> <p>Analysis 6.1.4 Levilimab versus placebo or standard care. Outcome: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-47.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-48" target="_blank"><b></b></a></p> </div><img alt="Analysis 6.1.5 Levilimab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0048" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-48.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 48</div> <div class="figure-caption"> <p>Analysis 6.1.5 Levilimab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-48.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-49" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.3.1 Funding. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28" data-id="CD013881-fig-0049" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-49.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 49</div> <div class="figure-caption"> <p>Subgroup analysis. 1.3.1 Funding. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-49.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-50" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis.1.3.2 Funding. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0050" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-50.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 50</div> <div class="figure-caption"> <p>Subgroup analysis.1.3.2 Funding. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-50.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-51" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis.1.3.3 Funding. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0051" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-51.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 51</div> <div class="figure-caption"> <p>Subgroup analysis.1.3.3 Funding. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-51.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-52" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.3.4 Funding. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0052" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-52.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 52</div> <div class="figure-caption"> <p>Subgroup analysis. 1.3.4 Funding. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-52.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-53" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.3.5 Funding. Tocilizumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0053" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-53.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 53</div> <div class="figure-caption"> <p>Subgroup analysis. 1.3.5 Funding. Tocilizumab versus placebo or standard care. Outcome: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-53.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-54" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.3.6 Funding. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0054" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-54.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 54</div> <div class="figure-caption"> <p>Subgroup analysis. 1.3.6 Funding. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-54.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-55" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.4.1 Location. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28" data-id="CD013881-fig-0055" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-55.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 55</div> <div class="figure-caption"> <p>Subgroup analysis. 1.4.1 Location. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-55.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-56" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.4.2 Location. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0056" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-56.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 56</div> <div class="figure-caption"> <p>Subgroup analysis. 1.4.2 Location. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-56.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-57" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis.1.4.3 Location. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0057" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-57.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 57</div> <div class="figure-caption"> <p>Subgroup analysis.1.4.3 Location. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-57.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-58" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.4.4 Location. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0058" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-58.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 58</div> <div class="figure-caption"> <p>Subgroup analysis. 1.4.4 Location. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-58.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-59" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.4.5 Location. Tocilizumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0059" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-59.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 59</div> <div class="figure-caption"> <p>Subgroup analysis. 1.4.5 Location. Tocilizumab versus placebo or standard care. Outcome: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-59.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-60" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.4.6 Location. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0060" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-60.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 60</div> <div class="figure-caption"> <p>Subgroup analysis. 1.4.6 Location. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-60.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-61" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.5.1 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28" data-id="CD013881-fig-0061" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-61.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 61</div> <div class="figure-caption"> <p>Subgroup analysis. 1.5.1 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-61.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-62" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.5.2 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0062" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-62.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 62</div> <div class="figure-caption"> <p>Subgroup analysis. 1.5.2 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-62.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-63" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.5.3 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0063" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-63.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 63</div> <div class="figure-caption"> <p>Subgroup analysis. 1.5.3 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-63.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-64" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.5.4 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0064" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-64.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 64</div> <div class="figure-caption"> <p>Subgroup analysis. 1.5.4 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-64.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-65" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.5.5 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0065" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-65.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 65</div> <div class="figure-caption"> <p>Subgroup analysis. 1.5.5 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-65.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-66" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.5.6 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0066" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-66.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 66</div> <div class="figure-caption"> <p>Subgroup analysis. 1.5.6 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-66.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-67" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.6.1 Severity. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28" data-id="CD013881-fig-0067" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-67.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 67</div> <div class="figure-caption"> <p>Subgroup analysis. 1.6.1 Severity. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-67.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-68" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.6.2 Severity. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0068" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-68.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 68</div> <div class="figure-caption"> <p>Subgroup analysis. 1.6.2 Severity. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-68.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-69" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.6.3 Severity. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0069" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-69.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 69</div> <div class="figure-caption"> <p>Subgroup analysis. 1.6.3 Severity. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-69.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-70" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.6.4 Severity. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0070" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-70.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 70</div> <div class="figure-caption"> <p>Subgroup analysis. 1.6.4 Severity. Tocilizumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-70.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-71" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 1.6.5 Severity. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0071" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-71.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 71</div> <div class="figure-caption"> <p>Subgroup analysis. 1.6.5 Severity. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-71.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-72" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 2.3.1 Funding. Sarilumab versus placebo or standard care. Outcome: Clinical improvement D28" data-id="CD013881-fig-0072" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-72.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 72</div> <div class="figure-caption"> <p>Subgroup analysis. 2.3.1 Funding. Sarilumab versus placebo or standard care. Outcome: Clinical improvement D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-72.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-73" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis.2.3.3 Funding. Sarilumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0073" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-73.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 73</div> <div class="figure-caption"> <p>Subgroup analysis.2.3.3 Funding. Sarilumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-73.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-74" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis.2.3.4 Funding. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0074" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-74.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 74</div> <div class="figure-caption"> <p>Subgroup analysis.2.3.4 Funding. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-74.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-75" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 2.3.5 Funding. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0075" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-75.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 75</div> <div class="figure-caption"> <p>Subgroup analysis. 2.3.5 Funding. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-75.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-76" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 2.3.6 Funding. Sarilumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0076" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-76.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 76</div> <div class="figure-caption"> <p>Subgroup analysis. 2.3.6 Funding. Sarilumab versus placebo or standard care. Outcome: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-76.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-77" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 2.3.7 Funding. Sarilumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0077" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-77.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 77</div> <div class="figure-caption"> <p>Subgroup analysis. 2.3.7 Funding. Sarilumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-77.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-78" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis.2.4.1 Location. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0078" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-78.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 78</div> <div class="figure-caption"> <p>Subgroup analysis.2.4.1 Location. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-78.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-79" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 2.4.2 Location. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0079" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-79.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 79</div> <div class="figure-caption"> <p>Subgroup analysis. 2.4.2 Location. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-79.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-80" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 2.4.3 Location. Sarilumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0080" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-80.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 80</div> <div class="figure-caption"> <p>Subgroup analysis. 2.4.3 Location. Sarilumab versus placebo or standard care. Outcome: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-80.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-81" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 2.4.4 Location. Sarilumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0081" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-81.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 81</div> <div class="figure-caption"> <p>Subgroup analysis. 2.4.4 Location. Sarilumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-81.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-82" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 2.5.1 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: Clinical improvement D28" data-id="CD013881-fig-0082" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-82.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 82</div> <div class="figure-caption"> <p>Subgroup analysis. 2.5.1 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: Clinical improvement D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-82.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-83" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 2.5.2 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28" data-id="CD013881-fig-0083" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-83.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 83</div> <div class="figure-caption"> <p>Subgroup analysis. 2.5.2 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-83.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-84" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 2.5.3 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0084" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-84.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 84</div> <div class="figure-caption"> <p>Subgroup analysis. 2.5.3 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-84.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-85" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 2.5.4 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0085" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-85.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 85</div> <div class="figure-caption"> <p>Subgroup analysis. 2.5.4 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-85.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-86" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 2.5.5 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: Adverse events" data-id="CD013881-fig-0086" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-86.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 86</div> <div class="figure-caption"> <p>Subgroup analysis. 2.5.5 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-86.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-87" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 2.5.6 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0087" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-87.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 87</div> <div class="figure-caption"> <p>Subgroup analysis. 2.5.6 Conflict of Interests. Sarilumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-87.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-88" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 3.3.1 Conflict of interest. Clazakizumab versus placebo. Outcome: All‐cause mortality D28" data-id="CD013881-fig-0088" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-88.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 88</div> <div class="figure-caption"> <p>Subgroup analysis. 3.3.1 Conflict of interest. Clazakizumab versus placebo. Outcome: All‐cause mortality D28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-88.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-89" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 3.3.2 Conflict of interest. Clazakizumab versus placebo or standard care. Outcome: All‐cause mortality D60" data-id="CD013881-fig-0089" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-89.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 89</div> <div class="figure-caption"> <p>Subgroup analysis. 3.3.2 Conflict of interest. Clazakizumab versus placebo or standard care. Outcome: All‐cause mortality D60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-89.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013881-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/urn:x-wiley:14651858:media:CD013881:CD013881-FIG-90" target="_blank"><b></b></a></p> </div><img alt="Subgroup analysis. 3.3.3 Conflict of interest. Clazakizumab versus placebo or standard care. Outcome: Serious adverse events" data-id="CD013881-fig-0090" src="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-90.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 90</div> <div class="figure-caption"> <p>Subgroup analysis. 3.3.3 Conflict of interest. Clazakizumab versus placebo or standard care. Outcome: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/media/CDSR/CD013881/image_n/nCD013881-FIG-90.jpg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013881-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Tociliuzumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Tociliuzumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19<sup>a</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild/moderate/severe/critical COVID‐19 </p> <p><b>Setting:</b> hospital inpatients worldwide </p> <p><b>Intervention:</b> tocilizumab </p> <p><b>Comparison:</b> standard care/placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard care/placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with tocilizumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D28<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>545 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>573 per 1000</b><br/>(545 to 605) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/>(1.00 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6116<br/>(15 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D60 or more<sup>f</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>609 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>670 per 1000</b><br/>(493 to 901) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b><br/>(0.81 to 1.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>h,i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO progression score (level 7 or above) D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>217 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>196 per 1000</b><br/>(157 to 244) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b><br/>(0.72 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2117<br/>(13 RCTs)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>j,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>284 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b><br/>(230 to 267) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b><br/>(0.81 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7428<br/>(18 RCTs)<sup>m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One additional study (<a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>) also reported on the outcome in 26 participants. There were zero events in both groups and the study not contribute to the pooled effect estimate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D60 or more</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>264 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b><br/>(211 to 274) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b><br/>(0.80 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2775<br/>(9 RCTs)<sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>j,o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One additional study (<a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>) also reported on the outcome in 26 participants. There were zero events in both groups and the study not contribute to the pooled effect estimate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>443 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>456 per 1000</b><br/>(421 to 496) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b><br/>(0.95 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1811<br/>(9 RCTs)<sup>p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>q,r</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>156 per 1000</b><br/>(136 to 180) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b><br/>(0.81 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2974<br/>(16 RCTs)<sup>s</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>j,r,t</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One additional study (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>) also reported on the outcome in 21 participants. There were zero events in both groups and the study not contribute to the pooled effect estimate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; D: day; RCT: randomized controlled trial; RR: risk ratio; WHO: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 22 July 2022<br/><sup>b</sup>Defined as a decrease in score by at least 2 points on the 7‐category ordinal scale (<a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>); an increase of at least 2 points on a 6‐category ordinal scale (compared with the worst status at day of randomization) or discharge from the hospital alive (<a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>); discharged at 28‐days (<a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>); not admitted to hospital (discharged alive) (<a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>).<br/><sup>c</sup><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a><br/><sup>d</sup>Despite some concerns or high risk regarding adequate randomization, deviations from intended interventions, missing data, outcome measurement and selection of reported results, not downgraded for risk of bias because the studies with these concerns contributed only a small proportion of weight to the effect estimate.<br/><sup>e</sup>Imprecision downgraded by 1 level: wide confidence interval consistent with the possibility for benefit and the possibility for a trivial/no effect<br/><sup>f</sup>Defined as hospital discharge.<br/><sup>g</sup><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a><br/><sup>h</sup>Risk of bias downgraded by 1 level: some concerns regarding missing data and outcome measurement.<br/><sup>i</sup>Indirectness downgraded by 1 level: despite a multicenter design this is a single study from a single country, therefore results in this population might not be generalizable to other settings.<br/><sup>j</sup>Imprecision downgraded by 2 levels: very wide confidence interval consistent with the possibility for benefit and the possibility for harm.<br/><sup>k</sup><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a><br/><sup>l</sup>Despite some concerns or high risk regarding adequate randomization, deviations from intended interventions, and selection of reported results, not downgraded for risk of bias because the studies with these concerns contributed only a small proportion of weight to the effect estimate.<br/><sup>m</sup><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a><br/><sup>n</sup><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a>; <a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a><br/><sup>o</sup>Despite some concerns or high risk regarding adequate randomization, deviations from intended interventions, and missing data, not downgraded for risk of bias because the studies with these concerns contributed only a small proportion of weight to the effect estimate.<br/><sup>p</sup><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a><br/><sup>q</sup>Imprecision downgraded by 1 level: wide confidence interval consistent with the possibility for a trivial/no effect and the possibility for harm.<br/><sup>r</sup>One additional study was identified that assessed this outcome (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>), but no results were reported.<br/><sup>s</sup><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>; <a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a>; <a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a>; <a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>; <a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a>; <a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a>; <a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a>; <a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>; <a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a>; <a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a>; <a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>; <a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>; <a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a><br/><sup>t</sup>Risk of bias downgraded by 1 level: some concerns regarding adequate randomization, deviations from intended interventions, missing data, outcome measurement and selection of the reported results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Tociliuzumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013881-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sarilumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Sarilumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19<sup>a</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild/moderate/severe/critical COVID‐19 </p> <p><b>Setting:</b> hospital inpatients worldwide </p> <p><b>Intervention:</b> sarilumab </p> <p><b>Comparison:</b> standard care/placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with<br/>standard<br/>care/placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sarilumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D28<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>643 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>637 per 1000</b><br/>(604 to 675) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b><br/>(0.94 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2425<br/>(7 RCTs)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D60 or more<sup>e</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>628 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>766 per 1000</b><br/>(572 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b><br/>(0.91 to 1.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>g,h,i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO progression score (level 7 or above) D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>275 per 1000</b><br/>(225 to 333) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b><br/>(0.90 to 1.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>886<br/>(5 RCTs)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>j,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>224 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>238 per 1000</b><br/>(193 to 292) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b><br/>(0.86 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3305<br/>(9 RCTs)<sup>m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>j,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D60 or more</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>294 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>279 per 1000</b><br/>(247 to 314) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b><br/>(0.84 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3379<br/>(6 RCTs)<sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>j,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>408 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>457 per 1000</b><br/>(396 to 522) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b><br/>(0.97 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>860<br/>(4 RCTs)<sup>o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>p,q,r</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>243 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>265 per 1000</b><br/>(236 to 294) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.09</b><br/>(0.97 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2936<br/>(6 RCTs)<sup>s</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>q,r,t</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; D: day; RCT: randomized controlled trial; RR: risk ratio; WHO: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 6 September 2022<br/><sup>b</sup>Defined as discharge at day 28 (<a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>); as a 2‐point rise in a 7‐category ordinal scale or hospital discharge, whichever occurred first (<a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>); as proportion with 1‐point improvement in clinical status using a 7‐point ordinal scale on day 22 (<a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>).<br/><sup>c</sup><a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (phase 2 and 3)<br/><sup>d</sup>Risk of bias downgraded by 1 level: some concerns regarding adequate randomization, deviations from intended intervention, missing data, outcome measurement and selection of the reported result.<br/><sup>e</sup>Defined as hospital discharge.<br/><sup>f</sup><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a><br/><sup>g</sup>Risk of bias downgraded by 1 level: some concerns regarding deviation from intended intervention, missing data, outcome measurement and selection of the reported results<br/><sup>h</sup>Inconsistency downgraded by 1 level: I² = 50.1%<br/><sup>i</sup>Indirectness downgraded by 1 level: studies from a single country, therefore results in this population might not be generalizable to other settings.<br/><sup>j</sup>Imprecision downgraded by 2 levels: very wide confidence interval consistent with the possibility for benefit and the possibility for harm<br/><sup>k</sup><a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (phase 2)<br/><sup>l</sup>Risk of bias downgraded by 1 level: some concerns regarding adequate randomization, deviations from intended interventions, and missing data<br/><sup>m</sup><a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (phase 2 and 3)<br/><sup>n</sup><a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>; <a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (phase 2)<br/><sup>o</sup><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a><br/><sup>p</sup>Risk of bias downgraded by 1 level: some concerns regarding deviations from intended intervention, missing data, outcome measurement and selection of the reported results.<br/><sup>q</sup>Imprecision downgraded by 1 level: wide confidence interval consistent with the possibility for no effect/trivial effect and the possibility for harm.<br/><sup>r</sup>One additional study was identified that assessed this outcome (<a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a>), but no results were reported.<br/><sup>s</sup><a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a>; <a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a>; <a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>; <a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a>; <a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a>; <a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a> (phase 2)<br/><sup>t</sup>Risk of bias downgraded by 1 level: some concerns regarding adequate randomization, deviations from intended intervention, missing data, and outcome measurement. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sarilumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013881-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Clazakizumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Clazakizumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19<sup>a</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild/moderate/severe/critical COVID‐19 </p> <p><b>Setting:</b> hospital inpatients worldwide </p> <p><b>Intervention:</b> clazakizumab </p> <p><b>Comparison:</b> standard care/placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard care/placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with clazakizumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D28<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>640 per 1000</b><br/>(485 to 850) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.28</b><br/>(0.97 to 1.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D60 or more</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>541 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>692 per 1000</b><br/>(535 to 897) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.28</b><br/>(0.99 to 1.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO progression score (level 7 or above) D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>446 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>294 per 1000</b><br/>(192 to 450) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.66</b><br/>(0.43 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>253 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1000</b><br/>(137 to 392) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.91</b><br/>(0.54 to 1.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>g,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D60 or more</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>361 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>278 per 1000</b><br/>(177 to 430) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.77</b><br/>(0.49 to 1.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>g,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>251 per 1000</b><br/>(44 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.12</b><br/>(0.20 to 6.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17<br/>(1 RCT)<sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>h,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>434 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>299 per 1000</b><br/>(200 to 451) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.69</b><br/>(0.46 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169<br/>(2 RCTs)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>h,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; D: day; RCT: randomized controlled trial; RR: risk ratio; WHO: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 21 July 2022<br/><sup>b</sup>Defined as change in clinical status, defined by an improvement in status by at least 2 score points on WHO 11‐point ordinal scale.<br/><sup>c</sup><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a><br/><sup>d</sup>Indirectness downgraded by 1 level: despite a multicenter design this is a single study from a single country, therefore results in this population might not be generalizable to other settings.<br/><sup>e</sup>Imprecision downgraded by 2 levels: due to wide confidence interval consistent with the possibility for benefit and the possibility of no effect/trivial effect and small sample. <br/><sup>f</sup><a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a>; <a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a><br/><sup>g</sup>Indirectness downgraded by 1 level: studies from a single country, therefore results in this population might not be generalizable to other settings.<br/><sup>h</sup>Imprecision downgraded by 2 levels: very wide confidence interval consistent with the possibility for benefit and the possibility for harm. <br/><sup>i</sup><a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a><br/><sup>j</sup>We presume that the adverse event rates, and the corresponding relative risks, are similar across diverse settings; therefore not downgraded for indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Clazakizumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013881-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Olokizumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Olokizumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19<sup>a</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild/moderate/severe/critical COVID‐19 </p> <p><b>Setting:</b> hospital inpatients worldwide </p> <p><b>Intervention:</b> olokizumab </p> <p><b>Comparison:</b> standard care/placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard care/placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with olokizumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D28<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>758 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>834 per 1000</b><br/>(728 to 940) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.10</b><br/>(0.96 to 1.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D60 or more ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO progression score (level 7 or above) D28 ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b><br/>(27 to 198) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.50</b><br/>(0.55 to 4.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D60 or more ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b><br/>(33 to 197) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b><br/>(0.51 to 3.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,g,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; D: day; RCT: randomized controlled trial; RR: risk ratio; WHO: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 29 June 2022<br/><sup>b</sup>Defined as the proportion of patients with an improvement in clinical status by 2 or more points on the 6‐point ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) during the study with no use of tocilizumab or sarilumab. <br/><sup>c</sup><a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a><br/><sup>d</sup>Risk of bias downgraded by 1 level: some concerns regarding adequate randomization and deviations from intended interventions.<br/><sup>e</sup>Indirectness downgraded by 1 level: despite a multicenter design this is a single study from a single country, therefore results in this population might not be generalizable to other settings.<br/><sup>f</sup>Imprecision downgraded by 2 levels: wide confidence interval consistent with the possibility for benefit and the possibility for trivial effect/no effect, and small sample size.<br/><sup>g</sup>Imprecision downgraded by 2 levels: very wide confidence interval consistent with the possibility for benefit and the possibility for harm.<br/><sup>h</sup>We presume that the adverse event rates and the corresponding relative risks are similar across diverse settings; therefore not downgraded for indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Olokizumab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013881-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Siltuximab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Siltuximab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19<sup>a</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild/moderate/severe/critical COVID‐19 </p> <p><b>Setting:</b> hospital inpatients worldwide </p> <p><b>Intervention:</b> siltuximab </p> <p><b>Comparison:</b> standard care/placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard care/placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with siltuximab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D28<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>736 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b><br/>(582 to 869) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b><br/>(0.79 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D60 or more ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO progression score (level 7 or above) D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b><br/>(178 to 605) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.97</b><br/>(1.07 to 3.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>131 per 1000</b><br/>(53 to 327) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.35</b><br/>(0.54 to 3.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D60 or more</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>198 per 1000</b><br/>(93 to 423) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.58</b><br/>(0.74 to 3.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>197 per 1000</b><br/>(98 to 400) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b><br/>(0.64 to 2.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>e,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; D: day; RCT: randomized controlled trial; RR: risk ratio; WHO: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 21 July 2022<br/><sup>b</sup>Defined as an increase of at least 2 points on a 6‐category ordinal scale (compared with the worst status at day of randomization) or discharge from the hospital alive.<br/><sup>c</sup><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a><br/><sup>d</sup>Indirectness downgraded by 1 level: despite a multicenter design this is a single study from a single country, therefore results in this population might not be generalizable to other settings.<br/><sup>e</sup>Imprecision downgraded by 2 levels: very wide confidence interval consistent with the possibility for benefit and the possibility for harm.<br/><sup>f</sup>Imprecision downgraded by 1 level: low number of events and/or participants.<br/><sup>g</sup>We presume that the adverse event rates and the corresponding relative risks are similar across diverse settings; therefore not downgraded for indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Siltuximab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013881-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Levilimab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Levilimab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19<sup>a</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild/moderate/severe/critical COVID‐19 </p> <p><b>Setting:</b> hospital inpatients worldwide </p> <p><b>Intervention:</b> levilimab </p> <p><b>Comparison:</b> standard care/placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard care/placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with levilimab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D28<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>553 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>847 per</b> 1000<br/>(697 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.53</b><br/>(1.26 to 1.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement D60 or more ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WHO progression score (level 7 or above) D28 ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per</b> 1000<br/>(10 to 151) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/>(0.26 to 3.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality D60 or more</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per</b> 1000<br/>(10 to 151) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/>(0.26 to 3.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>233 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273 per</b> 1000<br/>(170 to 436) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.17</b><br/>(0.73 to 1.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>(follow‐up: range 14 days to 90 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per</b> 1000<br/>(1 to 105) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b><br/>(0.05 to 5.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/>(1 RCT)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Last updated: 29 June 2022<br/><sup>b</sup>Defined as an improvement of 2 or more point scales of clinical status from baseline on the 7‐category ordinal scale or reaching the clinical status of categories 1 or 2 on Day 14.<br/><sup>c</sup><a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a><br/><sup>d</sup>Indirectness downgraded by 1 level: despite a multicenter design this is a single study from a single country, therefore results in this population might not be generalizable to other settings.<br/><sup>e</sup>Imprecision downgraded by 1 level: small sample size.<br/><sup>f</sup>Imprecision downgraded by 2 levels: very wide confidence interval consistent with the possibility for benefit and the possibility for harm.<br/><sup>g</sup>We presume that the adverse event rates and the corresponding relative risks are similar across diverse settings; therefore not downgraded for indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Levilimab compared to standard care/placebo for mild/moderate/severe/critical COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias table: tocilizumab vs standard care/placebo. Clinical improvement (D28)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>1.Randomization</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>2.Deviations from intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>3.Missing outcome data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>4.Measurement of the outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>5.Selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>. <b>Rob 2. Deviations from intervention</b>:<br/>Quote: “Open‐label study”<br/>Comment: Unblinded study.<br/>Deviations from intended intervention arising because of the study context:<br/>No participant cross over.<br/>Administration of co‐interventions of interest (antivirals, corticosteroids, and biologics) were reported. The proportions of patients receiving antivirals and steroids were imbalanced between two arms (&gt;10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced.<br/>Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect.<br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate.<br/>Measurement or ascertainment of outcome probably does not differ between groups.<br/>Unblinded study (outcome assessor).<br/>Mortality is an observer‐reported outcome not involving judgement. </p> <p><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>. <b>Rob 2. Deviations from intervention</b>:<br/>Quote: "the trial was open label" <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>Cross over: 15 (23%) patients in the standard care arm received the study treatment. For 12 (18%) the studied treatment was administered because of clinical worsening as planned in the protocol. Nevertheless, this decision could have been influenced by the trial context. <br/>Administration of co‐interventions of interest were reported and not balanced: antivirals (35% vs 47%) and corticosteroids (10% vs 10.6%). These deviations could affect the outcome. Nevertheless, this domain was rated as Some Concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of clinical improvement probably does not differ between groups. <br/>Unblinded study. <br/>Assessment of this outcome requires clinical judgement and can be influenced by knowledge of the intervention assignment, but is not likely in the context of the pandemic. <br/><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a>. <b>Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol and statistical analysis plan were available. <br/>Clinical improvement (defined as discharge) is not present in the protocol or registry. <br/>No information on whether the results were selected from multiple outcome measurements or analyses of the data. </p> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a>. <b>Rob 1. Randomization</b>:<br/>RoB assessment consulted from The WHO Rapid Evidence Appraisal for COVID‐19 Therapies (REACT) Working Group "Association Between Administration of IL‐6 Antagonists and Mortality Among Patients Hospitalized for COVID‐19: A Meta‐analysis." JAMA. 2021;326(6):499–518 due to unavailability of trial details. </p> <p><a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>. <b>Rob 1. Randomization</b>:<br/>Quote: "Eligible patients (one or two days after hospitalization) were randomly distributed to the control and intervention groups by block randomization (1:1 ratio." <br/>Comment: Allocation sequence probably random. Unclear allocation concealment. <br/><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>. <b>Rob 2. Deviations from intervention</b>:<br/>*Quote: "In this study, patients, investigators, and outcome assessors did not inform which group received an intervention. Besides, a placebo was not used in the control group." <br/>Comment: Unclear blinding (unclear if participants and personnel/carers blinded) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Biologics were the intervention. <br/>Corticosteroids reported and balanced between groups. Antivirals reported and not balanced between groups: 35% in the Tocilizumab versus 10% in the standard care arm. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were ana lysed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a>. <b>Rob 3. Missing outcome data</b>:<br/>Comment: 40 participants randomized; 36 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>3 participants in the treatment arm and 1 in the standard care arm refused to participate before start of the intervention. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome </p> <p><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a><b>. Rob 5. Selection of the reported results</b>:<br/>Comment: The trial registry was available. <br/>clinical improvement outcome (D28) (defined as discharge) not pre‐specified. <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> <p><a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>. <b>Rob 2. Deviations from intervention</b>:<br/>Quote: “open label” trial. <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>Cross over: 2/64 (3%) of the control arm received tocilizumab. <br/>Co‐interventions of interest, corticosteroids, and antivirals were reported, but no information on another co‐intervention of interest: biologics. Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis for this outcome. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study. <br/>Assessment of this outcome requires clinical judgement and can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>. <b>Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids. Antivirals were not administered. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention </p> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a>. <b>Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol and statistical analysis plan were not available, and the registry was retrospective (dated October 8, 2021). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as prespecified. </p> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>. <b>Rob 3. Missing outcome data</b>:<br/>Comment: 97 participants randomized; 92 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>. <b>Rob 5. Selection of the reported results</b>:<br/>Comment: The prospective registry was available (dated March 31st, 2020). <br/>Outcomes not pre‐specified in the registry (time point not reported/different).<br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial not analyzed as pre‐specified. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias table: tocilizumab vs standard care/placebo. Clinical improvement (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias table: tocilizumab vs standard care/placebo. Clinical improvement (D60)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>1.Randomization</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>2.Deviations from intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>3.Missing outcome data</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>4.Measurement of the outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>5.Selection of the reported results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Overall risk of bias</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>. <b>Rob 3. Missing outcome data</b>:<br/>Comment: 97 participants randomized; 92 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a>. <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias table: tocilizumab vs standard care/placebo. Clinical improvement (D60)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0009"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. WHO Clinical Progression Score level 7 or above (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Hermine 2020. Rob 2. Deviation from Intervention</b>:<br/>Quote: “Open‐label study”<br/>Comment: Unblinded study.<br/>Deviations from intended intervention arising because of the study context:<br/>No participant cross over.<br/>Administration of co‐interventions of interest (antivirals, corticosteroids, and biologics) were reported. The proportions of patients receiving antivirals and steroids were imbalanced between two arms (&gt;10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced.<br/>Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect.<br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>HMO‐0224‐20 2021. Rob 1. Randomization</b>:<br/>RoB assessment consulted from The WHO Rapid Evidence Appraisal for COVID‐19 Therapies (REACT) Working Group "Association Between Administration of IL‐6 Antagonists and Mortality Among Patients Hospitalized for COVID‐19: A Meta‐analysis." JAMA. 2021;326(6):499–518 due to unavailability of trial details. </p> <p><b>Rutgers 2021.Rob 1. Randomization</b>:<br/>Quote: “Randomization was stratified according to the use of hydroxychloroquine and to (on admission) agreed restrictions for ICU eligibility (ICU eligible or ICU non‐eligible).” <br/>Comment: Allocation sequence probably random. No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. </p> <p><b>Veiga 2021.Rob 2. Deviation from Intervention</b>:<br/>Quote: “open label” trial. <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>Cross over: 2/64 (3%) of the control arm received tocilizumab. <br/>Co‐interventions of interest, corticosteroids, and antivirals were reported, but no information on another co‐intervention of interest: biologics. Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis for this outcome. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Broman 2022. Rob 2. Deviation from Intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids. Antivirals were not administered. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Broman 2022. Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol and statistical analysis plan were not available, and the registry was retrospective (dated October 8, 2021).<br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data.<br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. WHO Clinical Progression Score level 7 or above (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0010"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. All‐cause mortality (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0013" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021 [Preprint]. [DOI: 10.1101/2021.02.11.21249258]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). isrctn.com/ISRCTN50189673 (first received 30 March 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10285):1637-45. [DOI: 10.1016/S0140-6736(21)00676-0]">Horby 2021b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rosas 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Hermine 2020.Rob 2. Deviations from intervention</b>:<br/>Quote: “Open‐label study”<br/>Comment: Unblinded study.<br/>Deviations from intended intervention arising because of the study context:<br/>No participant cross over.<br/>Administration of co‐interventions of interest (antivirals, corticosteroids, and biologics) were reported. The proportions of patients receiving antivirals and steroids were imbalanced between two arms (&gt;10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced.<br/>Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect.<br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Salvarani 2020. Rob 2. Deviations from intervention:</b> </p> <p>Quote: "the trial was open label"</p> <p>Comment: Unblinded study.</p> <p>Deviations from intended intervention arising because of the study context:</p> <p>Cross over: 15 (23%) patients in the standard care arm received the study treatment. For 12 (18%) the studied treatment was administered because of clinical </p> <p>worsening as planned in the protocol. Nevertheless, this decision could have been influenced by the trial context. </p> <p>Administration of co‐interventions of interest were reported and not balanced: antivirals (35% vs 47%) and corticosteroids (10% vs 10.6%). These deviations </p> <p>could affect the outcome. Nevertheless, this domain was rated as Some Concern as it is impossible to distinguish deviation because of trial context and </p> <p>deviation because of intervention effect.</p> <p>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to </p> <p>intervention.</p> <p><b>Gordon 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: corticosteroids (252/272 vs 46/48 vs 293/312) were administered and balanced; antivirals (remdesivir: 107/341 vs 21/48 vs 133/389) were reported and imbalanced. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>HMO‐0224‐20 2021.Rob 1. Randomization</b>:<br/>RoB assessment consulted from The WHO Rapid Evidence Appraisal for COVID‐19 Therapies (REACT) Working Group "Association Between Administration of IL‐6 Antagonists and Mortality Among Patients Hospitalized for COVID‐19: A Meta‐analysis." JAMA. 2021;326(6):499–518 due to unavailability of trial details. </p> <p><b>Rutgers 2021.Rob 1. Randomization</b>:<br/>Quote: “Randomization was stratified according to the use of hydroxychloroquine and to (on admission) agreed restrictions for ICU eligibility (ICU eligible or ICU non‐eligible).” <br/>Comment: Allocation sequence probably random. No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. </p> <p><b>Soin 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: "After randomization, none of the study personnel or patients was masked to treatment assignment in this open‐label trial." Comment: Unblinded study (participants and personnel/carers). <br/>Deviations from intended intervention arising because of the study context. <br/>One patient randomly assigned to the standard care group inadvertently received tocilizumab at baseline and was included in the tocilizumab group for all analyses (one cross‐over) <br/>Information on the administration of co‐interventions of interest was provided: antivirals and corticosteroids. Biologics were not reported. <br/>Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Participants were not analyzed according to their randomized groups for the outcome. <br/>Of note, 1 participant randomized to the control group was analyzed in the intervention group. Nevertheless, we considered the analysis to be probably appropriate to estimate the effect of assignment to intervention. </p> <p><b>Talaschian 2021.Rob 1. Randomization</b> :<br/>Quote: "Eligible patients (one or two days after hospitalization) were randomly distributed to the control and intervention groups by block randomization (1:1 ratio." <br/>Comment: Allocation sequence probably random. Unclear allocation concealment. <br/><b>Talaschian 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "In this study, patients, investigators, and outcome assessors did not inform which group received an intervention. Besides, a placebo was not used in the control group." <br/>Comment: Unclear blinding (unclear if participants and personnel/carers blinded) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Biologics were the intervention. <br/>Corticosteroids reported and balanced between groups. Antivirals reported and not balanced between groups: 35% in the Tocilizumab versus 10% in the standard care arm. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Talaschian 2021.Rob 3. Missing outcome data</b> :<br/>Comment: 40 participants randomized; 36 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>3 participants in the treatment arm and 1 in the standard care arm refused to participate before start of the intervention. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome <br/><b>Talaschian 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The trial registry was available. <br/>Outcome has different time point listed in the registry. <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> <p><b>Veiga 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: “open label” trial. <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>Cross over: 2/64 (3%) of the control arm received tocilizumab. <br/>Co‐interventions of interest, corticosteroids, and antivirals were reported, but no information on another co‐intervention of interest: biologics. Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis for this outcome. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Broman 2022. Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids. Antivirals were not administered. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention.<br/><b>Broman 2022. Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol and statistical analysis plan were not available, and the registry was retrospective (dated October 8, 2021). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> <p><b>Hermine 2022. Rob 3. Missing outcome data</b>:<br/>Comment: 97 participants randomized; 92 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. All‐cause mortality (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0011"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. All‐cause mortality (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.Randomization</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.Deviations from intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.Missing outcome data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.Measurement of the outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.Selection of the reported results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0012" title="HMO-0224-20. The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation. clinicaltrials.gov/ct2/show/NCT04377750 (first received 6 May 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">HMO‐0224‐20 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Hermine 2020.Rob 2. Deviations from intervention</b>:<br/>Quote: “Open‐label study”<br/>Comment: Unblinded study.<br/>Deviations from intended intervention arising because of the study context:<br/>No participant cross over.<br/>Administration of co‐interventions of interest (antivirals, corticosteroids, and biologics) were reported. The proportions of patients receiving antivirals and steroids were imbalanced between two arms (&gt;10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced.<br/>Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect.<br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Derde 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: "Open‐label design" <br/>Comment: Unblinded study (participants and personnel/carers). <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest, antivirals, biologics, and corticosteroids were reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>HMO‐0224‐20 2021</b> . <b>Rob 1. Randomization</b>:<br/>RoB assessment consulted from The WHO Rapid Evidence Appraisal for COVID‐19 Therapies (REACT) Working Group "Association Between Administration of IL‐6 Antagonists and Mortality Among Patients Hospitalized for COVID‐19: A Meta‐analysis." JAMA. 2021;326(6):499–518 due to unavailability of trial details. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b>:<br/>Comment: 97 participants randomized; 92 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. All‐cause mortality (≥ D60)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0012"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Incidence of any adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.Randomization</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.Deviations from intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.Missing outcome data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.Measurement of the outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.Selection of the reported results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>7</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>8</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sup>9</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns<sub>10</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0028" title="CTRI/2020/05/025369. A study on treatment of COVID-19 patients with study drug along with standard of care. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/05/025369 (first received 27 May 2020). SoinAS , KumarK , ChoudharyNS , SharmaP , MehtaY , KatariaS , et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine2021;9(5):511-21. ">Soin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Quote: “Open‐label study” Comment: unblinded study. </p> <p>Deviations from intended intervention arising because of the study context: three participants in the treatment group did not receive study drug. Administration of co‐interventions of interest (antivirals, corticosteroids and biologics) were reported. The proportions of participants receiving antivirals and steroids were imbalanced between two arms (&gt; 10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced. Nevertheless, this domain was rated as 'Some Concerns' as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><sup>2</sup> Comment: method of measuring the outcome probably appropriate. Measurement of outcome probably does not differ between groups. Unblinded study. The outcome may contain both clinically‐ and laboratory‐detected events. Assessment of this outcome can be influenced by knowledge of the intervention assignment but is not likely in the context of a pandemic. </p> <p><sup>3</sup> Quote: "the trial was open label" Comment: unblinded study. </p> <p>Deviations from intended intervention arising because of the study context: cross over: 15 (23%) participants in the standard care arm received the study treatment. For 12 (18%) the studied treatment was administered because of clinical worsening as planned in the protocol. Nevertheless, this decision could have been influenced by the trial context. Administration of co‐interventions of interest were reported and not balanced: antivirals (35% vs 47%) and corticosteroids (10% vs 10.6%). These deviations could affect the outcome and were not balanced. Nevertheless, this domain was rated as 'Some Concern' as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><sup>4</sup> Comment: method of measuring the outcome probably appropriate. Measurement of outcome probably does not differ between groups. Unblinded study. The outcome may contain both clinically‐ and laboratory‐detected events. Assessment of this outcome can be influenced by knowledge of the intervention assignment but is not likely in the context of a pandemic. </p> <p><sup>5</sup> Quote: "Randomisation numbers were generated using SAS statistical software package (SAS Institute, Cary, USA). A computer‐ generated 1:1 block randomization scheme was used to assign participants to either treatment group or control one. Each consecutively coded participant was randomly enrolled by the sub‐site investigators until the total number of cases allocated to the site was reached." Comment: Allocation sequence random. Allocation concealment unclear. </p> <p><sup>6</sup> Quote: "One case in the control group aggravated on day three after randomization was transferred to the tocilizumab group according to the rules of the study protocol." Comment: unblinded study. Deviations from intended intervention arising because of the study context: one participant cross‐over. No information on administration of any co‐interventions of interest: antivirals, corticosteroids, biologics. Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. Participants were not analyzed according to their randomized groups for the outcome. Of note, 1 participant randomized to the control group was analyzed in the intervention group. Nevertheless, we considered the analysis to be probably appropriate to estimate the effect of assignment to intervention. </p> <p><sup>7</sup> Comment: method of measuring the outcome probably appropriate. Measurement or ascertainment of outcome probably does not differ between groups. Unblinded study. The outcome contains both clinically‐ and laboratory‐detected events. Assessment of this outcome can be influenced by knowledge of the intervention assignment but is not likely in the context of a pandemic. </p> <p><sup>8</sup> Comment: the protocol and statistical analysis plan were not available. The registry was available. Adverse events were not mentioned in the registry but reported in the paper. No information on whether results were selected from multiple outcome measurements or analyses of the data. </p> <p>9 Quote: “open label” trial. Comment: unblinded study.</p> <p>Deviations from intended intervention arising because of the study context: cross over: 2/64 (3%) of the control arm received tocilizumab. Co‐interventions of interest (corticosteroids and antivirals) were reported, but no information on another co‐intervention of interest: biologics. Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. </p> <p>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><sup>10</sup> Comment: method of measuring the outcome probably appropriate. Measurement of outcome probably does not differ between groups. Unblinded study. The outcome contains both clinically‐ and laboratory‐detected events. Assessment of this outcome can be influenced by knowledge of the intervention assignment but is not likely in the context of a pandemic. </p> <p><b>Soin 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "After randomization, none of the study personnel or patients was masked to treatment assignment in this open‐label trial." Comment: Unblinded study (participants and personnel/carers). <br/>Deviations from intended intervention arising because of the study context. <br/>One patient randomly assigned to the standard care group inadvertently received tocilizumab at baseline and was included in the tocilizumab group for all analyses (one cross‐over) <br/>Information on the administration of co‐interventions of interest was provided: antivirals and corticosteroids. Biologics were not reported. <br/>Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Participants were not analyzed according to their randomized groups for the outcome. <br/>Of note, 1 participant randomized to the control group was analyzed in the intervention group. Nevertheless, we considered the analysis to be probably appropriate to estimate the effect of assignment to intervention. <br/><b>Soin 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor) <br/>The authors reported on adverse events and serious adverse events that may contain both clinically‐ and laboratory‐detected events. All these outcomes can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b> :<br/>Comment: 97 participants randomized; 92 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Incidence of any adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0013"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Incidence of serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0001" title="NCT04412772. Trial of tocilizumab for treatment of severe COVID-19: ARCHITECTS (ARCHITECTS). clinicaltrials.gov/ct2/show/NCT04412772 (first received 2 June 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">ARCHITECTS 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0004" title="NCT04479358. Low-dose Tocilizumab versus standard of care in hospitalized patients with COVID-19 (COVIDOSE-2). clinicaltrials.gov/ct2/show/NCT04479358 (first received 21 July 2020). WHO REACT Working Group 2021. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA 326;6:499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVIDOSE‐2 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0005" title="NCT04435717. Efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 (COVITOZ-01). clinicaltrials.gov/ct2/show/NCT04435717 (first received 17 June 2020). WHO REACT Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">COVITOZ‐01 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0014" title="EudraCT 2020-001748-24. A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001748-24/SE (first received 20 April 2020). NCT04412291. A study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with Anakinra and Tocilizumab treatment the immunomodulation-CoV assessment (ImmCoVA) Study. clinicaltrials.gov/ct2/show/NCT04412291 (first received 2 June 2020). WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-HariM , ValeCL , GodolphinPJ , FisherD , HigginsJPT , SpigaF , et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA2021;326(6):499-518. [DOI: 10.1001/jama.2021.11330] [PMID: 34228774]">IMMCOVA 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0031" title="NCT04403685. Safety and efficacy of tocilizumab in moderate to severe COVID-19 with inflammatory markers (TOCIBRAS). clinicaltrials.gov/ct2/show/NCT04403685 (first received 27 May 2020). VeigaVC , PratsJA , FariasDL , RosaRG , DouradoLK , ZampieriFG , et al, Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ2021;372:n84. [DOI: 10.1136/bmj.n84] [PMID: 33472855]">Veiga 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0032" title="ChiCTR2000029765. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). chictr.org.cn/showprojen.aspx?proj=49409 (first received 13 February 2020). WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. Available at SSRN: papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681 [Preprint with The Lancet]2020. [DOI: 10.2139/ssrn.3667681]WangD , FuB , PengZ , YangD , HanM , LiM , et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers in Medicine2021;15(3):486-494. ">Wang 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Hermine 2020.Rob 2. Deviations from intervention</b> :<br/>Quote: “Open‐label study”<br/>Comment: Unblinded study.<br/>Deviations from intended intervention arising because of the study context:<br/>No participant cross over.<br/>Administration of co‐interventions of interest (antivirals, corticosteroids, and biologics) were reported. The proportions of patients receiving antivirals and steroids were imbalanced between two arms (&gt;10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced.<br/>Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect.<br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention.<br/><b>Hermine 2020.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate.<br/>Measurement or ascertainment of outcome probably does not differ between groups.<br/>Unblinded study (outcome assessor).<br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Salvarani 2020.Rob 2. Deviations from intervention</b> :<br/>Quote: "the trial was open label" <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>Cross over: 15 (23%) patients in the standard care arm received the study treatment. For 12 (18%) the studied treatment was administered because of clinical worsening as planned in the protocol. Nevertheless, this decision could have been influenced by the trial context. <br/>Administration of co‐interventions of interest were reported and not balanced: antivirals (35% vs 47%) and corticosteroids (10% vs 10.6%). These deviations could affect the outcome. Nevertheless, this domain was rated as Some Concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Salvarani 2020.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study. <br/>The outcome contains both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Gordon 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: corticosteroids (252/272 vs 46/48 vs 293/312) were administered and balanced; antivirals (remdesivir: 107/341 vs 21/48 vs 133/389) were reported and imbalanced. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Gordon 2021</b> . <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ among groups. <br/>Unblinded study (outcome assessor) <br/>Outcome may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Soin 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "After randomisation, none of the study personnel or patients was masked to treatment assignment in this open‐label trial." Comment: Unblinded study (participants and personnel/carers). <br/>Deviations from intended intervention arising because of the study context. <br/>One patient randomly assigned to the standard care group inadvertently received tocilizumab at baseline and was included in the tocilizumab group for all analyses (one cross‐over) <br/>Information on the administration of co‐interventions of interest was provided: antivirals and corticosteroids. Biologics were not reported. <br/>Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Participants were not analyzed according to their randomized groups for the outcome. <br/>Of note, 1 participant randomized to the control group was analyzed in the intervention group. Nevertheless, we considered the analysis to be probably appropriate to estimate the effect of assignment to intervention. <br/><b>Soin 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor) <br/>The authors reported on adverse events and serious adverse events that may contain both clinically‐ and laboratory‐detected events. All these outcomes can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Talaschian 2021.Rob 1. Randomization</b> :<br/>Quote: "Eligible patients (one or two days after hospitalization) were randomly distributed to the control and intervention groups by block randomization (1:1 ratio." <br/>Comment: Allocation sequence probably random. Unclear allocation concealment. <br/><b>Talaschian 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "In this study, patients, investigators, and outcome assessors did not inform which group received an intervention. Besides, a placebo was not used in the control group." <br/>Comment: Unclear blinding (unclear if participants and personnel/carers blinded) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Biologics were the intervention. <br/>Corticosteroids reported and balanced between groups. Antivirals reported and not balanced between groups: 35% in the Tocilizumab versus 10% in the standard care arm. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Talaschian 2021.Rob 3. Missing outcome data</b> :<br/>Comment: 40 participants randomized; 36 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>3 participants in the treatment arm and 1 in the standard care arm refused to participate before start of the intervention. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome <br/><b>Talaschian 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The trial registry was available. <br/>Serious adverse events outcomes not pre‐specified. <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> <p><b>Veiga 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open label” trial. <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>Cross over: 2/64 (3%) of the control arm received tocilizumab. <br/>Co‐interventions of interest, corticosteroids, and antivirals were reported, but no information on another co‐intervention of interest: biologics. Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis for this outcome. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Veiga 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study. <br/>Assessment of this outcome requires clinical judgement and can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Wang 2021.Rob 1. Randomization</b> :<br/>Quote: "Randomization numbers were generated using SAS statistical software package (SAS Institute, Cary, USA). A computer‐ generated 1:1 block randomization scheme was used to assign patients to either treatment group or control one. Each consecutively coded patient was randomly enrolled by the sub‐site investigators until the total number of cases allocated to the site was reached." <br/>Allocation sequence random. Allocation concealment unclear. <br/><b>Wang 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "One case in the control group aggravated on day 3 after randomization was transferred to the tocilizumab group according to the rules of the study protocol." <br/>Comment: Unblinded study (participants and personnel/carers). <br/>Deviations from intended intervention arising because of the study context: <br/>One participant cross‐over. <br/>No information on administration of any co‐interventions of interest: antivirals, corticosteroids, biologics. <br/>Hence, this domain was rated as some concern as not enough information on deviations that arose because of the trial context were reported. <br/>Participants were not analyzed according to their randomized groups for the outcome. <br/>Of note, 1 participant randomized to the control group was analyzed in the intervention group. Nevertheless, we considered the analysis to be probably appropriate to estimate the effect of assignment to intervention. <br/><b>Wang 2021</b> . <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The outcome may contain both clinically‐ and laboratory‐detected events. Assessment of this outcome can be influenced by knowledge of the intervention assignment but is not likely in the context of a pandemic. </p> <p><b>Broman 2022. Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids. Antivirals were not administered. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention <br/><b>Broman 2022.Rob 4. Measurement of the outcome</b> :<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. <br/><b>Broman 2022.Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol and statistical analysis plan were not available, and the registry was retrospective (dated October 8, 2021). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b> :<br/>Comment: 97 participants randomized; 92 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Incidence of serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0014"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Time to clinical improvement</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0024" title="NCT04346355. Efficacy of early administration of tocilizumab in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04346355 (first received 15 April 2020). SalvaraniC , DolciG , MassariM , MerloDF , CavutoS , SavoldiL , et al, RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Internal Medicine2021;181(1):24-31. [DOI: 10.1001/jamainternmed.2020.6615] [PMID: 33080005]">Salvarani 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Hermine 2020</b> . <b>Rob 2. Deviations from intervention</b>:<br/>Quote: “Open‐label study”<br/>Comment: Unblinded study.<br/>Deviations from intended intervention arising because of the study context:<br/>No participant cross over.<br/>Administration of co‐interventions of interest (antivirals, corticosteroids, and biologics) were reported. The proportions of patients receiving antivirals and steroids were imbalanced between two arms (&gt;10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced.<br/>Nevertheless, this domain was rated as some Concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect.<br/>Participants were analyzed according to their randomized groups for the time‐to‐event outcome. Of note, 1 vs 0 participants were excluded from the analysis because of consent withdrawal which will be assessed in domain 3. Nevertheless, we consider the analysis appropriate to estimate the effect of assignment to intervention. </p> <p><b>Hermine 2020.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate.<br/>Measurement or ascertainment of outcome probably does not differ between groups.<br/>Unblinded study (outcome assessor).<br/>Mortality is an observer‐reported outcome not involving judgement. </p> <p><b>Salama 2020.Rob 2. Deviations from intervention</b>:<br/>Quote: “double‐blind, placebo‐controlled trial” <br/>"A site blinding plan was established at each site to identify which personnel would be blinded or unblinded at a site level. A pharmacy manual and specific training in addition to completion of a site blinding plan was provided to each site. Each site had an unblinded pharmacist that randomised the patient and prepared and labelled study medication in the same method for both tocilizumab and placebo. The remainder of the study team was blinded to treatment assignment. There was no communication during the study between unblinded and blinded members. In addition, there was an unblinded medical monitor available to answer questions from the unblinded site staff. Placebo was not provided and consisted of an unaltered saline infusion bag, the same as would be used to prepare tocilizumab. The volume of tocilizumab diluted in saline appears colorless and matches saline." <br/>Comment: Blinded study. Participants were blinded. Carers were probably blinded. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 10 vs 1 participants were excluded from the analysis post‐randomization because they did not receive the drug. This method was considered inappropriate to estimate the effect of assignment to intervention for this time‐to‐event outcome. There was probably no substantial impact of failure to analyze participants according to their randomized groups. </p> <p><b>Salvarani 2020.Rob 2. Deviations from intervention</b> :<br/>Quote: "the trial was open label" <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>Cross over: 15 (23%) patients in the standard care arm received the study treatment. For 12 (18%) the studied treatment was administered because of clinical worsening as planned in the protocol. Nevertheless, this decision could have been influenced by the trial context. <br/>Administration of co‐interventions of interest were reported and not balanced: antivirals (35% vs 47%) and corticosteroids (10% vs 10.6%). These deviations could affect the outcome. Nevertheless, this domain was rated as Some Concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Salvarani 2020.Rob 4. Measurement of the outcome</b> :<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of time to clinical improvement probably does not differ between groups. <br/>Unblinded study. <br/>Assessment of this outcome requires clinical judgement and can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. <br/><b>Salvarani 2020.Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol and statistical analysis plan were available. <br/>Time to clinical improvement (defined as discharge) is not present in the protocol or registry. <br/>No information on whether the results were selected from multiple outcome measurements or analyses of the data. </p> <p><b>Declercq 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Derde 2021. Rob 2. Deviations from intervention</b> :<br/>Quote: "Open‐label design" <br/>Comment: Unblinded study (participants and personnel/carers). <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest, antivirals, biologics and corticosteroids were reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 9 (tocilizumab), 2 (sarilumab), 8 (anakinra) participants were excluded from the analysis post‐randomization because outcome data were not available which is accounted for in domain 3. <br/>This method was considered appropriate to estimate the effect of assignment to intervention for this outcome. <br/><b>Derde 2021</b> . <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome does not differ among groups. <br/>Unblinded study (outcome assessor) <br/>Clinical improvement (defined as hospital discharge) require clinical judgement and could be affected by knowledge of intervention receipt. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b> :<br/>Comment: 97 participants randomized; 92 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022. Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Rosas 2022.Rob 2. Deviations from intervention</b>:<br/>Quote: "Masking: Double (Participant, Investigator)" <br/>Comment: Blinded study (participants and personnel/carers) <br/>Participants were analyzed according to their randomized groups for the time‐to‐event outcome. <br/>Of note, 2 vs 1 participants were excluded from the (time to clinical improvement) analysis post‐randomization for reasons other than missing data. 1 vs 1 were excluded from the (time to death) analysis post randomization because of a randomization error. 11 vs 12 participants were excluded from the (time to viral negative conversion) analysis post‐randomization because they did not have at least one virology assessment. <br/>This method was considered inappropriate to estimate the effect of assignment to intervention for this outcome. There was probably no substantial impact of failure to analyze participants according to their randomized groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Time to clinical improvement</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0015"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Time to WHO score 7 or above</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.Randomization</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.Deviations from</b> </p> <p><b>intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.Missing outcome</b> </p> <p><b>data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.Measurement of</b> </p> <p><b>the outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.Selection of the</b> </p> <p><b>reported results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns <sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0023" title="NCT04372186. A study to evaluate the efficacy and safety of tocilizumab in hospitalized participants with COVID-19 pneumonia (EMPACTA). clinicaltrials.gov/ct2/show/NCT04372186 (first received May 1 2020). SalamaC , HanJ , YauL , ReissWG , KramerB , NeidhartJD , et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;1(384):20-30. [DOI: 10.1056/NEJMoa2030340] [PMID: 33332779]">Salama 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns <sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Quote: “Open‐label study” Comment: unblinded study. </p> <p>Deviations from intended intervention arising because of the study context: 3 participants in the treatment group did not receive study drug. Administration of co‐interventions of interest (antivirals, corticosteroids and biologics) were reported. The proportions of participants receiving antivirals and steroids were imbalanced between 2 arms (&gt; 10% absolute difference between the 2 arms) for steroids. This deviation could affect the outcome and was not balanced. Nevertheless, this domain was rated as Some Concerns as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. Participants were analyzed according to their randomized groups for the outcome. Of note, 1 vs 0 participants were excluded from the analysis because of consent withdrawal. Nevertheless, we consider the analysis appropriate to estimate the effect of assignment to intervention. </p> <p><sup>2</sup> Quote: “double‐blind, placebo‐controlled trial.” “A site blinding plan was established at each site to identify which personnel would be blinded or unblinded at a site level. A pharmacy manual and specific training in addition to completion of a site blinding plan was provided to each site. Each site had an unblinded pharmacist that randomized the participant and prepared and labeled study medication in the same method for both tocilizumab and placebo. The remainder of the study team was blinded to treatment assignment. There was no communication during the study between unblinded and blinded members. In addition, there was an unblinded medical monitor available to answer questions from the unblinded site staff. Placebo was not provided and consisted of an unaltered saline infusion bag, the same as would be used to prepare tocilizumab. The volume of tocilizumab diluted in saline appears colorless and matches saline.” </p> <p>Comment: Blinded study. Participants were blinded. Carers were probably blinded. Participants were analyzed according to their randomized groups for the outcome. Of note, 10 vs 1 participants were excluded from the analysis post‐randomization because they did not receive the drug. This method was considered inappropriate to estimate the effect of assignment to intervention for this time‐to‐event outcome. There was probably no substantial impact of failure to analyze participants according to their randomized groups </p> <p><b>Rutgers 2021.Rob 1. Randomization</b>:<br/>Quote: “Randomization was stratified according to the use of hydroxychloroquine and to (on admission) agreed restrictions for ICU eligibility (ICU eligible or ICU non‐eligible).” <br/>Comment: Allocation sequence probably random. No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Time to WHO score 7 or above</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0016"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Time to death</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0010" title="HermineO , MarietteX , TharauxPL , Resche-RigonM , PorcherR , RavaudP , et al, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Internal Medicine2021;181(1):32-40. [DOI: 10.1001/jamainternmed.2020.6820] [PMID: 33080017]NCT04331808. CORIMUNO-19 - tocilizumab trial - TOCI (CORIMUNO-TOCI) (CORIMUNO-TOC). clinicaltrials.gov/ct2/show/NCT04331808 (first received 2 April 2020). ">Hermine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0029" title="NCT04356937. Efficacy of tocilizumab on patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04356937 (first received 22 April 2020). StoneJH , FrigaultMJ , Serling-BoydNJ , FernandesAD , HarveyL , FoulkesAS , et al, BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine2020;383(24):2333-44. [DOI: 10.1056/NEJMoa2028836] [PMID: 33085857]">Stone 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0003" title="BromanN , FeuthT , VuorinenT , ValtonenM , HohenthalU , Löyttyniemi E et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical Microbiology and Infection2022;28(6):844-851. NCT04577534. Use of tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease. clinicaltrials.gov/ct2/show/NCT04577534 (first received 8 October 2020). ">Broman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0022" title="NL8504. Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial. trialregister.nl/trial/8504 (first received 6 April 2020). RutgersA , WesterweelPE , van derHoltB , PostmaS , vanVonderenMGA , PiersmaDP , et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN 2021 [Preprint]. [DOI: 10.2139/ssrn.3834311]">Rutgers 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0030" title="IRCT20081027001411N4. Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19 [Study of tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎clinical trial study].. en.irct.ir/trial/48396 (first received 9 July 2020). TalaschianM , AkhtariM , MahmoudiM , MostafaeiS , JafaryM , Sadat Husseini S et al. Tocilizumab failed to reduce mortality in severe COVID-19 Patients: Results from a ‎randomized controlled clinical trial. Research Square 2021 [Preprint]. [DOI: 10.21203/rs.3.rs-463921/v1]">Talaschian 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0021" title="NCT04320615. A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA) [A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia]. clinicaltrials.gov/ct2/show/NCT04320615 (first received 25 March 2020). RosasIO , BrauN , WatersM , GoRC , MalhotraA , HunterBD , et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine2022;47:101409. RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv [Preprint]2020. [DOI: 10.1101/2020.08.27.20183442]RosasIO , BräuN , WatersM , GoR , HunterBD , BhaganiS , et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine2021;Feb 25:Epub ahead of print. [DOI: 10.1056/NEJMoa2028700] [PMID: 33631066]">Rosas 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Hermine 2020. Rob 2. Deviations from intervention</b>:<br/>Quote: “Open‐label study”<br/>Comment: Unblinded study.<br/>Deviations from intended intervention arising because of the study context:<br/>No participant cross over.<br/>Administration of co‐interventions of interest (antivirals, corticosteroids, and biologics) were reported. The proportions of patients receiving antivirals and steroids were imbalanced between two arms (&gt;10% absolute difference between the two arms) for steroids. This deviation could affect the outcome and was not balanced.<br/>Nevertheless, this domain was rated as some Concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect.<br/>Participants were analyzed according to their randomized groups for the time‐to‐event outcome. Of note, 1 vs 0 participants were excluded from the analysis because of consent withdrawal which will be assessed in domain 3. Nevertheless, we consider the analysis appropriate to estimate the effect of assignment to intervention. </p> <p><b>Derde 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: "Open‐label design" <br/>Comment: Unblinded study (participants and personnel/carers). </p> <p>No participant cross‐over. <br/>No information on administration of co‐interventions of interest, antivirals, biologics, and corticosteroids were reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 9 (tocilizumab), 2 (sarilumab), 8 (anakinra) participants were excluded from the analysis post‐randomization because outcome data were not available which is accounted for in domain 3. <br/>This method was considered appropriate to estimate the effect of assignment to intervention for this outcome.<br/><b>Rutgers 2021.Rob 1. Randomization</b>:<br/>Quote: “Randomization was stratified according to the use of hydroxychloroquine and to (on admission) agreed restrictions for ICU eligibility (ICU eligible or ICU non‐eligible).” <br/>Comment: Allocation sequence probably random. No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. </p> <p><b>Talaschian 2021.Rob 1. Randomization</b> :<br/>Quote: "Eligible patients (one or two days after hospitalization) were randomly distributed to the control and intervention groups by block randomization (1:1 ratio." <br/>Comment: Allocation sequence probably random. Unclear allocation concealment. <br/><b>Talaschian 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "In this study, patients, investigators, and outcome assessors did not inform which group received an intervention. Besides, a placebo was not used in the control group." <br/>Comment: Unclear blinding (unclear if participants and personnel/carers blinded) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Biologics were the intervention. <br/>Corticosteroids reported and balanced between groups. Antivirals reported and not balanced between groups: 35% in the Tocilizumab versus 10% in the standard care arm. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 3 vs 1 participants were excluded from the analysis post‐randomization due to missing data which is accounted for in domain 3. This method was considered appropriate to estimate the effect of assignment to intervention for this outcome. <br/><b>Talaschian 2021</b> . <b>Rob 3. Missing outcome data</b> :<br/>Comment: 40 participants randomized; 36 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>3 participants in the treatment arm and 1 in the standard care arm refused to participate before start of the intervention. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome <br/><b>Talaschian 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The trial registry was available. <br/>Outcome has different timepoint listed in the registry. <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b>:<br/>Comment: 97 participants randomized; 92 participants analyzed. </p> <p>Data not available for all or nearly all participants randomized.</p> <p>No evidence that the result is not biased. <br/>Reasons: 2 vs 3 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><b>Rosas 2022.Rob 2. Deviations from intervention</b>:<br/>Quote: "Masking: Double (Participant, Investigator)" <br/>Comment: Blinded study (participants and personnel/carers) <br/>Participants were analyzed according to their randomized groups for the time‐to‐event outcome. <br/>Of note, 2 vs 1 participants were excluded from the (time to clinical improvement) analysis post‐randomization for reasons other than missing data. 1 vs 1 were excluded from the (time to death) analysis post randomization because of a randomization error. 11 vs 12 participants were excluded from the (time to viral negative conversion) analysis post‐randomization beca use they did not have at least one virology assessment. <br/>This method was considered inappropriate to estimate the effect of assignment to intervention for this outcome. There was probably no substantial impact of failure to analyse participants according to their randomized groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">ROB table: tocilizumab vs standard care (SC)/placebo. Time to death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0017"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC)/placebo. Clinical improvement (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Mariette 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Mariette 2021.Rob 4. Measurement of the outcome</b> :<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. <br/><b>Mariette 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol, statistical analysis plan and registry were available (dated March 27, 2020). <br/>Outcome not pre‐specified (timepoint not reported/different). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial not analyzed as pre‐specified. </p> <p><b>Merchante 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids and biologics. Antivirals (3 vs 7 vs 4) and anticoagulant were reported (37 vs 39 vs 39) and were balanced between groups. <br/>Hence, no sufficient information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Merchante 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unclear blinding (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Sancho‐Lopez 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "Our clinical trial was a national, multicenter, randomized, open label, controlled clinical study". <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Corticosteroids were administered for all patients. Antiviral were provided but no numbers are reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Sancho‐Lopez 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Branch‐Elliman 2022.Rob 4. Measurement of the outcome</b> :<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. <br/><b>Branch‐Elliman 2022.Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol, statistical analysis plan, and registry (submitted April 20, 2020) were available. <br/>Outcome not pre‐specified. <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> <p><b>Garcia‐Vicuna 2022.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: antivirals, corticosteroids and biologics are reported: lopinavir/Ritonavir: 4 vs 1, methylprednisolone bolus: 14 vs 3 and tocilizumab: 0 vs 3. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Garcia‐Vicuna 2022. Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b> :<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022.Rob 4. Measurement of the outcome</b> :<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. <br/><b>Hermine 2022.Rob 5. Selection of the reported results</b>:<br/>Comment: The prospective registry was available (dated March 25th, 2020). <br/>Outcomes not pre‐specified in the registry (timepoint not reported/different).<br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial not analyzed as pre‐specified. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC)/placebo. Clinical improvement (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0018"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC)/placebo. Clinical Improvement (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Mariette 2021. Rob 2. Deviations from interventions:</b> </p> <p>Quote: “open‐label study”</p> <p>Comment: Unblinded study (participants and personnel/carers)</p> <p>Deviations from intended intervention arising because of the study context:</p> <p>No participant cross‐over.</p> <p>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). </p> <p>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. </p> <p>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Mariette 2021.Rob 4. Measurement of the outcome</b> :<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. <br/><b>Mariette 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol, statistical analysis plan and registry were available (dated March 27, 2020). <br/>Outcome not pre‐specified (timepoint not reported/different). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial not analyzed as pre‐specified. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b> :<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC)/placebo. Clinical Improvement (≥ D60)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0019"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC)/placebo. WHO Clinical Progression Score level 7 or above (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>a </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Mariette 2021.Rob 2. Deviation from Intervention</b>:<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Sancho‐Lopez 2021.Rob 2. Deviation from Intervention</b>:<br/>Quote: "Our clinical trial was a national, multicenter, randomized, open label, controlled clinical study". <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Corticosteroids were administered for all patients. Antiviral were provided but no numbers are reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Garcia‐Vicuna 2022.Rob 2. Deviation from Intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: antivirals, corticosteroids and biologics are reported: Lopinavir/Ritonavir: 4 vs 1, methylprednisolone bolus: 14 vs 3 and Tocilizumab: 0 vs 3. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Sivapalasingam 2022a.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022a. Rob 3. Missing outcome data</b>:<br/>Comment: 463 participants randomized; 436 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: randomized but not treated (n=6), withdrew consent(n=5), death before start of treatment(n=1) and lost to follow up (n=21). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC)/placebo. WHO Clinical Progression Score level 7 or above (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0020"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). All‐cause mortality (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0002" title="Branch-EllimanW , FergusonR , DorosG , WoodsP , LeathermanS , Strymish J et al. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One2022;17(2):e0263591. NCT04359901. Sarilumab for patients with moderate COVID-19 disease [Sarilumab for patients with moderate COVID-19 disease: a randomized controlled trial with a play-the-winner design]. clinicaltrials.gov/ct2/show/NCT04359901 (first received 24 April 2020). ">Branch‐Elliman 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>a </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>b </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Gordon 2021. Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: corticosteroids (252/272 vs 46/48 vs 293/312) were administered and balanced; antivirals (remdesivir: 107/341 vs 21/48 vs 133/389) were reported and imbalanced. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Mariette 2021.Rob 2. Deviation from Intervention</b>:<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Merchante 2021. Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids and biologics. Antivirals (3 vs 7 vs 4) and anticoagulant were reported (37 vs 39 vs 39) and were balanced between groups. <br/>Hence, no sufficient information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Sancho‐Lopez 2021.Rob 2. Deviation from Intervention</b> :<br/>Quote: "Our clinical trial was a national, multicenter, randomized, open label, controlled clinical study". <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Corticosteroids were administered for all patients. Antiviral were provided but no numbers are reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention.<br/><b>Garcia‐Vicuna 2022.Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: antivirals, corticosteroids and biologics are reported: Lopinavir/Ritonavir: 4 vs 1, methylprednisolone bolus: 14 vs 3 and Tocilizumab: 0 vs 3. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Hermine 2022. Rob 3. Missing outcome data</b>:<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><b>Sivapalasingam 2022a.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022a. Rob 3. Missing outcome data</b>:<br/>Comment: 463 participants randomized; 436 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: randomized but not treated (n=6), withdrew consent(n=5), death before start of treatment(n=1) and lost to follow up (n=21). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><b>Sivapalasingam 2022b.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022b.Rob 3. Missing outcome data</b>:<br/>Comment: 1407 participants randomized; 1330 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons for potential missing data: randomized but not treated (n=42), discontinuation due to investigator/sponsor decision (n=1), withdrawal of consent (n=9) and loss to follow‐up (n=75). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). All‐cause mortality (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0021"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). All‐cause mortality (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>a </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>b </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Derde 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: "Open‐label design" <br/>Comment: Unblinded study (participants and personnel/carers). <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest, antivirals, biologics and corticosteroids were reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Mariette 2021. Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Garcia‐Vicuna 2022.Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: antivirals, corticosteroids and biologics are reported: Lopinavir/Ritonavir: 4 vs 1, methylprednisolone bolus: 14 vs 3 and Tocilizumab: 0 vs 3. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b>:<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><b>Sivapalasingam 2022a.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022a. Rob 3. Missing outcome data</b>:<br/>Comment: 463 participants randomized; 436 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: randomized but not treated (n=6), withdrew consent(n=5), death before start of treatment(n=1) and lost to follow up (n=21). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><b>Sivapalasingam 2022b.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022b.Rob 3. Missing outcome data</b>:<br/>Comment: 1407 participants randomized; 1330 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons for potential missing data: randomized but not treated (n=42), discontinuation due to investigator/sponsor decision (n=1), withdrawal of consent (n=9) and loss to follow‐up (n=75). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). All‐cause mortality (≥ D60)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0022"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). Incidence of adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>a </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>b </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Lescure 2021.Rob 5. Selection of the reported results</b>: </p> <p>Comment: The trial registry was available and consulted (up to version dated April 3rd, 2020). <br/>Outcome not pre‐specified <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> <p><b>Mariette 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Mariette 2021.Rob 4. Measurement of the outcome</b> :<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. <br/><b>Sancho‐Lopez 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "Our clinical trial was a national, multicenter, randomized, open label, controlled clinical study". <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Corticosteroids were administered for all patients. Antiviral were provided but no numbers are reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Sancho‐Lopez 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that contains both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b> :<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Sivapalasingam 2022a. Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022a.Rob 3. Missing outcome data</b> :<br/>Comment: 463 participants randomized; 436 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: randomized but not treated (n=6), withdrew consent(n=5), death before start of treatment(n=1) and lost to follow up (n=21). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Sivapalasingam 2022a.Rob 5. Selection of the reported results</b>:<br/>Comment: The trial registry was available and consulted (up to version dated March 26th, 2020). <br/>Outcome not pre‐specified <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> <p><b>Sivapalasingam 2022b.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022b.Rob 3. Missing outcome data</b> :<br/>Comment: 1407 participants randomized; 1330 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons for potential missing data: randomized but not treated (n=42), discontinuation due to investigator/sponsor decision (n=1), withdrawal of consent (n=9) and loss to follow‐up (n=75). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Sivapalasingam 2022b. Rob 5. Selection of the reported results</b>:<br/>Comment: The trial registry was available and consulted (up to version dated March 26th, 2020). <br/>Outcome not pre‐specified <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>Trial probably not analyzed as pre‐specified. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). Incidence of adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0023"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). Incidence of serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0009" title="GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report.. medRxiv [Preprint]2021. [DOI: 10.1101/2021.01.07.21249390]GordonAC , MounceyPR , Al-BeidhF , RowanKM , NicholAD , ArabiYM , et al, The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. New England Journal of Medicine2021;384:1491-502. [DOI: 10.1056/NEJMoa2100433]NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">Gordon 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0008" title="Garcia-VicuñaR , Abad-SantosF , González-AlvaroI , Ramos-LimaF , SanzJS . Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):1-4. NCT04357808. Efficacy of subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection (SARCOVID) [Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection]. clinicaltrials.gov/ct2/show/ (first received 22 April 2020). ">Garcia‐Vicuna 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>a </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0027" title="NCT04315298. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19 [An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19]. clinicaltrials.gov/ct2/show/ (first received 19 March 2020). SivapalasingamS , LedererDJ , BhoreR , HajizadehN , CrinerG , HosainR , et al. Efficacy and safety of Sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases2022;75(1):e380-8. [DOI: 10.1093/cid/ciac153]">Sivapalasingam 2022</a>b </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Gordon 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study. <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: corticosteroids (252/272 vs 46/48 vs 293/312) were administered and balanced; antivirals (remdesivir: 107/341 vs 21/48 vs 133/389) were reported and imbalanced. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Data for the outcome were analyzed using intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Gordon 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ among groups. <br/>Unblinded study (outcome assessor).<br/>Outcome may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Mariette 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Mariette 2021</b> . <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Sivapalasingam 2022a.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022a.Rob 3. Missing outcome data</b>:<br/>Comment: 463 participants randomized; 436 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: randomized but not treated (n=6), withdrew consent(n=5), death before start of treatment(n=1) and lost to follow up (n=21). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><b>Sivapalasingam 2022b.Rob 1. Randomization</b> :<br/>Quote: "patients were randomized in a 2:2:1 ratio to IV sarilumab 400 mg, sarilumab 200 mg, or placebo" <br/>Comment: Allocation sequence probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Sivapalasingam 2022b.Rob 3. Missing outcome data</b>:<br/>Comment: 1407 participants randomized; 1330 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons for potential missing data: randomized but not treated (n=42), discontinuation due to investigator/sponsor decision (n=1), withdrawal of consent (n=9) and loss to follow‐up (n=75). <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> <p><b>Garcia‐Vicuna 2022. Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest: antivirals, corticosteroids and biologics are reported: lopinavir/Ritonavir: 4 vs 1, methylprednisolone bolus: 14 vs 3 and tocilizumab: 0 vs 3. <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Garcia‐Vicuna 2022.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> <p><b>Hermine 2022. Rob 3. Missing outcome data</b> :<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022. Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>The authors reported on this outcome that may contain both clinically‐ and laboratory‐detected events which can be influenced by knowledge of the intervention assignment but is not likely in the context of the pandemic. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). Incidence of serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0024"> <div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). Time to clinical improvement</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0016" title="LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine2021;9(5):522-532. LescureFX , HondaH , FowlerRA , LazarJS , ShiG , WungP , et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.02.01.21250769]NCT04327388. Sarilumab COVID-19. clinicaltrials.gov/ct2/show/NCT04327388 (first received 31 March 2020). ">Lescure 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Derde 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "Open‐label design" <br/>Comment: Unblinded study (participants and personnel/carers). <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest, antivirals, biologics, and corticosteroids were reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 9 (tocilizumab), 2 (sarilumab), 8 (anakinra) participants were excluded from the analysis post‐randomization because outcome data were not available which is accounted for in domain 3. <br/>This method was considered appropriate to estimate the effect of assignment to intervention for this outcome. <br/><b>Derde 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome does not differ among groups. <br/>Unblinded study (outcome assessor) <br/>Clinical improvement (defined as hospital discharge) require clinical judgement and could be affected by knowledge of intervention receipt. </p> <p><b>Mariette 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 0 vs 4 participants were excluded from the analysis post‐randomization because they withdrew consent which will be taken into account in ROB 3. <br/><b>Mariette 2021. Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Merchante 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids and biologics. Antivirals (3 vs 7 vs 4) and anticoagulant were reported (37 vs 39 vs 39) and were balanced between groups. <br/>Hence, no sufficient information on whether deviations arose because of the trial context. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 1 vs 1 vs 0 participants were excluded from the analysis post‐randomization because [1 in group (sarilumab 200) did not comply with protocol, 1 in group (sarilumab 400) they did not receive the drug. This method was considered inappropriate to estimate the effect of assignment to intervention for this outcome. There was probably no substantial impact of failure to analyse participants according to their randomized groups. <br/><b>Merchante 2021</b> . <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unclear blinding (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Sancho‐Lopez 2021.Rob 2. Deviations from intervention</b> :<br/>Quote: "Our clinical trial was a national, multicenter, randomized, open label, controlled clinical study". <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Corticosteroids were administered for all patients. Antiviral were provided but no numbers are reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. <br/><b>Sancho‐Lopez 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b> :<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. <br/><b>Hermine 2022. Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). Time to clinical improvement</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0025"> <div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC)/placebo. Time to WHO Score 7 or above</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0026" title="Sancho-LópezA , Caballero-BermejoAF , Ruiz-AntoránB , Múñez RubioE , García GasallaM , BuadesJ , et al. Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: A randomized, phase III clinical trial (SARTRE Study). Infectious Diseases and Therapy2021;10(4):2735-2748. ">Sancho‐Lopez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Mariette 2021. Rob 2. Deviations from interventions</b> </p> <p>Quote: “open‐label study”</p> <p>Comment: Unblinded study (participants and personnel/carers)</p> <p>Deviations from intended intervention arising because of the study context:</p> <p>No participant cross‐over.</p> <p>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). </p> <p>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. </p> <p>Participants were analyzed according to their randomized groups for the outcome.</p> <p>Of note, 0 vs 4 participants were excluded from the analysis post‐randomization because they withdrew consent which will be taken into account in ROB 3. </p> <p><b>Mariette 2021. Rob 5. Selection of the reported results</b> </p> <p>Comment: The protocol, statistical analysis plan and registry were available (dated March 27, 2020). </p> <p>Outcomes not pre‐specified.</p> <p>No information on whether the result was selected from multiple outcome measurements or analyses of the data. </p> <p>Trial not analyzed as pre‐specified.</p> <p><b>Sancho‐Lopez 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: "Our clinical trial was a national, multicenter, randomized, open label, controlled clinical study". <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Corticosteroids were administered for all patients. Antiviral were provided but no numbers are reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Our analysis is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC)/placebo. Time to WHO Score 7 or above</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0026"> <div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). Time to death</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0007" title="DerdeLPG , The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv 2021 [Preprint]. [DOI: https://doi.org/10.1101/2021.06.18.21259133]">Derde 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0019" title="MarietteX . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology2022;4(1):e24-e32. ">Mariette 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0020" title="MerchanteN , CárcelS , Garrido-GraciaJC , Trigo-RodríguezM , Moreno MÁE , León-LópezR , et al. Early use of Sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrobial Agents and Chemotherapy2022;66(2):e0210721. NCT04357860. Clinical trial of sarilumab in adults with COVID-19. clinicaltrials.gov/ct2/show/NCT04357860 (first received 22 April 2020). ">Merchante 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0011" title="HermineO , MarietteX , PorcherR , Resche-RigonM , TharauxPL , RavaudP , CORIMUNO-19 Collaborative Group. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal2022;60(2):2102523. [DOI: 10.1183/13993003.02523-2021] [PMID: 35115337]">Hermine 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Derde 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: "Open‐label design" <br/>Comment: Unblinded study (participants and personnel/carers). <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest, antivirals, biologics, and corticosteroids were reported. <br/>Hence, no information on whether deviations arose because of the trial context. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 9 (tocilizumab), 2 (sarilumab), 8 (anakinra) participants were excluded from the analysis post‐randomization because outcome data were not available which is accounted for in domain 3. <br/>This method was considered appropriate to estimate the effect of assignment to intervention for this outcome. </p> <p><b>Mariette 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label study” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>Administration of co‐interventions of interest were reported in Table S2: anticoagulants (41 vs 45), hydroxychloroquine (2 vs 8), antibiotics (42 vs 43), antivirals (2 vs 3), immuno‐modulators (0 vs 3) and corticosteroids (9 vs 17). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 0 vs 4 participants were excluded from the analysis post‐randomization because they withdrew consent which will be taken into account in ROB 3. </p> <p><b>Merchante 2021.Rob 2. Deviations from intervention</b>:<br/>Quote: “open‐label” <br/>Comment: Unblinded study (participants and personnel/carers) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: corticosteroids and biologics. Antivirals (3 vs 7 vs 4) and anticoagulant were reported (37 vs 39 vs 39) and were balanced between groups. <br/>Hence, no sufficient information on whether deviations arose because of the trial context. <br/>Participants were analyzed according to their randomized groups for the outcome. <br/>Of note, 1 vs 1 vs 0 participants were excluded from the analysis post‐randomization because [1 in group (sarilumab 200) did not comply with protocol, 1 in group (sarilumab 400) they did not receive the drug. This method was considered inappropriate to estimate the effect of assignment to intervention for this outcome. There was probably no substantial impact of failure to analyse participants according to their randomized groups. </p> <p><b>Hermine 2022.Rob 3. Missing outcome data</b>:<br/>Comment: 91 participants randomized; 81 participants analyzed. <br/>Data not available for all or nearly all participants randomized. <br/>No evidence that the result is not biased. <br/>Reasons: 2 vs 8 participants withdrew consent. <br/>Missingness could depend on the true value of the outcome. <br/>Not likely that missingness depended on the true value of the outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">ROB table: sarilumab vs standard care (SC). Time to death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0027"> <div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">ROB table: clazakizumab vs placebo. Clinical improvement (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Lonze 2022. Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol, statistical analysis plan and retrospective registry were available (dated April 9th, 2020). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">ROB table: clazakizumab vs placebo. Clinical improvement (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0028"> <div class="table-heading"><span class="table-label">Table 22.</span> <span class="table-title">ROB table: clazakizumab vs placebo. Clinical improvement (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Lonze 2022. Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol, statistical analysis plan and retrospective registry were available (dated April 9th, 2020). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 22.</span> <span class="table-title">ROB table: clazakizumab vs placebo. Clinical improvement (≥ D60)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0029"> <div class="table-heading"><span class="table-label">Table 23.</span> <span class="table-title">ROB table: clazakizumab vs placebo. WHO Score 7 or above (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Lonze 2022. Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol, statistical analysis plan and retrospective registry were available (dated April 9th, 2020).<br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data.<br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 23.</span> <span class="table-title">ROB table: clazakizumab vs placebo. WHO Score 7 or above (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0030"> <div class="table-heading"><span class="table-label">Table 24.</span> <span class="table-title">ROB table: clazakizumab vs placebo. All‐cause mortality (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Jordan 2021.Rob 1. Randomization</b>:<br/>Quote: “Randomized, double‐blind, placebo‐controlled, exploratory phase II study.” <br/>Comment: Allocation sequence probably random. No information on allocation concealment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 24.</span> <span class="table-title">ROB table: clazakizumab vs placebo. All‐cause mortality (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0031"> <div class="table-heading"><span class="table-label">Table 25.</span> <span class="table-title">ROB table: clazakizumab vs placebo. All‐cause mortality (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Jordan 2021.Rob 1. Randomization</b>:<br/>Quote: “Randomized, double‐blind, placebo‐controlled, exploratory phase II study.” <br/>Comment: Allocation sequence probably random. No information on allocation concealment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 25.</span> <span class="table-title">ROB table: clazakizumab vs placebo. All‐cause mortality (≥ D60)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0032"> <div class="table-heading"><span class="table-label">Table 26.</span> <span class="table-title">ROB table: clazakizumab vs placebo. Incidence of any adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Jordan 2021.Rob 1. Randomization</b>:<br/>Quote: “Randomized, double‐blind, placebo‐controlled, exploratory phase II study.” <br/>Comment: Allocation sequence probably random. No information on allocation concealment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 26.</span> <span class="table-title">ROB table: clazakizumab vs placebo. Incidence of any adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0033"> <div class="table-heading"><span class="table-label">Table 27.</span> <span class="table-title">ROB table: clazakizumab vs placebo. Incidence of serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0015" title="JordanS . Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) compared to placebo for coronavirus disease 2019 (COVID-19) NCT04348500. clinicaltrials.gov/ct2/show/NCT043485002021. ">Jordan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0018" title="LonzeBE , SpieglerP , WessonRN , AlachkarN , PetkovaE , WeldonEP , et al. A randomized double-blinded placebo controlled trial of Clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Critical Care Medicine2022;50(9):1348-59. [DOI: 10.1097/CCM.0000000000005591]NCT04343989. A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 Infection. clinicaltrials.gov/ct2/show/ (first received 14 April 2020). NCT04659772. A study to evaluate clazakizumab in patients with life-threatening COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04659772 (first received 9 December 2020). ">Lonze 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Jordan 2021.Rob 1. Randomization</b> :<br/>Quote: “Randomized, double‐blind, placebo‐controlled, exploratory phase II study.” <br/>Comment: Allocation sequence probably random. No information on allocation concealment.<br/><b>Lonze 2022. Rob 5. Selection of the reported results</b>:<br/>Comment: The protocol, statistical analysis plan and retrospective registry were available (dated April 9th, 2020). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 27.</span> <span class="table-title">ROB table: clazakizumab vs placebo. Incidence of serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0034"> <div class="table-heading"><span class="table-label">Table 28.</span> <span class="table-title">ROB table: olokizumab vs placebo. Clinical improvement (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Samsonov 2022.Rob 1. Randomization</b> :<br/>Quote: “Eligible patients were randomized to one of three treatment groups" <br/>Comment: Allocation probably random. <br/>No information on allocation concealment <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Samsonov 2022.Rob 2. Deviations from intervention</b>:<br/>Quote: “Masking: Double (Participant, Investigator)” <br/>Comment: Unclear blinding (unclear if personnel/carers blinded) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: antivirals and corticosteroids. Biologics (Tocilizumab and Sarilumab) were reported: 5 (Olokizumab arm) vs 15 (placebo arm). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 28.</span> <span class="table-title">ROB table: olokizumab vs placebo. Clinical improvement (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0035"> <div class="table-heading"><span class="table-label">Table 29.</span> <span class="table-title">ROB table: olokizumab vs placebo. All‐cause mortality (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Samsonov 2022.Rob 1. Randomization</b> :<br/>Quote: “Eligible patients were randomized to one of three treatment groups" <br/>Comment: Allocation probably random. <br/>No information on allocation concealment <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Samsonov 2022.Rob 2. Deviations from intervention</b>:<br/>Quote: “Masking: Double (Participant, Investigator)” <br/>Comment: Unclear blinding (unclear if personnel/carers blinded) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: antivirals and corticosteroids. Biologics (Tocilizumab and Sarilumab) were reported:5 (Olokizumab arm) vs 15 (placebo arm). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concerns as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 29.</span> <span class="table-title">ROB table: olokizumab vs placebo. All‐cause mortality (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0036"> <div class="table-heading"><span class="table-label">Table 30.</span> <span class="table-title">ROB table: olokizumab vs placebo. Incidence of serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0025" title="SamsonovM . Study of the efficacy and safety of a single administration of Olokizumab and RPH-104 with standard therapy in patients with severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04380519 (first received 24 January 2022). ">Samsonov 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Samsonov 2022.Rob 1. Randomization</b> :<br/>Quote: “Eligible patients were randomized to one of three treatment groups" <br/>Comment: Allocation probably random. <br/>No information on allocation concealment. <br/>Imbalances in baseline characteristics appear to be compatible with chance. <br/><b>Samsonov 2022.Rob 2. Deviations from intervention</b>:<br/>Quote: “Masking: Double (Participant, Investigator)” <br/>Comment: Unclear blinding (unclear if personnel/carers blinded) <br/>Deviations from intended intervention arising because of the study context: <br/>No participant cross‐over. <br/>No information on administration of co‐interventions of interest: antivirals and corticosteroids. Biologics (Tocilizumab and Sarilumab) were reported: 5 (Olokizumab arm) vs 15 (placebo arm). <br/>This deviation was not balanced and could affect the outcome. Nevertheless, this domain was rated as some concern as it is impossible to distinguish deviation because of trial context and deviation because of intervention effect. <br/>Our analysis for the binary outcome is an intention‐to‐treat analysis. This method was considered appropriate to estimate the effect of assignment to intervention. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 30.</span> <span class="table-title">ROB table: olokizumab vs placebo. Incidence of serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0037"> <div class="table-heading"><span class="table-label">Table 31.</span> <span class="table-title">ROB table: siltuximab vs placebo. Clinical improvement (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Declercq 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 31.</span> <span class="table-title">ROB table: siltuximab vs placebo. Clinical improvement (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0037">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0038"> <div class="table-heading"><span class="table-label">Table 32.</span> <span class="table-title">ROB table: siltuximab vs placebo. Clinical Improvement (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Declercq 2021</b> . <b>Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 32.</span> <span class="table-title">ROB table: siltuximab vs placebo. Clinical Improvement (≥ D60)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0038">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0039"> <div class="table-heading"><span class="table-label">Table 33.</span> <span class="table-title">ROB table: siltuximab vs placebo. All‐cause mortality (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 33.</span> <span class="table-title">ROB table: siltuximab vs placebo. All‐cause mortality (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0039">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0040"> <div class="table-heading"><span class="table-label">Table 34.</span> <span class="table-title">ROB table: siltuximab vs placebo. All‐cause mortality (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 34.</span> <span class="table-title">ROB table: siltuximab vs placebo. All‐cause mortality (≥ D60)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0040">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0041"> <div class="table-heading"><span class="table-label">Table 35.</span> <span class="table-title">ROB table: siltuximab vs placebo. WHO Score 7 or above (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 35.</span> <span class="table-title">ROB table: siltuximab vs placebo. WHO Score 7 or above (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0041">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0042"> <div class="table-heading"><span class="table-label">Table 36.</span> <span class="table-title">ROB table: siltuximab vs placebo. Incidence of serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 36.</span> <span class="table-title">ROB table: siltuximab vs placebo. Incidence of serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0042">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0043"> <div class="table-heading"><span class="table-label">Table 37.</span> <span class="table-title">ROB table: siltuximab vs placebo. Time to clinical improvement</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Declercq 2021.Rob 4. Measurement of the outcome</b>:<br/>Comment: Method of measuring the outcome probably appropriate. <br/>Measurement or ascertainment of outcome probably does not differ between groups. <br/>Unblinded study (outcome assessor). <br/>Clinical improvement requires clinical judgement and could be affected by knowledge of intervention receipt, but it is not considered likely in the context of a pandemic. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 37.</span> <span class="table-title">ROB table: siltuximab vs placebo. Time to clinical improvement</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0043">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0044"> <div class="table-heading"><span class="table-label">Table 38.</span> <span class="table-title">ROB table: siltuximab vs placebo. Time to death</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0006" title="DeclercqJ , Van DammeKFA , De LeeuwE , MaesB , BosteelsC , TavernierSJ , et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine2021;9(12):1427-38. NCT04330638. Treatment of COVID-19 patients with anti-interleukin drugs [A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome]. clinicaltrials.gov/ct2/show/ (first received 1 April 2020). ">Declercq 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 38.</span> <span class="table-title">ROB table: siltuximab vs placebo. Time to death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0044">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0045"> <div class="table-heading"><span class="table-label">Table 39.</span> <span class="table-title">ROB table: levilimab vs placebo. Clinical improvement (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Lomakin 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The registry was retrospective (dated May 21, 2020). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 39.</span> <span class="table-title">ROB table: levilimab vs placebo. Clinical improvement (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0045">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0046"> <div class="table-heading"><span class="table-label">Table 40.</span> <span class="table-title">ROB table: levilimab vs placebo. All‐cause mortality (D28)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Lomakin 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The registry was retrospective (dated May 21, 2020). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 40.</span> <span class="table-title">ROB table: levilimab vs placebo. All‐cause mortality (D28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0046">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0047"> <div class="table-heading"><span class="table-label">Table 41.</span> <span class="table-title">ROB table: levilimab vs placebo. All‐cause mortality (≥ D60)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 41.</span> <span class="table-title">ROB table: levilimab vs placebo. All‐cause mortality (≥ D60)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0047">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0048"> <div class="table-heading"><span class="table-label">Table 42.</span> <span class="table-title">ROB table: levilimab vs placebo. Incidence of any adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Lomakin 2021</b> . <b>Rob 5. Selection of the reported results</b>:<br/>Comment: The registry was retrospective (dated May 21, 2020). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 42.</span> <span class="table-title">ROB table: levilimab vs placebo. Incidence of any adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0048">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013881-tbl-0049"> <div class="table-heading"><span class="table-label">Table 43.</span> <span class="table-title">ROB table: levilimab vs placebo. Incidence of serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.Deviations from intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.Missing outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.Measurement of the outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.Selection of the reported results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall risk of bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013881-bbs2-0017" title="LomakinNV , BakirovBA , ProtsenkoDN , MazurovVI , MusaevGH , MoiseevaOM , et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflammation Research2021;70(10-12):1233-1246. NCT04397562. A clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 [A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19]. clinicaltrials.gov/ct2/show/NCT04397562 (first received 21 May 2020). ">Lomakin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Some concerns</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Lomakin 2021.Rob 5. Selection of the reported results</b>:<br/>Comment: The registry was retrospective (dated May 21, 2020). <br/>No information on whether the result was selected from multiple outcome measurements or analyses of the data. <br/>No information on whether the trial was analyzed as pre‐specified. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 43.</span> <span class="table-title">ROB table: levilimab vs placebo. Incidence of serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013881.pub2/full#CD013881-tbl-0049">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013881.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD013881-note-0045">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD013881-note-0053">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013881-note-0050">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013881-note-0052">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD013881-note-0049">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD013881-note-0048">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013881-note-0051">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD013881-note-0047">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013881-note-0046">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013881\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013881\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013881\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013881\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013881\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013881.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013881.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013881.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013881.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013881.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724473783"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013881.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724473786"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013881.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e63a28cc4f3fd',t:'MTc0MDcyNDQ3NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 